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TUBERCULOSIS CHEMOTHERAPY CENTRE, MADRAS 1
A previous report from the Tuberculosis Chemotherapy Centre, Madras, demonstrated
the value of a fully supervised twice-weekly regimen of high-dosage isoniazid plus strepto-
mycin in the treatment of newly diagnosed tuberculous patients with drug-sensitive cultures.
A logical consequence of this finding was an investigation of regimens with a longer interval
between successive doses. The present report describes the findings of a controlled study
of 3 once-weekly regimens and the twice-weekly regimen. The results confirm that the
twice-weekly regimen is highly effective and demonstrate that its efficacy is not influenced
by the rate of inactivation of isoniazid or by a reduction (by one-fourth) in the dosage
of streptomycin. The results also show that once-weekly chemotherapy from the be-
ginning, whether with high-dosage isoniazid plus streptomycin or high-dosage isoniazid
plus streptomycin plus high-dosage pyrazinamide, gives unsatisfactory results. However,
when an initial daily phase of 4 weeks with a moderate dosage of isoniazid plus strepto-
mycin preceded the once-weekly phase of high-dosage isoniazid plus streptomycin, the
response was highly satisfactory in slow inactivators of isoniazid (as good as with the
twice-weekly regimen) but was considerably less satisfactory in rapid inactivators. These
findings suggest that if a method of compensating for the insufficiency of this regimen
in rapid inactivators of isoniazid can be found, the prospects for evolving a highly satisfactory
once-weekly regimen are bright.
1 The Tuberculosis Chemotherapy Centre, Madras-31,
India, is under the joint auspices of the Indian Council of
Medical Research (ICMR), the Tamil Nadu (Madras State)
Government, and the World Health Organization (WHO) in
collaboration with the Medical Research Council of Great
Britain (BMRC).
The research of the Centre has been guided by a Project
Committee consisting of the Adviser in Tuberculosis to the
Government of India (Dr N. L. Bordia, Chairman), the
Director-General of the ICMR (Dr C. G. Pandit, succeeded by
Col. B. L. Taneja in August 1964), the Director of Health
Services and Family Planning, Tamil Nadu (Dr A. B. Mari-
kar), the Director of the Centre (Dr N. K. Menon), the WHO
Senior Medical Officer of the Centre (Dr Hugh Stott),
Dr J. Frimodt-Møller, Dr K. S. Sanjivi, a WHO representa-
tive and a BMRC representative. The BMRC, acting through
its Tuberculosis and Chest Diseases Unit, is responsible
for advising WHO on the research in accordance with plans
prepared by the Project Committee. Close contact has been
maintained between the Centre and Dr Wallace Fox (BMRC
Tuberculosis and Chest Diseases Unit) and Professor
D. A. Mitchison (BMRC Unit on Drug Sensitivity in
Tuberculosis).
The members of the scientific staff of the Centre
with major responsibility for the work reported here are:
Dr N. K. Menon, Director: Dr Hugh Stott (WHO), Senior
Medical Officer; the late Dr S. Velu, Dr C. V. Ramakrishnan,
Dr S. Devadatta, Dr O. Nazareth, Dr S. R. Kamat, Dr J. J.
Y. Dawson (WHO) and Dr C. Evans (WHO), Medical
Officers; Mrs M. Jeyalakshmi Monga, Senior Public Health
Nurse; Dr S. P. Tripathy and Dr. L. Eidus (WHO), Senior
Bacteriologists; Dr P. R. J. Gangadharam, Bacteriologist;
Mrs S. Subbammal, Assistant Bacteriologist; Dr D. V.
Krishnamurthy and Dr K. V. Nageswara Rao, Biochemists;
Mr C. V. Jacob, Miss S. Joseph, Mr P. Venkataraman,
Mr S. Kailasam, Miss K. Prema and Mr R. Raghunathan,
Laboratory Research Assistants; Mr A. G. Beer (WHO),
Laboratory Technician; Dr S. Radhakrishna, Senior Statis-
tician; Mr P. R. Somasundaram, Mr K. Ramachandran and
Mr N. G. K. Nair, Statisticians; and Mr B. Janardhanam
and Mr A. S. L. Narayana, Statistical Assistants.
The report was prepared by Dr S. Radhakrishna,
Dr Wallace Fox and Professor D. A. Mitchison, in collabora-
tion with Dr N. K. Menon, Mr P. R. Somasundaram and
other scientific staff of the Centre.
The great majority of the patients in the present study
were referred to the Centre from the Government Tuberculo-
sis Demonstration and Training Centre (Director: Dr M.
A. Hamid) and a Corporation Tuberculosis Clinic (Medical
Officer in Charge: Dr V. S. Selvapathy).
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I. INTRODUCTION
One of the major problems in the treatment of
tuberculosis is the difficulty experienced in ensuring
regularity in the long-term daily self-administration
of drugs. This difficulty is encountered both in the
developing countries and in the technically advanced
countries (see review by Fox, 1962), and is largely
due to the fact that patients rapidly become symptom-
free after the commencement of chemotherapy.
Fully supervised chemotherapy has the advantage
that it permits a precise knowledge of, and con-
sequently greater scope for control over, the actual
drug-intake of the patients. However, daily super-
vision on a large scale is impracticable, especially in
developing countries. On the other hand, if the
drugs could be administered intermittently, super-
vision might become a more practicable proposition.
Studies of fully supervised intermittent regimens
were therefore initiated at this Centre in 1961. The
rationale, mode of action and advantages of such
regimens, together with the literature, have been
discussed in detail elsewhere (Tuberculosis Chemo-
therapy Centre, Madras, 1964; Mitchison, 1965 ;
Fox, 1968).
An earlier study from this Centre (Tuberculosis
Chemotherapy Centre, Madras, 1964) showed that
a completely supervised, twice-weekly regimen of
isoniazid (approximately 14 mg/kg body-weight,
orally) plus streptomycin (1 g, intramuscularly), both
drugs given at the same time, for 1 year, was at least
as effective as a standard self-administered daily oral
regimen of isoniazid plus PAS 1 in the treatment
of newly diagnosed tuberculous patients with drug-
sensitive cultures. Regimens with a longer interval
between successive doses-for instance, once-weekly
regimens-would have the further advantages of
being more convenient for the patient and easier to
organize. Also, for any given combination of drugs,
they would probably be less expensive and less toxic.
Thus, the potential advantages of such regimens
appear to be substantial, especially if the number of
patients involved is large, as in a mass treatment
programme. A study was therefore undertaken at
the Centre to investigate the efficacies of three
once-weekly regimens (one of which included an
initial daily phase) in comparison with that of the
twice-weekly regimen (SHTW) described above. One
1p-aminosalicylic acid.
of these regimens (SHOW) consisted of isoniazid
and streptomycin in the same dosages as in the
twice-weekly regimen but administered once weekly.
As it was felt that this regimen might prove to be
insufficiently effective, two modifications were also
studied:
(1) In one modification (SHZOW), pyrazinamide
in high dosage was administered at the same time as
the isoniazid plus streptomycin, making a once-
weekly triple-drug regimen. Preliminary studies
had shown that high-dosage pyrazinamide resulted
in appreciably high serum concentrations in Madras
patients (Subbammal et al., 1968) and, when admin-
istered once weekly for up to a year, did not produce
acute or chronic toxicity (Ramakrishnan et al.,
1968). These findings, together with the fact that
pyrazinamide is bactericidal, made it preferable to
PAS, thioacetazone, ethionamide and cycloserine,
for each of which there is a greater limitation on the
size of the individual dose, due to considerations
such as acute intolerance or bulk.
(2) In the other modification (SH/SHOW),
streptomycin plus moderate-dosage isoniazid was
administered daily for the first 4 weeks, followed by
streptomycin plus high-dosage isoniazid adminis-
tered once weekly for the rest of the year. The
initial daily phase was introduced because of
laboratory and clinical evidence that the intensity of
treatment in the first few weeks has a substantial
influence on the outcome of chemotherapy (see
review by Fox, 1968).
In the earlier study (Tuberculosis Chemotherapy
Centre, Madras, 1964), the proportion of patients
who became uncooperative and stopped treatment
during the year was higher with the twice-weekly
regimen of isoniazid plus streptomycin than with the
standard daily regimen of isoniazid plus PAS. This
finding, together with the fact that the incidence of
giddiness was substantially higher with the former
regimen, raised the possibility that side-effects due
to streptomycin (1 g) might have an influence on the
acceptability of the twice-weekly regimen, and
possibly also on the acceptability of the once-weekly
regimens. In consequence, only half the patients in
this study (selected at random) were prescribed the
same dosage of streptomycin as in the earlier study–
namely, 1 g–and the other half were prescribed a
lower dosage–0.75 g. As there is an element of
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subjectivity, and therefore a possibility of bias, in patients were aware of the dosage of streptomycin
the assessment of streptomycin toxicity, the study employed for any individual patient.
was conducted double-blind in respect of strepto- The findings over a 1-year period are presented in
mycin dosage–that is, neither the physicians nor the this report.
II. PLAN AND CONDUCT OF THE STUDY
The great majority of patients came from the
poorest sections of the population of Madras city,
and had been referred to the Centre from tuberculosis
clinics, at which they had attended with symptoms.
The criteria for admission were similar to those in
previous studies (Tuberculosis Chemotherapy Centre,
Madras, 1959, 1960, 19.64, 1966). In brief, the
patients were aged 12 years or more, had at least
2 sputum cultures positive for Mycobacterium
tuberculosis (patients with 2 or more positive smears
ware provisionally admitted), had either received no
netituberculosis chemotherapy or had received it for
not more than 2 weeks, and were judged to be
S H T W
Streptomycin sulfate by intramuscular injection in
a dose equivalent to 1 g (high dosage) or 0.75 g
co-operative. (low dosage) of streptomycin base plus isoniazid in
CHEMOTHERAPEUTIC REGIMENS
Four chemotherapeutic regimens, each of l-year
duration, were studied. The details of the regimens
are set out below, together with the dosages for a
patient weighing 100 lb (45.4 kg) (the detailed dosage
schedule is presented in Table 1, together with the
mean dosages and ranges on admission).
TABLE 1
DOSAGE SCHEDULE, AND MEAN DOSAGE AND RANGE
ON ADMISSION TO TREATMENT
Drug
Streptomycin
lsoniazid
Pyrazinamide
Rhythm
Daily or
intermittent
Daily
Intermittent
Intermittent
Bodt-&weight Dosage
Any
1 g (high) or
0.75 g (low)
Any 400 mg b
50-69 400 mg b
70-99 600 mg b
100 or more 750 mg b
50-69 2.5 g
70-79 3.0 g
80-89 3.5 g
90 or more 4.0 g
Dosage in relation to
body-weight on
admission (mg/kg)
Mean Range
26.7 14.5-46.8
19.8 12.1-36.4
15.4 12.1-20.5
88.9 75.2-97.8
a 1 lb = 0.45 kg.
b lncorporating 6 mg of pyridoxine.
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a single oral dose of 750 mg, both drugs being given
at the same time, twice weekly (at intervals of 3 and
4 days alternately).
S H O W
Streptomycin and isoniazid in the same dosages as
in the SHTW regimen, both drugs being given at
the same time, once weekly.
S H Z O W
Streptomycin and isoniazid in the same dosages
as in the SHTW regimen, plus pyrazinamide in a
dosage of 4 g,1 all three drugs being given at the
same time, once weekly.
S H / S H O W
Streptomycin in the same dosage as in the SHTW
regimen plus isoniazid in a single oral dose of
400 mg, both drugs being given at the same time,
daily (except Sundays) for 4 weeks, followed by
streptomycin in the same dosage as in the first
4 weeks plus isoniazid in the same dosage as in the
SHTW regimen, both drugs being given at the same
time, once weekly for the remaining 48 weeks.
The dosage of streptomycin, whether administered
daily or intermittently, and of isoniazid when
administered daily, did not depend on the patient’s
body-weight.
The dosage of pyrazinamide, and of isoniazid
when administered intermittently, did depend on
body-weight (Table 1). If, at a monthly examination,
a patient was found to have gained weight and to
have moved into a higher weight category, the dosage
was increased; however, the dosage was never
reduced for loss in weight.
Pyridoxine supplement
All the patients in this study were prescribed
6 mg of pyridoxine, incorporated in the isoniazid
tablets, with every dose of isoniazid, in order to
prevent isoniazid toxicity (Tuberculosis Chemo-
therapy Centre, Madras, 1963b).
1 The safety of pyrazinamide in high dosage (that is,
3 g for a 100-lb patient), when given once weekly for up to
one year? had already been established in Madras patients by
Ramakrishnan et al. (1968). Also, Subbammal et al. (1968)
had shown that increasing the dosage from 3 g to 4 g resulted
in appreciably higher serum concentrations, but no acute
hepatic toxicity. It was therefore decided to employ 4 g in the
present study, but with safeguards (see pages 147 and 148).
ALLOCATION OF CHEMOTHERAPY AND
DOUBLE-BLIND NATURE OF THE STUDY
The regimen and streptomycin dosage were
allocated at random by the statisticians from one of
four series of sealed envelopes, according to whether
the smear result of the first overnight collection
specimen of sputum was 3-plus, 2-plus, 1-plus or
negative.
The study was conducted double-blind in respect
of streptomycin dosage. Immediately after the
allocation of chemotherapy, a treatment record sheet
was prepared for each patient by the statisticians,
and the streptomycin dosage was entered on it. This
sheet was then kept in a confidential file in the
treatment room, and every dose of streptomycin
received by the patient was recorded on it by the
nurses in the injection room. Apart from the stat-
isticians and these nurses, no staff member of the
Centre had access to the register or knew the dosage
of streptomycin received by any individual patient;
the dosage was also unknown to the patients them-
selves.
EVOLUTION OF THE STUDY
The intake to the study was in three phases (Fig. 1).
It began in July 1963, with patients being allocated
in equal proportions to the SHTW and SHOW
regimens only (Phase I). From February 1964, when
the Centre was fully organized to undertake the
study of two additional regimens (SHZOW and
SH/SHOW), patients were allocated in equal pro-
portions to each of the four regimens (Phase II).
By September 1965, it became clear that the SHOW
regimen was unsatisfactory. The intake of patients
to this regimen was therefore stopped and, sub-
sequently, patients were allocated in equal propor-
tions to the other three regimens only (Phase III)
until January 1966, when the intake to the study
was completed. In each phase, half the patients on
each regimen were allocated to receive 1 g of strepto-
mycin and the other half to receive 0.75 g of strepto-
mycin.
PRETREATMENT INVESTIGATIONS
The pretreatment investigations included the
following :
(1) A clinical examination and assessment of the
general clinical condition, the weight (lb), an intra-
cutaneous tuberculin (Mantoux) test (5 TU of PPD,
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FIG. 1
INTAKE OF PATIENTS TO THE STUDY
Batch RT 22 without Tween), and examination of
urine for albumin and sugar.
(2) A full-plate postero-anterior chest radiograph.
(3) The examination by direct smear and culture
of a minimum of 4 sputum specimens. Two were
produced overnight in the home (collection speci-
mens) and 2 were expectorated (after the patient had
had his throat tickled with a swab) under the direct
supervision of a health visitor at the Centre (super-
vised spot specimens).
(4) Tests of sensitivity to streptomycin and iso-
niazid on 2 positive cultures.
(5) Identification tests on the 2 cultures tested for
drug sensitivity.
(6) Rotating-chair test for vestibular function.
The following additional investigations were under-
taken for patients in phases II and III:
(a) Urine test for urobilinogen (Harrison, 1957)
for all patients.
(b) For SHZOW and, as a control, SHOW
patients, determinations of the serum L-aspartate:
2-oxoglutarate aminotransferase 1 (glutamic-oxalo-
1  Terminology recommended by the Commission on
Enzymes of the International Union of Biochemistry (Florkin
& Stotz, 1965).
acetic transaminase, SGOT) activity and serum
L-alanine: 2-oxoglutarate aminotransferase 1 (gluta-
mic-pyruvic transaminase, SGPT) activity.
(c) For SHZOW and, as a control, SHOW
patients, tests of sensitivity to pyrazinamide on
2 cultures.
GENERAL MANAGEMENT
All patients were treated as out-patients from the
start, and their progress was assessed at monthly
intervals. At each scheduled attendance (daily,
twice weekly or once weekly), the patient took a dose
of the oral medicament(s) under the careful super-
vision of a nurse, and immediately afterwards
received the injection of streptomycin. If the patient
failed to attend on an appointed day, a visit to the
home was made by a health visitor the next day as
a reminder; if this and further visits by her were
unsuccessful, special efforts (including home visits)
were made by the social workers and the physicians.
Towards the end of each month of treatment, a
health visitor made a routine visit to the patient’s
home to collect a bottle of sputum and to deliver
another for collecting sputum.
Very ill patients were asked to restrict their
activities, and were brought to the Centre by
ambulance or had their chemotherapy administered
at home. However, this occurred very infrequently
(see page 190).
It was the policy to avoid, as far as possible,
collapse therapy and resection; no patient in this
study had either measure.
INVESTIGATIONS DURING TREATMENT
Assessments made at monthly intervals after the
start of chemotherapy included (1) the weight (lb),
(2) the examination of 2 collection specimens and
1 supervised spot specimen of sputum by smear and
by culture, (3) tests of sensitivity to streptomycin
and isoniazid on 1 positive culture from the 3rd
month onwards, (4) identification tests on the culture
tested for drug sensitivity, and (5) the regularity of
attendance for the allocated chemotherapy. Further,
a routine postero-anterior chest radiograph was
taken at 1,2,3,6 and 12 months, and at other months
only if at least one sputum smear was positive. A
rotating-chair test for vestibular function was under-
taken at 1 year for all patients unless their allocated
chemotherapy had been terminated in the mean-
time; extra tests were undertaken in specific situa-
tions, namely-after a second complaint of giddiness
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or just prior to a reduction in dosage or the with-
drawal of streptomycin on account of toxicity.
The following additional investigations were under-
taken for patients in phases II and III:
(a) Determination of the rate of inactivation of
isoniazid, at 1 month. (When it was found that the
inactivation rate had prognostic importance in
phases II and III, it was decided to perform the test
for patients who had been admitted in phase I also;
the tests were undertaken between 24 and 36 months
after admission.)
(b) Estimations of the serum concentrations of
isoniazid and streptomycin for all patients, and of
serum pyrazinamide concentrations also for the
SHZOW patients, at 1, 2, 3 and 6 hours after the
first supervised dose of chemotherapy; however, for
the SH/SHOW patients, the isoniazid dosage
appropriate to the once-weekly rhythm (not the daily
rhythm) was administered, as the object of the
investigation was to determine the serum drug con-
centrations attained during intermittent chemo-
therapy.
The total amount of urine passed during the 6-hour
period was collected, and the isoniazid, acetylisonia-
zid and isonicotinic acid contents were estimated.
(c) Determinations of the SGOT and SGPT
activity at 1 and at 12 months for the SHZOW
patients and, as a control, for the SHOW patients.
(d) A test for urobilinogen on a specimen of urine
collected at each weekly attendance, prior to the
administration of drugs, for the SHZOW patients
and, as a control, for the SHOW patients. If
2 successive results were positive, the SGOT and
SGPT activities were determined.
(e) A pyrazinamide sensitivity test on 1 positive
culture each month from the third month onwards
for the SHZOW patients and, as a control, on
1 positive culture at 6 months and at 12 months for
the SHOW patients.
URINE TESTS FOR INGESTION OF ISONIAZID
Since it is known that tablets are not always
swallowed even when given under direct supervision
(Gilroy, 1952), it was desirable to obtain confirmation
of drug ingestion. For this purpose, surprise visits
to the patients’ homes were made from 2 to 24 hours
after the supervised administration of chemotherapy,
and specimens of urine were collected and tested for
a metabolite of isoniazid. Up to July 1964 (that is,
in the first year of the intake), the practice was to
collect 1 specimen per patient per month. As
interim analyses showed the proportion of specimens
with a positive result to be very high-namely,
92% of 645–this practice was thereafter modified
(to lessen the work-load) to testing about 25 speci-
mens per month from the same number of patients,
selected at random.
It was also important to ensure that the patients
in this study, approximately two-thirds of whom
received once-weekly regimens, did not supplement
their chemotherapy from other sources. Therefore,
during the year of treatment, a specimen of urine
was collected once weekly from all patients im-
mediately prior to the administration of the drugs
(i.e., 3-7 days after the previous dose of drugs) and
was tested for a metabolite of isoniazid.
The isonicotinic acid test (Kasik et al., 1962) was
employed in the first 8 months of the study, and the
acetylisoniazid test (Eidus & Hamilton, 1964) there-
after; the two tests have been found to be of similar
sensitivity (Venkataraman et al., 1965).
III. BACTERIOLOGICAL AND ASSAY PROCEDURES
SMEARS AND CULTURES for growth (or presence of contamination), and
Sputum specimens were examined by methods
reported as negative if no growth was present by
similar to those described previously (Tuberculosis
8-9 weeks.
Chemotherapy Centre, Madras, 1959). In brief,
smears were examined by fluorescence microscopy
SENSITIVITY TESTS
(Holst et al., 1959), and graded as 3-plus, 2-plus, Sensitivity tests were performed on slopes of
1-plus or negative. Sputum specimens were cultured, Löwenstein-Jensen medium, employing the minimal
after treatment with 4% sodium hydroxide, on inhibitory concentration (MIC) and proportion
Löwenstein-Jensen medium (Cruickshank, 1965). The methods for isoniazid, the resistance-ratio (RR)
cultures were incubated at 37°C, examined weekly method for streptomycin, and the proportion method
for dihydrostreptomycin (Canetti et al., 1963). For
pyrazinamide, sensitivity tests were performed on
slopes of acidsed Löwenstein-Jensen medium, with
a pre-inspissation pH of 4.85, by the MIC and
proportion methods (Tripathy, 1966; Tripathy et al.,
in press).
The inoculum suspension for the sensitivity tests
was made by adding 4 mg (moist weight) of bacilli,
as judged by eye, to a previously sterilized “ bijou ”
bottle containing glass beads and 0.2 ml of sterile
distilled water. The bottle was shaken mechanically
for 1 minute, and 0.8 ml of sterile distilled water
was added to give a standard suspension. From this
suspension, 4 serial 10-fold dilutions were made.
Slopes of the medium, containing the range of drug
concentrations indicated in Table 2, were each
inoculated with a standard (approximately 3-mm)
loopful of the appropriate suspension.
With each batch of streptomycin sensitivity tests,
the standard sensitive strain, H37Rv, was also set up,
using the same range of drug concentrations.
Although this was not done for isoniazid, dihydro-
streptomycin and pyrazinamide, every batch of
medium was tested, as soon as it was prepared,
with the H37Rv strain, using the proportion method
and the same range of drug concentrations as for the
test strains.
The results of sensitivity tests by the MIC and
RR methods were read at the end of 28 days of
incubation at 37°C, and those by the proportion
method at the end of 40 days. The main measures of
sensitivity used in this report are as follows:
Isoniazid : MIC–the minimum concentration
inhibiting growth (defined as 20 colonies or more) on
the slopes inoculated with the standard suspension.
Streptomycin : RR–the ratio of the MIC of the
test strain to the MIC of strain H37Rv, both MICs
being based on the findings on the slopes inoculated
with the standard suspension.
Pyrazinamide : The proportion resistant to
100 µg/ml, i.e., the bacterial population growing on
100 µg/ml expressed as a proportion of the total
bacterial population, the latter being assessed from
the counts on the acidified drug-free slopes.
The MIC and RR results were accepted only if
more than 100 colonies grew on the drug-free slope.
If the MIC of isoniazid was 0.4 µg/ml or 1 µg/ml, or
if the RR for streptomycin was 4, the test was
repeated.
DEFINITIONS OF DRUG RESISTANCE
Isoniazid
Pretreatment:
(a) growth on 1 µg/ml on at least 1 of the 2 cultures; or
(b) growth on 0.2 µg/ml but not on 1 µg/ml on 1 of
the 2 cultures, followed by growth on 0.2 µg/ml in
the repeat test on the same culture; or
(c) growth on 0.2 µg/ml but not on 1 µg/ml, on both
cultures.
During treatment: growth on 0.2 µg/ml.
Streptomycin
Pretreatment:
(a) an RR of 8 or more on at least 1 of the 2 cultures;
TABLE 2
INOCULUM SUSPENSIONS AND DRUG CONCENTRATIONS µg/mI) a EMPLOYED IN SENSITIVITY TESTS
Löwenstein-Jensen medium Acidified 
b Löwenstein-
Jensen medium
Standard + + + + + + + + + + + + + + +  +
1 in 10 + + + + + + + + +
1 in 102 + + + + + +  +  + + + + +
1 in 103 + + + + + +  +  +  + + + +
1 in 104 + + + +
a Expressed as the amounts added before inspissation.
b With a pre-inspissation pH of 4.85.
Pyrazinamide
12.5 25 50 100
(b) an RR of 4 on 1 of the 2 cultures, followed by
an RR of 4 or more in the repeat test on the same
culture; or
(c) an RR of 4 on both cultures.
During treatment:
(a) an RR of 8 or more; or
(b) an RR of 4 followed by an RR of 4 or more in
the repeat test.
Pyrazinamide
Pretreatment and during treatment: growth on
100 µg/ml of at least 1% of the bacterial population
(Tripathy, 1966; Tripathy et al., in press).
and a specimen of blood was collected 4½ hours
later. The concentration of isoniazid in the serum
was estimated by microbiological assay, using a
vertical diffusion technique similar to that reported
by Lloyd & Mitchison (1964). Fig. 2 illustrates the
tidings in 529 patients in this study. On the basis of
this histogram, patients with concentrations of
0.63 µg/ml or more were classified as slow inactiva-
tors of isoniazid, and those with concentrations
below 0.63 µg/ml as rapid inactivators.
SERIAL ESTIMATIONS OF DRUG CONCENTRATIONS
IN SERUM
IDENTIFICATION TESTS The serum concentration of streptomycin was
estimated by microbiological assay with Staphylo-
The following tests were employed for identifying coccus aureus (Mitchison & Spicer, 1949) and using
cultures as Mycobacterium tuberculosis. horse serum for the standards, that of isoniazid was
Pretreatment : growth at 25°C, pigment production, estimated by the vertical diffusion technique men-
catalase activity (qualitative test) and niacin production. tioned above (after diluting the serum 4-fold with
4% bovine albumen solution) and using water for
During treatment : catalase activity (qualitative test) the standards, and that of pyrazinamide by a
and niacin production. chemical procedure (Subbammal et al., 1968).
RATE! OF INACTIVATION OF ISONIAZID DETERMINATIONS OF THE SGOT AND
The rate of inactivation of isoniazid was deter-
SGPT ACTIVITY
mined after verifying that a urine specimen obtained The SGOT and SGPT activities were determined
immediately before was negative for acetylisoniazid by the procedures described by the Sigma Chemi-
(Eidus & Hamilton, 1964). A test dose of 3 mg/kg cal Company (1961), and the activities are expressed
body-weight of isoniazid was given intramuscularly, in Karmen units.
FIG. 2
DISTRIBUTION OF 529 PATIENTS ACCORDING TO THE LOG. SERUM ISONIAZID CONCENTRATION
4% HOURS AFTER AN INTRAMUSCULAR DOSE OF 3 mg/kg BODY-WEIGHT
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IV. PATIENTS IN ANALYSES AND PLAN OF THE REPORT
NUMBERS IN MAIN AND SUBSIDIARY ANALYSES
In all, 554 patients were admitted to the study.
It was subsequently found that 7 patients failed to
conform to the criteria for admission; 3 had received
previous chemotherapy for more than 2 weeks and
4 did not have 2 positive cultures on admission.
These 7 patients and 5 who had unclassified myco-
bacterial infections, together with 2 who refused
further treatment after just 1 dose of drugs, have not
been considered further in this report.
Cultures resistant to isoniazid or streptomycin
or to both drugs were isolated from 56 patients on
admission. These patients have been excluded from
the main analyses, but their progress is described in
Section XI. No patient has been excluded for
initial resistance to pyrazinamide, since the drug
had scarcely been used in Madras city.
There were 14 patients with no isoniazid inactiva-
tion test result, 8 in phase I, 5 in phase II and 1 in
phase III of the intake. However, for the 6 patients
in phases II and III, the inactivation rate could be
determined from the serum concentrations obtained
after an oral dose of high-dosage isoniazid (page 148).
For the remaining 8 patients, this was not possible
as such investigations had not been undertaken for
patients in phase I. These patients have had to be ex-
cluded from the main analyses, as only statistically
standardized percentages (for isoniazid inactivation
rate and streptomycin dosage) have been employed
in this report when comparing the efficacies of the
various regimens (the reasons for this are given on
page 152); however, their progress is reported on
page 160).
After all these exclusions, 476 patients remained
in the main analyses. All of them had cultures
sensitive to isoniazid and streptomycin on admission,
and had received, as far as is known, no previous
chemotherapy, apart from 34 patients who had
received up to 2 weeks of chemotherapy. The
findings in these 476 patients are presented in
Sections V to X of this paper.
PLAN OF THE REPORT
Comparisons between the SHTW and SHOW
regimens in phases I and II combined are described
in Section V of this report (Fig. l), and this is fol-
lowed by Section VI that describes comparisons
between the SHTW, SH/SHOW, SHZOW and
SHOW regimens in phases II and III combined. The
comparisons between the SHTW, SH/SHOW and
SHZOW regimens are concurrent. However, those
between the SHOW regimen and the above three
regimens are not fully concurrent, since, as stated
earlier, there was no intake to the SHOW regimen in
phase III. Nevertheless, all the comparisons have
been undertaken in phases II and III combined
(thereby greatly simplifying the presentation), as the
number of patients in the main analysis was relatively
small in phase III (75 as compared with 319 in phase
II) and, furthermore, the condition of the patients on
admission (not tabulated here) was similar in the
two phases.
In Sections VII to X the patients from all three
phases are considered together. Section VII deals
in detail with laboratory findings, especially (1)
the influence of streptomycin dosage and iso-
niazid inactivation rate on the pattern of drug-
sensitivity test results, (2) pyrazinamide sensitivity
test results, and (3) the influence of serum drug
concentrations on response to treatment and drug
toxicity. Sections VIII, IX and X, respectively,
describe the prognostic importance of various factors
on admission to treatment, the drug toxicity, and the
regularity of administration of chemotherapy.
The progress of the 56 patients with initial drug
resistance to isoniazid or to streptomycin or both is
described in Section XI and this is followed by a
discussion of the findings (Section XII) and the
conclusions (Section XIII).
V. COMPARISON OF THE SHTW AND SHOW SERIES
CONDITION ON ADMISSION TO TREATMENT for all 240 patients are presented in Table 3; the
average age was 32 years and the mean weight 85 lb
The comparisons in this section are based on (38.6 kg). Further analyses, not tabulated here,
240 patients (123 SHTW, 117 SHOW), of whom showed that the SHTW and SHOW series were
63 % were males. The distributions by age and weight similar in respect of sex, age and weight.
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TABLE 3
DISTRIBUTIONS OF PATIENTS ACCORDING TO
AGE AND WEIGHT ON ADMISSION TO TREATMENT
Patients
Weight (lb) a
<70 40 17
70-79 39 16
80-89 71 30
90-99 49 20
100-109 23 10
> 110 18 8
Total 240 100
a 1 lb = 0.45 kg.
The extent of cavitation and the total extent of
disease were assessed, as described previously
(Tuberculosis Chemotherapy Centre, Madras, 1960),
from a single full-plate postero-anterior radiograph
by an independent assessor, Dr K. V. Krishnaswamy.1
Moderate or extensive cavitation was reported in
80% of the 123 SHTW patients and in 79 % of the
117 SHOW patients (Table 4, Part A), while the
total extent of disease was moderate, extensive or
gross in 71% of the SHTW and 72% of the SHOW
patients. Direct smear examination of the first
collection specimen of sputum yielded a positive
result in 89 % of the SHTW and 90 % of the SHOW
patients, including 50% and 56%, respectively, in
whom it was 3-plus or 2-plus. Among the SHTW
patients 32% were rapid inactivators of isoniazid as
compared with 47% of the SHOW patients, an
unusually large difference (P=0.02). Apart from
this finding, it is clear that the two series were
1 Professor of Tuberculosis, Stanley Medical College;
and Physician and Medical Superintendent, Government
Tuberculosis Sanatorium, Madras, India.
similar on admission. Furthermore, within each
series, the condition on admission was broadly
similar for patients receiving the high dosage of
streptomycin and those receiving the low dosage
(Table 4, Part B), and for the slow and the rapid
inactivators of isoniazid (Table 4, Part C).
STATISTICAL STANDARDIZATION
In view of the dissimilarity between the two series
in the proportions of rapid inactivators of isoniazid,
and the finding that the slow inactivators in the
SHOW series responded appreciably better than the
rapid inactivators (page 160), the results of treatment
needed some adjustment before precise comparisons
could be undertaken. Further, there was a suggestion
that the difference in streptomycin dosage might
have had a slight effect in the SHOW series (page 158).
Consequently, statistical standardization of the
results was undertaken using the “ indirect ” method
(Hill, 1961), and percentages standardized for iso-
niazid inactivation rate and streptomycin dosage
have been employed throughout for comparing the
response to treatment in the two series (except in
Table 8, where standardization was not undertaken
as the numbers were too small). Similarly, for the
comparisons between the streptomycin high-dosage
and the low-dosage groups, percentages standardized
for isoniazid inactivation rate were employed, while
for the comparisons between the slow and the rapid
inactivators of isoniazid, percentages standardized
for streptomycin dosage were employed.
DEATHS 2
Four patients (1 SHTW, 3 SHOW) died of
pulmonary tuberculosis, all with a positive sputum.
Of these, 2 died while on their allocated chemo-
therapy, 1 (SHTW, high, rapid) on the 4th day and
the other (SHOW, high, slow) on the 39th day.
The other 2 (1 SHOW, high, slow; 1 SHOW, low,
rapid) had their chemotherapy changed (to a daily
regimen of streptomycin plus isoniazid) because of
serious clinical deterioration on the 15th and 25th
days, respectively, but died 17 days and 3 days later.
One patient (SHOW, low, slow), all of whose
smears and cultures were negative from the 1st month
onwards, died of an acute respiratory infection,
believed to be pneumonia, in the 4th month. An
autopsy was not performed.
2 The numbers of patients are set out in Table 9.
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T ABLE 4
CONDITION ON ADMISSION TO TREATMENT
Percentage of patients
Part A
(by regimen)
SHTW SHOW
0 1
20 21
49 54
31 25
4 3
25 25
45 42
17 21
9 9
11 10
38 34
33 38
17 17
68 53
32 47
Pa r t  B Part C
(by streptomycin dosage) (by isoniazid inactivation rate)Condition on admission
SHOW SHTW SHOWSHTW
High Low
0 0
22 18
47 51
31 31
High Low Slow Rapid Slow Rapid
2 0
18 24
53 55
27 22
Extent of cavitation:
Nil
Slight
Moderate
Extensive
2 0 0 0
22 19 24 13
52 56 50 46
24 25 26 41
Total extent of disease:
Slight
Limited
Moderate
3 5 3 3 6 0 3 4
31 20 29 20 26 23 24 25
34 54 33 51 46 41 37 47
19 15 26 15 13 26 26 15
12 6 9 10 8 10 10 9
12 1 1
40 37
34 32
14 20
9 12
34 34
40 37
17 17
69 68 48 58
31 32 52 42
14 5 11 9
37 41 34 35
31 38 40 36
18 15 15 20
Gross
Direct smear result of first
collection specimen:
Negative
Positive:
1-plus (scanty)
2-plus(moderate)
3-plus (heavy)
lsoniazid inactivation rate:
Slow
Rapid
123 117 58 65 58 59 84 39 62 55Total no. of patients
TERMINATION OF THE ALLOCATED CHEMOTHERAPY’
Because of radiographic or serious clinical deteriora-
tion in the presence of a positive sputum
If a patient was considered by the Centre’s
physicians to have a definite radiographic extension
of the disease (after the 1st month) in the presence of
a positive sputum, a 10-day course of penicillin was
given. If the lesion persisted or spread, the complete
radiographic series was shown to an independent
assessor (Dr K. S. Sanjivi) 2 who decided whether a
change of chemotherapy was necessary. In all,
5 patients (all SHOW) had their allocated chemo-
therapy terminated on account of radiographic
deterioration, 1 (low, rapid) in the 5th month, 1
(low, rapid) in the 6th month, 1 (high, rapid) in the
7th month and 2 (1 high, rapid; 1 low, slow) in the
11 th month.
Serious clinical deterioration in the presence of a
2  Emeritus Professor of Medicine, Madras Medical
College; and Director of Projects, Voluntary Health Services,
Madras, India.
1 The numbers of patients are set out in Table 9.
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Standardized percentage of patients
Assessment of progress
Radiographic improve-
ment (all grades)
Considerable or
exceptional radiogra-
phic improvement
Cavitation less or
disappeared
Cavitation disappeared
Total no. of patients b
TABLE 5
RADIOGRAPHIC PROGRESS DURING THE 12-MONTH PERIOD a
Part A
(by regimen)
SHTW SHOW
High Low
Part
High Low
96 89 94 97 89 88
76 60 76 77 63 58 76 80 63 56
96
48
91
43
94 98
48 49
92 90
43 39
117 115c 56 61 58c 57
(by streptom
SHTW
B Part C
ycin dosage) (by isoniazid inactivation rate)
SHOW SHTW SHOW
Slow Rapid  Slow
98 94
Rapid
82
98 94 93 87
51 43 44 42
82 35 60c 55
a Assessment on standard radiographs taken on admission to treatment and at 12 months.
b Excluding patients who died of non-tuberculous causes, who dischargedthemselves against medical advice or who had their
allocated chemotherapy terminated on account of toxicity.
c Including 1 patient who had no cavitation initially; she had no cavitation at 12 months either.
positive sputum was regarded as a reason for
terminating the allocated chemotherapy without
recourse to an independent assessor. In addition to
the 2 patients who died after having their chemo-
therapy changed (see above), 2 SHTW patients
(1 high, slow; 1 low, rapid) and 3 SHOW patients
(1 high, slow; 2 low, rapid) had their allocated
chemotherapy terminated for this reason in the 1st
and 8th months and in the 1st, 3rd and 8th months,
respectively.
Because of toxicity
The allocated chemotherapy was terminated in the
5th month for 1 patient (SHTW, low, rapid) on
account of cutaneous hypersensitivity to isoniazid
and streptomycin.
DISCHARGE AGAINST MEDICAL ADVICE 1
Three patients (all SHTW) became uncooperative
and stopped treatment, 1 (low, rapid) in the 3rd
month, 1 (high, slow) in the 6th month and 1 (high,
rapid) in the 11th month; streptomycin toxicity
(giddiness) was a contributory factor in the latter 2
patients.
Three patients, although co-operative, left Madras
for domestic reasons, 1 (SHTW, low, slow) in the
1The numbers of patients are set out in Table 9.
2nd month, 1 (SHOW, low, slow) in the 9th month
and 1 (SHTW, low, rapid) in the 12th month.
RADIOGRAPHIC PROGRESS
Radiographic changes during the 12-month period
were assessed by an independent assessor (Dr
K. V. Krishnaswamy), who was unaware of the
treatment or bacteriological results of any individual
patient. Over-all improvement was shown by 96 % of
the SHTW patients and 89 % of the SHOW patients
(Table 5, Part A), a significant difference (P=0.03).
It was considerable or exceptional in 76 % and 60 %,
respectively (P < 0.01). Further, cavitation became
less or disappeared in 96 % of the SHTW and 91%
of the SHOW patients (P=0.09).
There was no evidence that the difference in
streptomycin dosage influenced the radiographic
response in either series (Table 5, Part B), all the
contrasts between the high-dosage and the low-
dosage patients being clearly non-significant (P > 0.3).
For example, in the SHTW series, over-all improve-
ment was shown by 94 % of the high-dosage patients
and 97 % of the low-dosage patients, while cavitation
became less or disappeared in 94% and 98 %,
respectively. In the SHOW series, the corresponding
proportions were 89 % and 88 %, and 92 % and 90 %,
respectively.
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The rate of inactivation of isoniazid had no effect
on the radiographic response in the SHTW series
(Table 5, Part C), all the contrasts between the slow
and the rapid inactivators being clearly non-signi-
ficant (P > 0.4). In the SHOW series, the proportion
with over-all radiographic improvement was appre-
ciably higher in the slow (93%) than in the rapid
inactivators (82 %), the difference bordering on signi-
ficance (P=0.06); however, all the other contrasts
were clearly non-significant (P > 0.3).
In summary, the radiographic response to treat-
ment was highly satisfactory in the SHTW series and
less satisfactory in the SHOW series. In both the
series, the radiographic response was not influenced
by the difference in streptomycin dosage and, in the
SHTW series, it was not influenced by the isoniazid
inactivation rate. However, in the SHOW series,
there was some evidence that the over-all radio-
graphic progress was slightly more satisfactory in
the slow inactivators.
CULTURE RESULTS
Table 6 sets out the percentages of patients with
a negative culture from a single collection specimen
of sputum at monthly intervals. Considering first the
over-all comparisons between the SHTW and the
SHOW series (Part A of Table 6, and Fig. 3), the per-
centages with a negative culture were similar in the
two series, both at 1 and at 2 months. However, at
3 months, a clear difference emerged between the
two series, the proportions with a negative culture
being 80% for the SHTW and 69% for the SHOW
series (P=0.06). The proportions increased to 88%
and 76%, respectively, at 4 months, a significant
difference (P=0.01), and were 90% and 74%,
TABLE 6
STANDARDIZED PERCENTAGES OF PATIENTS WITH A NEGATIVE CULTURE FROM A SINGLE COLLECTION
SPECIMEN OF SPUTUM
Months after
start of chemotherapy
7-12 (mean)
No. of patients
in analysis (range) a
Part A
(by regimen)
SHTW
1
21
53
80
88
90
90
92
92
92
92
91
92
92
123-113
Part B
(by streptomycin dosage)
SHOW
2
27
55
69
76
79
74
75
76
77
74
75
78
78
117-111
SHTW
High Low
2 1
16 25
49 58
70 88
84 92
84 96
88 90
90 94
90 94
90 94
90 94
88 94
90 94
90 94
58-54 85-59
SHOW
High Low
0 4
26 27
58 52
78 60
83 69
83 74
81 68
82 68
34 68
82 73
77 7 1
81 70
81 75
81 71
53-58 59-55
Part C
(by isoniazid inactivation rate)
SHTW
S l o w Rapid
2 0
21 20
51 58
78 84
88 90
93 86
93 86
93 95      
93 95
93 94
92 94
92 92
92 94
93 94
84-77 39-35
SHOW
Slow Rapid
3 0
27 26
53 58
73 65
80 70
80 76
80 66
81 66
82 67
84 68
81 65
83 65
85 69
82 67
82-57 55-52
a The highest and the lowest number of patients In the analysis at any of the months. Patients who died of non-tuberculous
causes, who discharged themselves against medical advice or who had their allocated chemotherapy terminated on account of
toxicity are excludedthereafter. Patients who died oftuberculosis or who had theirallocated chemotherapy terminated on accountof
radiographic or clinical deterioration are included throughout.
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FIG. 3
STANDARDIZED PERCENTAGES OF PATIENTS WITH A POSITIVE CULTURE
FROM A SINGLE COLLECTION SPECIMEN OF SPUTUM
respectively, at 6 months (P < 0.01); thereafter, they
showed little change, the mean for the period from
month 7 to month 12 being 92% for the SHTW
patients and 76% for the SHOW patients, a highly
significant difference (P < 0.001).
There was no evidence that the difference in
streptomycin dosage affected the culture results in
the SHTW series, the mean culture negativity during
the period from month 7 to month 12 being 90%
for the high-dosage patients and 94% for the low-
dosage patients (Table 6, Part B). In the SHOW
series, however, there was a suggestion that the
high-dosage patients responded slightly better than
the low-dosage patients; thus, the proportions with
a negative culture at 6 months were 81% and 68 %,
respectively (P=0.1), and the values for mean
culture negativity during the period from month 7
to month 12 were 81% and 71%, respectively
(P=0.2).
The rate of inactivation of isoniazid did not
influence the culture results in the SHTW series, the
mean culture negativity during the period from
month 7 to month 12 being 93% for the slow and
94% for the rapid inactivators (Table 6, Part C).
In contrast, in the SHOW series, the slow inactivators
responded more satisfactorily than the rapid
inactivators; thus, 80 % and 66 %, respectively, were
culture-negative at 6 months (P=0.09), while the
mean culture negativity during the period from
month 7 to month 12 was 82% and 67%, respec-
tively, a significant difference (P=0.04).
In summary, culture negativity was attained
considerably more frequently in the SHTW series
than in the SHOW series. The difference in strepto-
mycin dosage hardly affected the culture results in
the SHTW series but appeared to have had some
effect in the SHOW series. The isoniazid inactivation
rate had no effect in the SHTW series, but the slow
inactivators in the SHOW series responded more
satisfactorily than the rapid inactivators.
SENSITIVITY TEST RESULTS
The findings of tests of sensitivity to isoniazid and
streptomycin, at monthly intervals from the 3rd
month onwards, are presented in Tables 7 and 8
(isoniazid sensitivity test results were not available
for 5.1% of the cultures and streptomycin sensitivity
test results for 6.6 %). The comparisons between the
streptomycin high-dosage and the low-dosage groups
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TABLE 7
STANDARDIZED PERCENTAGES OF PATIENTS
WITH DRUG-RESISTANT CULTURES
in each series, and between the slow and the rapid
inactivators of isoniazid, are presented in Section VII
(pages 173 et seq.).
Of the 10 patients who had the allocated chemo-
therapy terminated on account of radiographic or
serious clinical deterioration, 3 had the termination
within 3 months and do not therefore appear in
Tables 7 and 8. In the remaining 7, the last 2 sensi-
tivity test results prior to the termination showed
isoniazid resistance for all and streptomycin resis-
tance for 5. Since the removal of these patients from
the analyses after the termination would result in
underestimates of resistance, it has been assumed (in
Tables 7 and 8) that all 7 patients would have con-
tinued to yield isoniazid-resistant cultures and
5 would have continued to yield streptomycin-
resistant cultures for the rest of the year; for strepto-
mycin-sensitivity analyses, the remaining 2 patients
have been excluded from the time of the termination.
Percentages of patients with resistant cultures
Isoniazid. Resistance to isoniazid occurred more
frequently in the SHOW series, even in the early
months of treatment (Table 7). Thus, at 3 months,
4% of the SHTW patients had a resistant culture as
compared with 17% of the SHOW patients, a
of chemotherapy
Isoniazid-
resistant
Streptomycin-
SHTW SHOW
0 3
2 6
2 13
8 10
5 17
5 16
7 16
7 16
7 16
7 18
118-115
SHTW SHOW
4 17
5 16
4 18
6 16
6 19
6 21
8 19
7 19
7 20
8 19
113-115 111-107
3
4
5
6
7
8
9
10
11
12
No. of patients
in analysis (range) a 110-104
a The highest and the lowest number of patients In the
analysis at any of the months. Patients who died, who dis-
charged themselves against medical advice or who had their
allocated chemotherapy terminated on account of toxicity are
excluded thereafter. The policy for patients who had their
allocated chemotherapy terminated on account of radiographic
or clinical deterioration Is described below.
TABLE 8
PERCENTAGES (UNSTANDARDIZED) OF POSITIVE CULTURES WITH DRUG-RESISTANT BACILLI a
lsoniazid
SHTW patients SHOW patients SHTW patientsMonths after
chemotherapy
Culture-
positive
3 30
4 16
5 11
6 12
7 8
8 8
9 10
10 9
11 11
12 8
SHOW patients
ResistantCulture-
positive No. %
Resistant ResistantResistant
No. %
19 50
18 58
20 67
18 64
24 86
23 82
38
31
30
25
25
26
23
27
24
24
Culture-
positive
30
16
11
12
8
8
10
9
11
a
Culture-
positive
33
31
30
28
27
27
24
28
27
27
No. %b No. %b
4 13
6 (38)
5 (45)
7 (58)
0 0
2 (12)
2 (18)
6 (50)
5
5 69
8
7
8 79
7
4 11
8 26
16 53
12 48
20
19 77
18
18
18 78
21
8
8 38
8
a Patients whose allocated chemotherapy was terminated for deterioration are included subsequently also (and regarded as
having resistant cultures) provided the last 2 sensitivity test results prior to the termination were resistant (see above).
b Parentheses indicate that the percentage is based on fewer than 25 observations.
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highly significant difference (P <0.001). Subse-
quently, the proportions increased slightly, the
figures at 12 months being 8 % and 19 %, respectively
(P <0.01).
Streptomycin. Resistance to streptomycin had not
emerged in any of the SHTW patients by 3 months
but had done so in 3% of the SHOW patients
(Table 7). At 6 months, the proportions with a
resistant culture were 6% in the SHTW series and
10% in the SHOW series; the corresponding
proportions were 7 % and 16 % at 9 months (P=0.04),
and 7 % and 18 % at 12 months (P<0.01).
Percentages of positive cultures with resistant bacilli
Table 8 presents unstandardized percentages of
positive cultures with resistant bacilli, at monthly
intervals from the 3rd month onwards (statistical
standardization of the results was not undertaken on
account of the small numbers of positive cultures
obtained in the SHTW series, especially in the later
months of treatment).
Isoniazid. Resistance to isoniazid emerged more
rapidly in the SHOW series; thus, at 3 months,
13 % of 30 positive cultures in the SHTW series
were resistant as compared with 50% of 38 in the
SHOW series, a significant difference (P <0.01). By
6 months, however, the proportions in the two series
were very similar, being 58% for the SHTW and
64% for the SHOW series. The similarity was
maintained at subsequent months.
Streptomycin. Resistance to streptomycin emerged
more rapidly in the SHOW series. Thus, the
proportions resistant were 0% for the SHTW and
11% for the SHOW series at 3 months, 12 % and 26 %
at 4 months, and 18 % and 53 % at 5 months; these
proportions, however, are based on small numbers
and none of the differences was statistically signi-
ficant. At 6 months and subsequently, the findings
were similar in the two series.
Summarizing the findings in Tables 7 and 8,
resistance to isoniazid and to streptomycin occurred
more frequently and more rapidly in the SHOW
series than in the SHTW series.
CLASSIFICATION OF PATIENTS AT 1 YEAR
ACCORDING TO THEIR RESPONSE TO TREATMENT
Table 9 presents a classification of all the patients
at 1 year, based primarily on the bacteriological
response to treatment.
Over-all efficacies of the two regimens
Of 117 SHTW patients, 100 had bacteriologically
quiescent disease at 1 year, as compared with 75 of
115 SHOW patients (Table 9, Part A). There were
14 patients (7 SHTW, 7 SHOW) who had disease of
bacteriologically doubtful status at 1 year. In view of
the high frequency with which sputum specimens are
collected at the Centre (see page 147), and previous
experience with similar groups of patients (Dawson
et al., 1966; Evans et al., 1969; Ramakrishnan et al.,
1969), these patients also have been regarded as having
a favourable response to treatment; moreover, a
follow-up of the 14 patients (9 of whom received
maintenancechemotherapy in the second year) showed
that all of them had produced only negative cultures
in the 6 months following the single positive culture.
Thus, 91% of the 117 SHTW and 71% of the 115
SHOW patients had a favourable response; the
corresponding proportions after standardization for
isoniazid inactivation rate and streptomycin dosage
were 90 % and 72 %, respectively, the difference being
highly significant (P <0.001) (unstandardized per-
centages are presented in Table 9 in addition to the
standardized percentages in order to illustrate the
size of the changes resulting from statistical stan-
dardization).
In the patients with bacteriologically quiescent
disease at 1 year, there was no evidence (analyses
not tabulated here) that persisting culture negativ-
ity had commenced earlier in the SHTW series.
Thus, in each of the two series, it was attained within
3 months in 64 % of the patients, and within 6 months
in 90 %.
An unfavourable response to treatment occurred
in 10 SHTW and 33 SHOW patients (Table 9). It
should be noted that 8 of 10 patients who had
their allocated chemotherapy terminated for radio-
graphic or serious clinical deterioration and 3 of
4 who died of tuberculosis had received the SHOW
regimen.
In summary, the response to treatment was sub-
stantially better in the SHTW series.
Influence of streptomycin dosage on the response to
treatment
The difference in streptomycin dosage had no
effect on the response to treatment in the SHTW
series, but appears to have had a slight effect in the
SHOW series (Table 9, Part B). Thus, the standard-
ized proportions with a favourable response were
90% in both the high-dosage and the low-dosage
TABLE 9
CLASSIFICATION OF ALL PATIENTS AT 1 YEAR ACCORDING TO THEIR RESPONSE TO TREATMENT
Part B
(by streptomycin dosage)
Part C
(by isoniazid inactivation rate)
Part A
(by regimen)
Classification at 1 year
SHTW SHOW
100
7
No. 107
% 91
Standardized % 90
2
1
10
117
1
5
0
123
75
7
82
71
72
5
17
5
3
3
33
115
0
1
1
117
SHOWSHTW
Slow Rapid
SHTW
High Low
48 52
SHOW
High Low
40 35
3 4
51 56
91 92
90 90
4 3
44 38
76 67
78 67
1 1 4 1
2 3 5 12
0 0 2 3
1 1 1 2
1 0 2 1
5 5 14 19
56 61 58 57
0 1 0 0
2 3 0 1
0 0 0 1
58 65 58 59
Slow Rapid
45 30
4 3
Bacteriologically quiescent disease:
that is, all cultures negative at the last 3 monthly
examinations, i.e., at 10, 11 and 12 months
Disease of bacteriologically doubtful status:
that is, ail cultures negative at 3 or more consecutive monthly
examinations but a single positive culture at 10, 11 or 12 months
Total patients with a
f a v o u r a b l e  r e s p o n s e
Bacteriologically relapsed disease:
that is, ail cultures negative at 3 or more consecutive monthly
examinations but a total of 2 or more positive cultures at IO,
11 and 12 months
Bacteriologically active disease:
that is (1) cultures never ail negative at 3 consecutive monthly
examinations
or (2) termination of allocated chemotherapy on account of
(a) radiographic deterioration
(b) serious clinical deterioration
72 28
3 4
75 32
     91 91
92 91
49 33
82 60
82 60
2 0 0 5
7 10
1 4
1 2
4 1
0 0
1 1
0 1 2 1Tuberculous death
11 227 3Total no. of patients with an unfavourable response
60 55Total no. of patients 82 35
0 1
2 3
0 0
0 0
1 0
1 0
Termination of allocated chemotherapy on account of toxicity
Discharge against medical advice
Non-tubercuious death
62 5584 39Grand total of patients
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patients in the SHTW series; the corresponding
proportions in the SHOW series were 78 % and 67 %,
respectively, a non-significant difference (P =0.2).
In the patients with bacteriologically quiescent
disease at 1 year, there was no evidence (analyses not
tabulated here) that persisting culture negativity had
commenced earlier in the high-dosage patients; thus,
the proportion in whom it was attained within
3 months was 56% for the high-dosage and 71%
for the low-dosage patients in the SHTW series,
and 68 % and 60%, respectively, in the SHOW
series.
Influence of isoniazid inactivation rate on the response
to treatment
The rate of inactivation of isoniazid had no effect
on the outcome of treatment in the SHTW series,
the standardized percentages with a favourable
response being 92% for the slow and 91% for the
rapid inactivators (Table 9, Part C). In the SHOW
series, however, the slow inactivators responded
much more satisfactorily, 82% having a favourable
response as compared with 60% of the rapid
inactivators, a highly significant difference (P <0.01).
In the patients with bacteriologically quiescent
disease at 1 year, there has no evidence (analyses not
tabulated here) that persisting culture negativity had
commenced earlier in the slow inactivators. Thus, it
was attained within 3 months in 64% of the slow
and 64% of the rapid inactivators in the SHTW
series, and in 67 % and 60%, respectively, in the
SHOW series.
Conclusion
The SHTW regimen was highly effective and was
not influenced by differences in isoniazid inactivation
rate and streptomycin dosage. In contrast, the
SHOW regimen was much less effective, and was
considerably influenced by the isoniazid inactivation
rate, and possibly influenced by the streptomycin
dosage. Finally, there was no evidence that persisting
culture negativity commenced earlier in the SHTW
patients, the streptoniycin high-dosage patients or
the slow inactivators of isoniazid.
DISEASE STATUS AT 1 YEAR IN PATIENTS WHO
TOOK THEIR DISCHARGE AGAINST MEDICAL ADVICE
In all, 6 patients (5 SHTW, 1 SHOW) took their
discharge against medical advice (Table 9, Part A);
they have been excluded from the above compari-
sons. However, attempts were made to obtain
sputum specimens from these patients at 12 months,
in order to classify their disease status at 1 year.
Of the 6 patients, 1 (SHTW) died of tuberculosis
in the 8th month, 2 (1 SHTW, 1 SHOW) had
bacteriologically active disease at 1 year, and 1
(SHTW) had 2 positive cultures at 6 months (no
specimens were collected subsequently in the first
year, but 7 of 8 cultures obtained at 15, 16 and 17
months were positive). These 4 patients, who stop-
ped treatment in the 3rd, 6th, 9th and 2nd month,
respectively, may be regarded as having an un-
favourable disease status at 1 year. Two patients
(both SHTW), who had stopped treatment in the
11th and 12th month, respectively, had all of
5 cultures negative during the period from month 10
to month 12; neither had had a history of treatment
subsequent to the discharge and both may be
regarded as having a favourable disease status at
1 year.
If the 6 patients are included in the comparison of
the therapeutic efficacies of the regimens, the pro-
portion with a favourable disease status at 1 year
becomes 89 % for the SHTW series and 71% for the
SHOW series, the corresponding standardized pro-
portions being 88 % and 72 %, respectively.
RESPONSE TO TREATMENT OF PATIENTS WHOSE
RATE OF INACTIVATION OF ISONIAZID WAS NOT KNOWN
As mentioned on page 151, the rate of inactivation
of isoniazid was not known for 8 patients (1 SHTW,
7 SHOW), all of whom were therefore excluded
from the main analyses. Of these, 7 (all SHOW) had
died by the time the decision was made to undertake
isoniazid inactivation tests in phase I patients
(see page 148), and 1 patient (SHTW) refused the
test. The response of these patients to the allocated
chemotherapy is considered below.
The SHTW patient (high) had bacteriologically
quiescent disease at 1 year. Of the 7 SHOW patients,
1 (low) died of tuberculosis on the 16th day,
4 (2 high, 2 low) had bacteriologically active or
relapsed disease and 1 (high) had bacteriologically
quiescent disease at 1 year; the 7th patient (low)
died of a non-tuberculous cause, believed to be
agranulocytosis, in the 3rd month, having had all
smears and cultures negative at 2 months. If the
7 patients (1 SHTW, 6 SHOW) with an assessable
response (that is, the non-tuberculous death apart)
are amalgamated with those in the main analyses, the
unstandardized proportions with a favourable re-
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sponse become 92 % of 118 in the SHTW series and high-dosage patients and 92% of 61 in the low-
69% of 121 in the SHOW series; the corresponding dosage patients in the SHTW series, and 74% of 61
unstandardized proportions are 91% of 57 in the and 63% of 60, respectively, in the SHOW series.
VI. COMPARISONS BETWEEN THE SHTW, SH/SHOW, SHZOW AND SHOW SERIES
CONDITION ON ADMISSION TO TREATMENT
The comparisons in this section are based on
394 patients (104 SHTW, 106 SH/SHOW, 105
SHZOW, 79 SHOW), of whom 66% were males.
The distributions by age and by weight were closely
similar to those in Table 2, the average age of the
patients being 33 years and the mean weight 86 lb
(39.1 kg). Analyses, not tabulated here, showed that
the four individual series were similar in respect of
sex, age and weight.
Considering the radiographic and bacteriological
condition on admission in the four series (Table 10,
Part A), moderate or extensive cavitation was
present in 80% of the 104 SHTW, 89 % of the
106 SH/SHOW, 87 % of the 105 SHZOW and 80 % of
the 79 SHOW patients, while the total extent of
disease was moderate, extensive or gross in 75%,
75 %, 70% and 76%, respectively. Direct smear
examination of the first collection specimen of
sputum yielded a positive result in 88% of the
SHTW, 90 % of the SH/SHOW, 90 % of the SHZOW
and 90% of the SHOW patients, including 62%,
67 %, 64% and 67 %, respectively, in whom it was
3-plus or 2-plus. Lastly, 37% of the SHTW, 37%
of the SH/SHOW, 33% of the SHZOW, and
49% of the SHOW patients were rapid inactiva-
tors of isoniazid; the difference between the SHZOW
and the SHOW series is unusually large (P=0.04).
Apart from this finding, it is clear that the four
series of patients were similar on admission.
Within each of the four series, the condition on
admission of the streptomycin high-dosage patients
was broadly similar to that of the streptomycin
low-dosage patients (Table 10, Part B), apart from
one exception; this was in the SHOW series, where
62% of the high-dosage patients were rapid
inactivators of isoniazid as compared with 38% of
the low-dosage patients (P = 0.06). Considering next
the comparisons between the slow and the rapid
inactivators of isoniazid in each series (Table 10,
Part C), all the differences were non-signficant in the
1 For the implications of this difference on the classifica-
tion at 1 year according to the response to treatment, see
footnote on page 172.
SHTW, SH/SHOW and the SHOW series. However,
in the SHZOW series, there was some evidence that
rapid inactivators had a larger bacterial content in
the sputum; 1 thus, 86% had a 2-plus or 3-plus
smear result from the first collection specimen as
compared with 53% of the slow inactivators
(P <0.01). 2
STATISTICAL STANDARDIZATION
In view of the dissimilarities between the series in
the proportions of rapid inactivators of isoniazid,
and the finding that the slow inactivators in the
SH/SHOW, SHZOW and SHOW series responded
appreciably better than the rapid inactivators
(page 172), the results of treatment needed some
adjustment before precise comparisons between the
series could be undertaken. Further, there was a
suggestion that the difference in streptomycin dos-
age might have had a slight effect in the SH/SHOW
and the SHOW series (page 169). Consequently,
statistical standardization of the results was under-
taken using the “ indirect ” method (Hill, 1961), and
percentages standardized for isoniazid inactivation
rate and streptomycin dosage have been employed
throughout for comparing the response to treatment
in the four series (except in Table 14, where standard-
ization was not undertaken as the numbers were too
small). Similarly, for the comparisons between the
streptomycin high-dosage and the low-dosage
groups, percentages standardized for isoniazid
inactivation rate were employed, while for those
between the slow and the rapid inactivators of
isoniazid, percentages standardized for streptomycin
dosage were employed.
DEATHS 3
Six patients (1 SHTW, 2 SHZOW, 3 SHOW) died
of pulmonary tuberculosis, all with a positive
2 Analyses of the results of the second collection specimen
confirmed this finding, the corresponding proportions being
83 % for the rapid and 59 % for the slow inactivators (P =
0.02).
3 The numbers of patients are set out in Table 15.
TABLE 10
CONDITION ON ADMISSION TO TREATMENT
Percentage of patients
Part A Part B
(by regimen) (by streptomycin dosage)
Part C
(by isoniazid inactivation rate)
Condition on admission
SHTW
0
20
50
30
5
20
55
12
9
12
26
40
22
63
37
104
SH/
SHOW SHZOW SHOW
SHTW
High Low
SH/SHOW SHZOW
High Low High Low
SHOW SH/SHOW SHZOW SHOW
High Low
SHTW
Slow Rapid Slow Rapid Slow Rapid Slow Rapid
0 1 0 0 0 0 0 2 0 0 0 0 0 0 0 1 0 0 0
11 12 20 22 19 8 15 10          15 26 15 24 13 12 10 14 9 18 23
51 51 53 53 47 52 50 49 54 49 58 48 53 51 51 51 51 52 54
 38 35 27 25 34 40 35 39 31 26 28 27 34 37 38 33 40   30 23
4 1 6 4 0 2 2 6 0 2 8 0 1 0 6 0 2 0
27 23 24 17 19 28 25 28 28 18 23 16 27 18 26 29 15 31
38 44 45 64 44 31 35 41 36 52 55 55 36 41 36 43 42 46
28 22 14 9 27 35 33 22 23 20 8 18 30 33 30 23 30 13
4 10 12 6 10 4 4 4 13 8 8 11 6 8 3 a IO IO
10 10 12 11 10 11 10 11 14 8 10 10 16 0 15 5
26 23 27 25 21 24 25 26
39 43 39 42 44 41 41 37
25 24 22 23 25 24 24 26
8 12
23 22
44 42
26 22
24 29 19 28 31 14 20 25
38 45 48 33 29 60 42 44
24 18 22 28 24 26 22 26
63 67
37 33
51
49
79
65 62 63 63 71 63
35 38 37 37 29 37
38 62
62 38
105 105 51 53 52 54 51 54 39 40 66 38 67 39 70 35 40 39
Extent of cavitation:
Nil
Slight
Moderate
Extensive
Total extent of disease:
Slight
Limited
Moderate
Extensive
Gross
Direct smear result of first
collection specimen:
Negative
Positive:
1-plus (scanty)
2-plus (moderate)
3-plus (heavy)
Isoniazid inactivation rate.
Slow
Rapid
Total no. of patients
TWICE-WEEKLY AND ONCE-WEEKLY REGIMENS IN THE TREATMENT OF TUBERCULOSIS 163
sputum: Of these, 4 (1 SHTW, high, rapid;
1 SHZOW, high, rapid; 1 SHZOW, low, slow;
1 SHOW, high, slow) died while on their allocated
chemotherapy, the deaths occurring on the 4th, 6th,
12th and 39th days, respectively. The other 2
(1 SHOW, high, slow; 1 SHOW, low, rapid) had
their chemotherapy changed (to daily streptomycin
plus isoniazid) for serious clinical deterioration on
the 15th and 25th days, respectively, but died 17 and
3 days later.
Three patients (1 SHTW, 1 SH/SHOW, 1 SHOW)
died of non-tuberculous causes. The SHTW patient
(high, slow) committed suicide (following a domestic
quarrel) in the 8th month, the SH/SHOW patient
(low, rapid) died of intestinal obstruction in the
6th month, and the SHOW patient (low, slow) died
of an acute respiratory infection, believed to be
pneumonia, in the 4th month. These patients had all
smears and cultures negative from the 2nd, 2nd and
1st month onwards, respectively. An autopsy was
not performed on any of the patients.
TERMINATION OF THE ALLOCATED CHEMOTHERAPY 1
Because of radiographic or serious clinical deteriora-
tion in the presence of a positive sputum
Eleven patients (6 SHZOW, 5 SHOW) had their
allocated chemotherapy terminated on account of
radiographic deterioration. For the 6 SHZOW
patients, this was in the 6th month in 1 (high, slow),
8th month in 1 (high, slow), 9th month in 2 (both
low, rapid), 10th month in 1 (low, slow), and
12th month in 1 patient (high, slow). For the
5 SHOW patients, the month of termination was the
5th in 1 (low, rapid), 6th in 1 (low, rapid), 7th in 1
(high, rapid) and 11th in 2 patients (1 high, rapid;
1 low, slow).
In addition to the 2 patients who died after having
their chemotherapy changed (see above), there were
2 patients who had their allocated chemotherapy ter-
minated on account of serious clinical deterioration,
one (SHZOW, low, rapid) in the 8th month, and the
other (SHOW, high, slow) in the 1st month.
Because of toxicity
Three patients had their allocated chemotherapy
terminated on account of toxicity, 1 (SHTW, low,
rapid) in the 5th month for cutaneous hypersensiti-
vity to isoniazid and streptomycin, and the other 2
(1 SHTW, high, rapid; 1 SH/SHOW, high, slow)
in the 11th and 9th month, respectively, for vesti-
bular toxicity.
DISCHARGE AGAINST MEDICAL ADVICE 1
Nine patients (3 SHTW, 2 SH/SHOW, 4 SHZOW)
became uncooperative and stopped treatment,
2 (1 SHTW, low, rapid; 1 SHZOW, low, slow) in the
3rd month, 3 (1 SH/SHOW, low, rapid; 1 SHZOW,
low, slow; 1 SHZOW, low, rapid) in the 4th month,
1 (SHTW, high, slow) in the 6th month, 1 (SH/
SHOW, low, slow) in the 10th month and 2 (1 SHTW,
high, rapid; 1 SHZOW, high, slow) in the 11th
month; streptomycin toxicity (giddiness) was a
contributory factor in 2 of these patients (1 SHTW,
high, slow; 1 SHTW, high, rapid).
Four patients, although co-operative, left Madras
for domestic reasons, 1 (SHTW, low, slow) in the
2nd month, 1 (SH/SHOW, high, slow) in the 8th,
1 (SHOW, low, slow) in the 9th, and 1 (SHTW, low,
rapid) in the 12th month.
RADIOGRAPHIC PROGRESS
Radiographic changes during the 12-month period,
as reported by the independent assessor, are set out
in Table 11. Over-all improvement was shown by
99 % of 96 SHTW patients, 100% of 101 SH/SHOW,
90 % of 101 SHZOW and 86 % of 77 SHOW patients
(Part A). It was considerable or exceptional in 79 %,
73 %, 65 % and 57%, respectively; three of the
contrasts were statistically significant-namely, those
between the SHTW and SHZOW (P=0.02), the
SHTW and SHOW (P<0.01), and the SH/SHOW
and SHOW regimens (P=0.02). Cavitation became
less or disappeared in 99% of the SHTW, 100% of
the SH/SHOW, 91% of the SHZOW and 88 % of the
SHOW patients; the differences between the SHTW
or the SH/SHOW series on the one hand and the
SHZOW or the SHOW series on the other hand
were all statistically significant (P <0.01). Thus, the
radiographic response to treatment was similar and
highly satisfactory in the SHTW and the SH/SHOW
series, and less satisfactory but similar in the
SHZOW and the SHOW series.
Considering differences in streptomycin dosage
and isoniazid inactivation rate, there was little
evidence that these influenced the radiographic re-
sponse in any of the four series (Table 10, Parts B
and C). Combining the findings in the four series,
over-all radiographic improvement was observed in
94% of 186 high-dosage patients and 95 % of
189 low-dosage patients, including 71% and 68 %,
1 The numbers of patients are set out in Table 15.
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respectively, in whom it was classified as considerable
or exceptional; further, in both the groups, cavitation
became less or disappeared in 95% of the patients.
(These proportions were obtained by standardizing
for isoniazid inactivation rate, and by weighting
appropriately (Snedecor, 1956) on the basis of the
numbers of high-dosage and low-dosage patients in
each of the four series.) The radiographic response
was also similar in the slow and the rapid inactivators
of isoniazid. Thus, 95% of 232 slow inactivators
showed over-all improvement as compared with
92 % of 143 rapid inactivators, including 69 % in each
group with considerable or exceptional improve-
ment ; cavitation became less or disappeared in 96 %
and 93 %, respectively. (These proportions were
obtained by standardizing for streptomycin dosage,
and by weighting appropriately on the basis of the
numbers of slow and rapid inactivators in each of
the four series.)
In summary, the radiographic response to treat-
ment was highly satisfactory in the SHTW and the
SH/SHOW series, and less satisfactory in the
SHZOW and the SHOW series. There was little
evidence that it was influenced by differences in
streptomycin dosage or isoniazid inactivation rate.
CULTURE RESULTS
Table 12 sets out the percentages of patients with
a negative culture from a single collection specimen
of sputum at monthly intervals. Considering first the
over-all comparisons between the four series (Part A
of Table 12, and Fig. 4) the percentages with a nega-
tive culture were broadly similar in the four series,
both at 1 and at 2 months. However, at 3 months, a
clear difference emerged between the SHTW or the
SH/SHOW series on the one hand, and the SHZOW
or the SHOW series on the other hand. Thus,
84% of the SHTW and 86% of the SH/SHOW
patients were culturenegative, as compared with
73 % of the SHZOW and 65 % of the SHOW patients,
the ‘difference between each of the former two and
each of the latter two regimens being statistically
significant (P<0.05). The proportions increased to
94 %, 89 %, 81% and 71%, respectively, at 6 months,
and showed little change thereafter. Thus, the mean
value for the period from month 7 to month 12 was
95 % for the SHTW, 91% for the SH/SHOW, 80 %
for the SHZOW and 72 % for the SHOW series. The
difference between the SHTW and the SH/SHOW
series was neither large nor significant (P = 0.1), and
this was also the case with the difference between the
TABLE 12
STANDARDIZED PERCENTAGES OF PATIENTS WITH A NEGATIVE CULTURE FROM A SINGLE COLLECTION SPECIMEN OF SPUTUM
Months after
chemotherapy
7-12 (mean)
No. of patients
in analysis (range) a
SHTW
96
96
95
94
94
95
95
104-93
-
Part A
(by regimen)
SHOW
SHTW
SH/SHOW SHZOW
SH/SHOW SHZOW SHOW
High Low High Low High Low High Low
2 2 2 2 2 2 2 2 0 5
25 29 18 25 29 20 20 37 26 27
59 63 59 63 54 63 62 63 54 54
86 73 78 90 86 87 68 77 71 60
93 74 86 94 94 92 73 75 76 67
87 76 86 98 90 85 73 78 79 72
89 81 91 96 90 88 79 82 79 64
92 80 93 98 92 91 76 84 76 66
93 76 93 98 94 91 75 78 80 64
92 82 93 97 96 88 79 84 76 70
92 78 93 95 94 90 77 80 74 64
89 76 90 98 92 85 76 76 76 68
91 77 93 97 92 89 76 78 75 73
91 80 93 97 92 89 77 82 77 67
3
27
54
65
71
75
71
70
72
73
69
72
74
72
106-99 105-96 79-74 51-46 53-47 52-48 54-49 51-47 54-47 39-37 40-36
Part B
(by streptomycin dosage)
SHTW
Slow Rapid
3 0
20 24
55 70
83 86
92 86
94 89
94 94
SH/SHOW SHZOW
Slow Rapid Slow Rapid
1  3 1 3
19 33 38 11
61 55 70 48
88 84 81 57
97 87 86 53
91 82 86 56
93 84 88 68
SHOW
Slow Rapid
5 0
27 26
50 59
67 62
71 68
74 74
76 65
97 94 95 86 87 68 76 63
97 94 95 89 88 55 77 64
97 94 95 86 88 71 77 67
97 91 95 86 88 62 74 61
97 91 95 78 88 56 78 61
97 94 95 83 86 62 81 63 
97 94 94 85 89 63 77 64
66-59 39-33 67-62 39-35 70-63 35-32 40-35 39-36
a The highest and the lowest number of patients in the analysis at any of the months. Patients who died of non-tuberculous causes, who discharged themselves
against medical advice or who had their allocated chemotherapyterminated on accountof toxicity are excluded thereafter. Patients who died of tuberculosis or who had their
allocated chemotherapy terminated on account of radiographic or clinical deterioration are included throughout.
Part C
(by isoniazid Inactivation rate)
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FIG. 4
STANDARDIZED PERCENTAGES OF PATIENTS WITH A POSITIVE CULTURE
FROM A SINGLE COLLECTION SPECIMEN OF SPUTUM
SHZOW and the SHOW series (P=0.2); however,
the response in both the SHTW and the SH/SHOW
series was significantly superior to that in the
SHZOW and the SHOW series (SHTW-SHZOW,
P <0.0001 ; SHTW-SHOW,P <0.00001 ; SH/SHOW-
SHZOW, P=0.01 ; SH/SHOW-SHOW, P <0.001).
There was no evidence that the difference in
streptomycin dosage affected the culture results in
the SHTW, SH/SHOW or the SHZOW series
(Table 12, Part B). Thus, the mean culture negativity
during the period from month 7 to month 12 was
93 % for the high-dosage patients and 97 % for the
low-dosage patients in the SHTW series, the corre-
sponding proportions being 92% and 89 % in the
SH/SHOW series, and 77 % and 82 % in the SHZOW
series. In the SHOW series, however, there was a
slight suggestion that the high-dosage patients re-
sponded slightly better than the low-dosage patients,
the percentages with a negative culture at 6 months
being 79% and 64%, respectively (P=0.2), and the
mean culture negativity from month 7 to month 12
being 77 % and 67 %, respectively (P=0.4).
There was no evidence that the rate of inactivation
of isoniazid influenced the culture results in the
SHTW series (Table 12, Part C), the mean culture
negativity between month 7 and month 12 being
97 % for the slow inactivators and 94 % for the rapid
inactivators (P=0.5). In contrast, in all the other
series, there was some evidence that the slow in-
activators responded better than the rapid inactiva-
tors. Thus, the mean culture negativity between
month 7 and month 12 was 94% for the slow
inactivators and 85% for the rapid inactivators in
the SH/SHOW series (P=0.1), 89% and 63%,
respectively, in the SHZOW series (P=0.001), and
77% and 64%, respectively, in the SHOW series
(P=0.2).
In summary, culture negativity was attained most
frequently in the SHTW series, only slightly less
frequently in the SH/SHOW series, and appreciably
less frequently in the SHZOW and the SHOW series.
The difference in streptomycin dosage hardly
affected the culture results in the SHTW, SH/SHOW
and the SHZOW series, but may have had a slight
effect in the SHOW series. The rate of inactivation of
isoniazid had little effect in the SHTW series, but
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there was some evidence that the slow inactivators in
the SH/SHOW, SHZOW and the SHOW series
responded better than the rapid inactivators.
SENSITIVITY TEST RESULTS
The findings of tests of sensitivity to isoniazid and
streptomycin, at monthly intervals from the 3rd
month onwards, are presented in Tables 13 and 14
(isoniazid sensitivity test results were not available
for 3.7 % of the cultures and streptomycin sensitivity
test results for 5.8 %). The comparisons between the
high-dosage and the low-dosage groups in each
series, and between the slow and the rapid in-
activators, are described in Section VII (page 173 et
seq.), as also are all the findings of pyrazinamide
sensitivity tests.
Of the 13 patients who had the allocated chemo-
therapy terminated on account of radiographic or
serious clinical deterioration, 1 had the termination
within 3 months and does not therefore appear in
Tables 13 and 14. In the remaining 12, the last
2 sensitivity test results prior to the termination
showed isoniazid-resistance for all and streptomycin-
resistance for 7. Consequently, for the reason stated
earlier (page 157), it has been assumed in Tables 13
and 14 that all 12 patients would have continued to
yield isoniazid-resistant cultures and that 7 would
have continued to yield streptomycin-resistant cul-
tures for the rest of the year; for streptomycin-
sensitivity analyses, the remaining 5 patients have
been excluded from the time of the termination.
Percentage of patients with resistant cultures
Isoniazid. Resistance to isoniazid occurred more
frequently in the SHZOW and the SHOW series than
in the SHTW and the SH/SHOW series, even in the
early months of treatment. Thus, at 3 months,
2% of the SHTW and 3 % of the SH/SHOW
patients yielded a resistant culture, as compared with
11% of the SHZOW and 19% of the SHOW
patients (Table 13), the differences between each of
the former two and each of the latter two series being
statistically significant (P < 0.02). Thereafter, the
proportions increased slightly in all four series, the
figures at 12 months being 5% for the SHTW,
TABLE 13
STANDARDIZED PERCENTAGES OF PATIENTS WITH DRUG-RESISTANT CULTURES
chemotherapy
3
4
5
6
7
8
9
10
11
12
No. of
patients in
analysis
(range) a
SHTW
2
3
4
5
4
4
5
5
5
5
100-95
Isoniazid-resistant
SW
SHOW SHZOW SHOW
3 11 19
3 13 20
4 13 21
5 12 20
5 14 23
5 15 24
6 14 23
7 14 19
7 16 23
9 16 22
105-99 102-97 74-70
Streptomycin-resistant
SHTW
0
2
2
4
4
4
4
4
6
4
100-95
SW
SHOW
2
1
4
2
4
5
8
5
6
8
105-98 
SHZOW
6
11
10
10
12
13
15
14
10
15
102-93
SHOW
5
9
12
1 1
17
18
17
16
16
19
74-67
a The highest and the lowest number of patients in the analysis at any of the months. Patients
who died, who discharged themselves against medical advice or who had their allocated chemo-
therapy terminated on account of toxicity are excluded thereafter. The policy for patients who had
their allocated chemotherapy terminated on account of radiographic or clinical deterioration is
described above.
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9% for the SH/SHOW, 16% for the SHZOW and
22% for the SHOW patients; the differences were
significant in three of the comparisons–namely
those between SHTW and SHZOW (P=0.02),
SHTW and SHOW (P <0.001), and SH/SHOW and
SHOW (P=0.01).
Streptomycin. Resistance to streptomycin occurred
more frequently in the SHZOW and the SHOW
series than in the SHTW and the SH/SHOW series,
especially from the 4th month onwards, at which
time the proportion of patients with a resistant cul-
ture was 2% for the SHTW, 1% for the SH/SHOW,
11% for the SHZOW and 9% for the SHOW series
(Table 13); the differences between each of the
former two and each of the latter two regimens were
significant (P < 0.03). The corresponding propor-
tions at 12 months were 4 %, 8 %, 16 % and 19 %,
respectively; three of the differences were significant
–namely, those between SHTW and SHZOW
(P<0.01), SHTW and SHOW (P=0.001), and
SH/SHOW and SHOW (P=0.02).
Percentage of positive cultures with resistant bacilli
Table 14 presents unstandardized percentages of
positive cultures with resistant bacilli, at monthly
intervals from the 3rd month onwards (statistical
standardization of the results was not undertaken on
account of the small number of positive cultures
obtained in the SHTW and the SH/SHOW series,
especially in the later months of treatment).
Isoniazid. Resistance to isoniazid emerged more
rapidly in the SHZOW and the SHOW series than
in the SHTW and the SH/SHOW series. Thus, at
3 months, 10% of 21 positive cultures in the SHTW
series and 16% of 19 in the SH/SHOW series were
resistant, as compared with 35% of 31 in the
SHZOW and 47% of 30 in the SHOW series. Sub-
sequently, the increase was substantial in the SHTW
series, less substantial in the SH/SHOW series, and
even smaller in the SHZOW and the SHOW series.
For months 10, 11 and 12, combined the proportions
resistant were 94% in the SHTW series, 72% in the
SH/SHOW series, 65% in the SHZOW series and
85% in the SHOW series.
Streptomycin. At 3 months, none of 21 positive
cultures in the SHTW series was streptomycin-
resistant as compared with 11% of 19 in the
SH/SHOW, 19 % of 31 in the SHZOW and 13 % of 30
in the SHOW series; the corresponding proportions
for months 4, 5 and 6 combined were 32%, 19%,
41% and 42 %, respectively. These findings indicate
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that resistance to streptomycin emerged more rapidly
in the SHZOW and the SHOW series than in the
SHTW and the SH/SHOW series. For months 10,
11 and 12 combined, the proportions resistant were
76% in the SHTW series, 61% in the SH/SHOW,
64% in the SHZOW and 79% in the SHOW series.
Summarizing the findings in Tables 13 and 14,
resistance to isoniazid and streptomycin occurred
more frequently and more rapidly in the SHZOW
and the SHOW series than in the SHTW and the
SH/SHOW series.
CLASSIFICATION OF PATIENTS AT 1 YEAR
ACCORDING TO THEIR RESPONSE TO TREATMENT
Table 15 presents a classification of all the patients
at 1 year, based primarily on the bacteriological
response to treatment.
Over-all efficacies of the four regimens
Of 96 SHTW patients, 86 had bacteriologically
quiescent disease at 1 year, as compared with 86 of
101 SH/SHOW, 73 of 101 SHZOW and 49 of
77 SHOW patients (Table 15, Part A). There were
13 patients (5 SHTW, 3 SH/SHOW, 3 SHZOW,
2 SHOW) who had disease of bacteriologically
doubtful status at 1 year; these also have been re-
garded as having a favourable response to treatment,
for reasons stated earlier (page 158). [A follow-up of
these 13 patients (9 of whom received maintenance
chemotherapy in the second year) showed that 12
had produced only negative cultures in the 6 months
following the single positive culture; in the remain-
ing patient, the single positive culture occurred at
12 months and proved to be the commencement of
a bacteriological relapse.] In all, therefore, 91 (95 %)
of the SHTW patients, 89 (88 %) of the SH/SHOW,
76 (75 %) of the SHZOW and 51(66 %) of the SHOW
patients had a favourable response. The correspond-
ing percentages, after standardization for isoniazid
inactivation rate and streptomycin dosage, were
94 % for the SHTW, 88 % for the SH/SHOW, 74 %
for the SHZOW and 68 % for the SHOW series. The
difference between the SHTW and the SH/SHOW
series was small and not significant (P=0,1), as
was the difference between the SHZOW and the
SHOW series (P=0.4). However, the response in
both the SHTW series and the SH/SHOW series was
significantly superior to that in the SHZOW series
and the SHOW series (SHTW-SHZOW, P =0.00001 ;
SHTW-SHOW, P = 0.00001; SH/SHOW-SHZOW,
P<0.01 ; SH/SHOW-SHOW, P < 0.01).
Considering next the speed of sputum conversion
in patients with bacteriologically quiescent disease
at 1 year (analyses not tabulated here), persisting
culture negativity was attained within 6 months in
93 % of the SHTW patients, 91% of the SH/SHOW,
97 % of the SHZOW and 95 % of the SHOW patients,
including 69 %, 75 %, 76 % and 60 %, respectively, in
whom it was attained within 3 months; none of the
differences was statistically significant. Thus, in
patients with bacteriologically quiescent disease at
1 year, there was no evidence that sputum conversion
had occurred earlier with the more effective regimens.
An unfavourable response to treatment occurred
in 5 SHTW, 12 SH/SHOW, 25 SHZOW and
26 SHOW patients (Table 15). It should be noted
that all 13 patients who had their allocated chemo-
therapy terminated for radiographic or serious
clinical deterioration, and 5 of 6 who died of tubercu-
losis, had received either the SHZOW or the SHOW
regimen, that is once-weekly chemotherapy from the
very beginning. Next, it is of interest that of the
12 SH/SHOW patients who had an unfavourable
response, 6 (50%) had had a sputum conversion
followed by a bacteriological relapse in the first year;
the corresponding proportions were 0 of 5 in the
SHTW, 2 of 25 in the SHZOW and 4 of 26 in the
SHOW series.
In summary, the response to treatment was similar
and highly satisfactory in the SHTW and the
SH/SHOW series, and appreciably less satisfactory
but similar in the SHZOW and the SHOW series.
Influence of streptomycin dosage on the response to
treatment
Amalgamating all four series, 153 (82 %) of 186
high-dosage patients had a favourable response to
treatment, as compared with 154 (81%) of 189 low-
dosage patients. The corresponding percentages,
standardized for isoniazid inactivation rate and
weighted appropriately on the basis of the numbers
of high-dosage and low-dosage patients in each of the
four series, were also similar-namely, 83 % and
81%, respectively.
Considering the findings (standardized percent-
ages) in the individual series (Table 15, Part B),
93 % of the high-dosage patients in the SHTW series
had a favourable response as compared with 95 % of
the low-dosage patients; the corresponding propor-
tions were 92% and 84% in the SH/SHOW series,
70 % and 78 % in the SHZOW series, and 74 % and
63 % in the SHOW series. Thus, the proportion was
higher in the high-dosage patients in two of the
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TABLE
CLASSIFICATION OF ALL PATIENTS AT 1 YEAR
Part A
(by regimen)
Part
(by streptomycin
SH/SHOW
High Low
Classification at 1 year
- -
SHTW
SH/
SHOW
86
3
89
88
88
SHTW
86
5
91
95
94
SHZOW
73
SHOW
49
High Low
43 43
Bacteriologically quiescent disease:
that is, all cultures negative at the last 3 monthly
examinations, i.e., at 10, 11 and 12 months
Disease of bacteriologically doubtful status:
that is, all cultures negative at 3 or more con-
secutive monthly examinations but a single
positive culture at 10, 11 or 12 months
46 40
0 33 2 1 4
76
75
74
51
66
68
44 47
94 96
93 95
46
92
92
43
84
84
Total patients with a
favourable response
No.
%
Standardized %
Bacteriologically relapsed disease:
that is, all cultures negative at 3 or more con-
secutive monthly examinations but a total of
2 of more positive cultures at 10, 11 and 12 months
0 0 0 1 56 2
6 14
0
0
0
12
6
1
2
25
3 3
0 0
0 0
Bacteriologically active disease:
that is, (1) cultures never all negative at 3
consecutive monthly examinations
or (2) termination of allocated chemo-
therapy on account of
(a) radiographic deterioration
(b) serious clinical deterioration
Tuberculous death
Total no. of patients with an unfavourable
response
2 2
0 0
0 0
1 0 0 0
26 3 2 4 8
Total patients 96 101 101 77 47 49 50 51
Termination of allocated chemotherapy on
account of toxicity
Discharge against medical advice
Non-tuberculous death
0 1 1
4 2 3 1 2
0 10 1 0
Grand total of patients 104 106 79 51 53 52 54
a See footnote on page 172.
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 ACCORDING TO THEIR RESPONSE TO TREATMENT
Part C
(by lsoniazid inactivation rate)
SHZOW SHOW SHTW SH/SHOW SHZOW SHOW
Slow Rapid
29 20
Slow RapidSlow Rapid Slow RapidHigh Low High Low
36 37 25 24
0 3 2 0
36 40 27 24
72 78 69 63
70 78 74 63
1 1 3 1
60 26 59 27 56 17
2 1 2 1
58 18
87 53
87 a 53 a
0 2
29 22
76 56
76 56
1 4
61 30
97 91
97 91
61 28
95 76
95 76
0 0 2 4 0 2 0 4
9 5 4 9 2 2 1 5 4 10 5 8
4 2
0 1
1 4
1 0
0 0
0 0
0 0
0 0
3 3 2 3
0 1 1 0
0 1 0 0 1 1 2 11 1 2 1
9 16 9 1714 11 12 14 2 3 3 9
50 51 39 38 63 33 64 37 67 34 38 39
0 0 0 0 0 2 1 0 0 0 0 0
2 3 2 1 3 1 1 01 3 0 1
0 0 0 1 1 0 0 1 0 0 1 0
66 38 67 39 70   35 40 3951 54 39 40
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series but lower in the other two; further, the differ- lated here) that ‘persisting culture negativity had
ence was not statistically significant in any of the four commenced earlier in the slow inactivators. Thus,
series (P > 0.2). Also, the variation between the combining all four series, it was attained within
four series in the difference in response between the 6 months in 94 % of the slow inactivators and 92 % of
high-dosage and the low-dosage patients (that is the the rapid inactivators, including 71% and 67%,
interaction between streptomycin dosage and chemo-
therapeutic regimen) was non-significant (P=0.2).
In patients with bacteriologically quiescent disease at
1 year, there was no evidence (analyses not tabulated
here) that persisting culture negativity had com-
menced earlier in the high-dosage patients. Thus,
combining all four series, it was attained within
6 months in 93% of the high-dosage patients and
94% of the low-dosage patients, including 71% and
71%, respectively, in whom it was attained within
3 months (these proportions are standardized and
weighted, as above). Considering the findings in the
individual series, the corresponding proportions with
sputum conversion by 3 months were 68 % and 70 %
in the SHTW series, 68 % and 82 % in the SH/SHOW
series, 82% and 70% in the SHZOW series (P=0.2),
and 65 % and 54 % in the SHOW series (P=0.4).
In summary, the difference in streptomycin dosage
appears to have had little effect on the response to
treatment. However, the possibility cannot be
excluded that it had a slight effect in the SH/SHOW
and the SHOW series (see also page 173 et seq.).
Influence of the rate of inactivation of isoniazid on the
response to treatment
Amalgamating all four series, 209 (90%) of 232
slow inactivators of isoniazid had a favourable
response as compared with 98 (69%) of 143 rapid
inactivators. The corresponding percentages, stan-
dardized for streptomycin dosage and weighted
appropriately on the basis of the numbers of slow
and rapid inactivators in each of the four series,
were 89 % and 69 %, respectively, the difference being
highly significant (P <0.00001).
Considering the findings (standardized percent-
ages) in the individual series (Table 15, Part C), the
response was favourable in 97% of the slow in-
activators and 91 % of the rapid inactivators in the
SHTW series, a non-significant difference (P=0.3).
The corresponding figures were 95 % and 76 % in the
SH/SHOW series (P <0.01), 87 % and 53 % in the
SHZOW series 1 (P <0.001), and 76 % and 56 % in
the SHOW series (P=0.05).
In patients with bacteriologically quiescent disease
at 1 year, there was no evidence (analyses not tabu-
1 Since the rapid inactivators in this series had, by chance,
a larger bacterial content in the sputum than the slow
respectively, in whom it was attained within 3 months
(these proportions are standardized and weighted, as
above). Considering the findings in the individual
series, the corresponding proportions with sputum
conversion by 3 months were 70 % and 65 % in the
SHTW series (P=0.7), 71% and 81% in the
SH/SHOW series, 82% and 59% in the SHZOW
series (P=0.06), and 62% and 55% in the SHOW
series (P=0.6).
In summary, the rate of inactivation of isoniazid
had a considerable influence on the response to
treatment in the SH/SHOW, SHZOW and the
SHOW series, but had little effect in the SHTW
series.
Conclusion
The SHTW regimen was highly effective and,
furthermore, unaffected by differences in isoniazid
inactivation rate and streptomycin dosage. Although
the SH/SHOW regimen achieved highly satisfactory
over-all results, its efficacy was considerably affected
by the rate of inactivation of isoniazid, and possibly
affected by the streptomycin dosage as well. Both
the SHZOW and the SHOW regimens were markedly
inferior to the SHTW and the SH/SHOW regimens,
their efficacies being considerably influenced by the
rate of inactivation of isoniazid and, in the case of
the SHOW regimen, possibly influenced by the
streptomycin dosage as well. Finally, there was no
evidence that persisting culture negativity com-
menced earlier with the more effective regimens or
in the streptomycin high-dosage patients or in the
slow inactivators of isoniazid.
DISEASE STATUS AT 1 YEAR IN PATIENTS WHO
TOOK THEIR DISCHARGE AGAINST MEDICAL ADVICE
In all, 13 patients (5 SHTW, 3 SH/SHOW,
4 SHZOW, 1 SHOW) took their discharge against
medical advice (Table 15, Part A); they have been
excluded from the above comparisons. However,
attempts were made to obtain sputum specimens
inactivators (see page 161), and since the bacterial content
affected significantly the response to the SHZOW regimen
(see page 185), statistical standardization was undertaken to
allow for the difference in bacterial content. The standardized
percentages were 85 % for the slow inactivators and 60 % for
the rapid inactivators, the difference being highly significant
(P < 0.01).
from these patients at 12 months, in order to
classify their disease status at 1 year.
Of the 13 patients, 1 (SHTW) died of tuberculosis
in the 8th month, and 1 (SHZOW) restarted treat-
ment in the 9th month (after a break of 6 month%)
but developed tuberculous meningitis in the 11th
month and was prescribed daily chemotherapy;
3 (1 SHTW, 1 SHZOW, 1 SHOW) had bacterio-
logically active disease at 1 year, 1 (SH/SHOW) had
1 positive culture at 12 months (followed by positive
cultures at 14 and 15 months), and 1 (SHTW) had
2 positive cultures at 6 months (no specimens were
obtained subsequently in the first year, but 7 of 8 cul-
tures obtained at 15, 16 and 17 months were positive);
these 7 patients, who stopped treatment in the 3rd,
3rd, 6th, 4th, 9th, 10th and 2nd month, respectively,
may be regarded as having had an unfavourable
disease status at 1 year. Four patients (2 SHTW,
1 SH/SHOW, 1 SHZOW) had all cultures negative
between month 10 and month 12 (the numbers
varying from 2 to 5), and a fifth (SH/SHOW) had all
cultures negative from month 2 to month 7 (and,
subsequently, at 18 months). These patients had
taken their discharge in the 11 th, 12th, 4th, 11th and
8th month, respectively, and none had a history of
treatment subsequent to the discharge. All 5 may be
regarded as having a favourable disease status at
1 year. The 13th patient (SHZOW) took his dis-
charge in the 4th month, at which time his sputum
was smear-negative but culture-positive; no speci-
mens were obtained from him subsequently, so that
the disease status at 1 year is not assessable.
If the 12 patients with an assessable disease
status are included in the comparison of the thera-
peutic efficacies of the regimens, the proportion with
a favourable disease status at 1 year becomes 92%
for the SHTW, 88 % for the SH/SHOW, 74% for the
SHZOW and 65 % for the SHOW series, the corres-
ponding standardized proportions being 92 %, 87 %,
73 % and 67 %, respectively.
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VII. OTHER LABORATORY FINDINGS
STREPTOMYCIN AND ISONIAZID SENSITIVITY
TEST RESULTS
Influence of regimen on the findings
As stated earlier (page 169), resistance to isoniazid
and to streptomycin occurred more frequently
(Table 13) and more rapidly (Table 14) with the less
effective SHOW and SHZOW regimens than with
the more effective SH/SHOW and SHTW regimens.
Table 16 sets out for the various regimens the
standardized percentages of patients with (1) an
isoniazid-sensitive culture, and (2) a streptomycin-
sensitive culture. The findings suggest that the
decline during treatment in the proportion of
patients with a sensitive culture was more gradual
with the SHOW and the SHZOW regimens than with
the SH/SHOW and the SHTW regimens. In other
words, the less effective regimens appear to have
eliminated drug-sensitive organisms more slowly
than the more effective regimens.
Influence of streptomycin dosage and isoniazid
inactivation rate on the findings within each series
Patients in all three phases of intake have been
considered together in the analyses below. The
comparisons are within each of the four series, that
is, between streptomycin high-dosage and low-
dosage patients, and between slow and rapid
inactivators of isoniazid in each series. Since slow
inactivators have higher serum isoniazid concentra-
tions than rapid inactivators (Table 26), the con-
trasts between these two groups of patients may be
regarded as analogous, in pharmacological terms, to
comparisons between a higher and a lower dosage of
isoniazid.
SHOW series. Table 17 sets out the results of
streptomycin and isoniazid sensitivity tests in SHOW
patients, according to (1) the streptomycin dosage
(low or high) and (2) the isoniazid inactivation rate
(rapid or slow). Considering first the influence of
streptomycin dosage (left half of table), strepto-
mycin-sensitive cultures were obtained more
frequently from the low-dosage patients in the first
6 months–for instance, the proportion with a
sensitive culture was 40% for the low-dosage pa-
tients at 3 months as compared with 22% for the
high-dosage patients, the corresponding proportions
at 6 months being 17 % and 7 %, respectively.
However, the proportions with streptomycin resist-
ance were usually similar in the two groups, being
4% and 3% at 3 months, and 12% and 7% at
6 months. Thus, in the first 6 months, the adminis-
tration of the low dosage of streptomycin resulted
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TABLE 15
STANDARDIZED PERCENTAGES OF PATIENTS WITH DRUG-SENSITIVE CULTURES
Phases I and II
chemo the rapy        
S H T W  
Isoniazld-sensitive Streptomycin-sensitive
0 100
3 22
4 9
5 6
6 5
9 1
12 0
SHOW
100
18
11
8
5
2
3
Phases II and Ill  Phases I and II Phases II and III
SHTW SH/SHOW
100 100
19 15
7 10
4 10
2 7
0 5
0 2
111-107 100-95 105-99
I
SHOW  SHTW  SHOW  SHTW  SH/SHOW
100 100 100 100 100
22 28 32 21 16
14 12 22 5 12
8 8 12 6 10
5 12 3 8
2 2 5 1 4
3 1 2 1 3
74-90   118-114   110-104   100-95     105-98    
SHZOW    SHOW
100 100
25 36
18 24
16 15
7 12
5 6
5 3
102-93 74-87
SHZOW
100
20
15
13
6
8
8
102-97I 
Total patients
118-114
a The highest and the lowest number of patients in the analysis at any of the months. Patients who died, who discharged
themselves against medical advice or who had theirallocated chemotherapy terminated on account of toxicity are excluded thereafter.
The policy for patients who had their allocated chemotherapy terminated on account of radiographic or clinical deterioration is
described on pages 157 and 167.
TABLE 17
SHOW SERIES: RESULTS OF STREPTOMYCIN AND ISONIAZID SENSITIVITY TESTS,
RELATED TO STREPTOMYCIN DOSAGE AND ISONIAZID INACTIVATION RATE
Standardized percentage of patients a
Contrast between streptomycin high-
dosage and low-dosage patients
Contrast between slow and rapid
inactivators of isoniazid
chemotherapy Streptomycin sensitivity
Sensitive
Low High
Resistant Sensitive Resistant
Low High Low High Low High
lsoniazid sensitivity lsoniazid sensitivity Streptomycin sensitivity
3 40 22 4 3 16 18 27 7
4 34 7 2 10 9 12 27 5
5 16 8 14 12 2 13 28 7
6 17 7 12 7 3 11 29 3
7 9 0 23 11 5 3 28 10
8 11 2 21 10 2 3 31 10
9 7 2 19 12 0 4 28 10
10 9 6 18 13 2 8 27 10
11 9 2 19 13 2 4 29 11
12 4 1 22 14 2 4 25 14
Total patients
in analysis (range) b
56-51 55-53 56-51 55-53 56-52 55-53 56-52 55-53
Sensitive
Rapid Slow
22 14
19 5
13 5
15 4
8 2
5 0
6 0
9 4
6 2
8 0
53-49 59-54
Resistant Sensitive
Rapid Slow Rapid Slow
17 18
18 16
19 17
18 16
25 15
29 15
27 13
24 15
30 14
31 12
33 31
21 21
10 15
12 13
6 3
8 5
8 2
6 10
7 5
7 0
53-49 59-54
Resistant
Rapid Slow
6 2
14 0
22 7
18 5
24 14
25 10
23 11
26 9
25 11
28 12
53-48 59-54
a The figures in bold type show contrasts that are statistically significant at the 5% level.
b The highest and the lowest number of patients in the analysis at any of the months. Patients who died, who discharged them-
selves against medical advice or who had their allocated chemotherapy terminated on account of toxicity are excluded thereafter.
The policy for patients who had their allocated chemotherapy terminated on account of radiographic or clinical deterioration is
described on pages 157 and 167.
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in a slower elimination of streptomycin-sensitive
organisms (but not in an increased emergence of
streptomycin resistance). It resulted also in an in-
creased emergence of isoniazid resistance, the propor-
tions resistant being 27 % for the low-dosage patients
and 7 % for the high-dosage patients at 3 months, 29 %
and 3 % at 6 months, and 25 % and 14 % at 12 months.
Finally, from the 7th month onwards, streptomycin
resistance occurred more frequently in the low-dosage
patients (unlike in the first 6 months), the proportions
resistant being 19 % at 9 months and 22% at
12 months as compared with 12 % and 14 %, respec-
tively, for the high-dosage patients. This excess in
the low-dosage group is presumably due to the
emergence of secondary streptomycin resistance in
patients whose cultures were already resistant to
isoniazid, of whom there was an excess in the low-
dosage group in the first 6 months.
An analogous pattern was found when the con-
trasts between the slow and the rapid inactivators of
isoniazid (Table 17, right half) were considered.
During the first 6 months of treatment, isoniazid-
sensitive cultures were obtained more frequently from
the rapid inactivators, the proportions being 22%
for the rapid inactivators and 14 % for the slow inac-
tivators at 3 months, and 15 % and 4 %, respectively,
at 6 months. Isoniazid-resistant cultures, however,
were obtained from similar proportions in the two
groups-for instance, 17% and 18% at 3 months,
and 18 % and 16% at 6 months. Thus, in the first
6 months, rapid inactivation of isoniazid resulted in
a slower elimination of isoniazid-sensitive organisms
(but not in an increased emergence of isoniazid
resistance). It led also to an increased emergence of
streptomycin resistance, the proportions resistant
being 14% for the rapid inactivators and 0% for
the slow inactivators at 4 months, 18 % and 5 % at
6 months, and 28 % and 12% at 12 months. In the
second 6 months, isoniazid-resistant cultures were
obtained more frequently from rapid inactivators
(presumably secondary resistance), the proportion
ranging from 24% to 31% as compared with 12%
to 15 % in slow inactivators.
In summary, in the patients who received the low
dosage of streptomycin, a streptomycin deficiency
was indicated by a slower elimination of strepto-
mycin-sensitive organisms, and a relative failure to
prevent the emergence of isoniazid resistance and,
subsequently, of secondary streptomycin resistance.
Similarly, in the rapid inactivators of isoniazid, an
isoniazid deficiency was indicated by a slower
elimination of isoniazid-sensitive organisms, and a
relative failure to prevent the emergence of strepto-
mycin resistance and, subsequently, of secondary
isoniazid resistance.
SHZOW series. The mode of interpretation of the
findings for this series is the same as that em-
ployed for the SHOW series. Considering first the
influence of streptomycin dosage (Table 18, left half),
the proportions with a streptomycin-sensitive culture
were similar for the high-dosage and the low-dosage
patients (apart from minor and inconsistent differ-
ences in the second 6 months). Next, there was no
evidence, either in the first 6 months or in the
second 6 months of treatment, that streptomycin
resistance or isoniazid resistance had occurred more
frequently in the low-dosage patients. These find-
ings, when considered with the experience in the
SHOW series (see above), suggest that the pyrazin-
amide in the SHZOW regimen compensated for the
streptomycin deficiency in the low-dosage patients
by assisting in (1) the elimination of streptomycin-
sensitive bacilli, (2) the prevention of isoniazid
resistance, and (3) the prevention of secondary
streptomycin resistance.
Considering next the influence of the rate of
inactivation of isoniazid (Table 18, right half),
(1) isoniazid-sensitive cultures were produced more
frequently by the rapid inactivators, especially in the
early months of treatment; thus, at 3 months, 39%
of the rapid inactivators had an isoniazid-sensitive
culture as compared with 10% of the slow inactiva-
tors, the corresponding proportions being 32% and
7 % at 4 months, 28 % and 4 % at 5 months, 16 % and
0% at 6 months, and 18 % and 2% at 12 months;
(2) appreciably higher proportions of rapid in-
activators produced streptomycin-resistant cultures
from 4 months onwards; thus, the proportions
resistant were 23% for the rapid inactivators and
4% for the slow inactivators at 4 months, 22% and
3 % at 6 months, and 28 % and 8 % at 12 months;
and (3) isoniazid-resistant cultures were produced
more frequently by the rapid inactivators, the pro-
portion resistant being 14%-21 % between month 3
and month 6 as compared with 9%-11% in the slow
inactivators, and 18 %-27 % and 9 %-12 %, respective-
ly, between month 7 and month 12. These findings,
when considered together with those in the SHOW
series, suggest that the pyrazinamide in the SHZOW
regimen was unable to compensate for the isoniazid
deficiency in the rapid inactivators of isoniazid.
(Other findings in the table, for which there are no
ready explanations, have not been described here.)
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TABLE 18
SHZOW SERIES: RESULTS OF STREPTOMYCIN AND ISONIAZID SENSITIVITY TESTS.
RELATED TO STREPTOMYCIN DOSAGE AND ISONIAZID INACTIVATION RATE
Standardized percentage of patients a
Contrast between slow and rapid
inactivators of isoniazid
Contrast between streptomycin high-
dosage and low-dosage patients
chemotherapy lsoniazid sensitivity lsoniazid sensitivity
Resistant
Rapid Slow
Sensitive
Rapid Slow
14 9 41 16
21 9 30 12
18 11 27 9
15 11 9 6
18 12 11 8
21 11 10 6
21 11 9 3
18 11 16 2
27 9 22 3
24 11 12 2
34-32 68-65 34-30 68-62
Streptomycin sensitivity
Sensitive Resistant Sensitive
Low High Low High Low High
25 24
20 17
18 13
8 7
10 8
11 5
4 7
2 11
9 12
8 2
2 11
6 16
6 14
8 12
10 13
6 19
14 16
14 14
7 14
8 23
19 20
14 18
12 14
4 8
6 10
4 13
8 7
6 15
6 10
6 10
52-45 50-47 52-45 50-47 52-48 56-48
Resistant Sensitive Resistant
Rapid Slow
12 3
23 4
19 4
22 3
24 5
27 5
28 8
25 8
23 3
28 8
34-36 68-62
Low High
8 14
12 14
12 14
12 13
14 15
14 15
12 17
14 13
15 18
14 18
52-48 50-48
rapid Slow
39 10
32 7
28 4
16 0
18 2
19 1
18 2
25 1
19 2
18 2
3
4
5
6
7
8
9
10
11
12
Total patients
n analysis (range) b 34-32 66-65
a The figures in bold type show contrasts that are statistically significant at the 5% level.
b The highest and the lowest number of patients In the analysis at any of the months. Patients who died, who discharged
themselves against medical advice or who had their allocated chemotherapy terminated on account of toxicity are excluded there-
after. The policy for patients who had their allocated chemotherapy terminated on account of radiographic or clinical deterioration
is described on page 167.
SH/SHOW series. The mode of interpretation of
the tidings for this series is the same as that
employed for the SHOW and the SHZOW series.
The dosage of streptomycin had little effect on the
findings of streptomycin and isoniazid sensitivity
tests (Table 19, left half).
Considering the influence of the rate of inactiva-
tion of isoniazid (Table 19, right half), (1) the rapid
inactivators produced isoniazid-sensitive cultures
more frequently than the slow inactivators, the
proportions being 18 % and 5 % at 4 months, 19 %
and 0 % at 6 months, 14 % and 2 % at 9 months, and
5 % and 0 % at 12 months; (2) there was some evid-
ence that resistance to streptomycin developed more
frequently in the rapid inactivators in the later
months, the proportions resistant being 14 % for the
rapid and 5 % for the slow inactivators at 9 months,
and 13 % and 5 %, respectively, at 12 months; and
(3) isoniazid-resistant cultures were produced by
similar proportions in the two groups up to 9 months;
thereafter, they occurred more frequently in the
rapid inactivators, the proportion resistant at
12 months being 14% as compared with 6% in the
slow inactivators. These findings suggest that,
despite the 4 weeks of initial daily chemotherapy,
the rapid inactivators of isoniazid had an isoniazid
deficiency. However, the effect of this deficiency
occurred later in treatment than in the SHOW series.
SHTW series. Neither the speed of elimination of
sensitive organisms nor the emergence of resistance
appeared to be influenced by the dosage of strepto-
mycin (Table 20, left half) or the rate of inactivation
of isoniazid (Table 20, right half).
Occurrence of drug-sensitive cultures at 10, 11 and
12 months
An interesting feature of this study (evident from
the percentages in Tables 16-20) is the occurrence of
drug-sensitive cultures in the later months of treat-
ment. Thus, among patients who produced at least
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TABLE 19
SH/SHOW SERIES: RESULTS OF STREPTOMYCIN AND ISONIAZID SENSITIVITY TESTS,
RELATED TO STREPTOMYCIN DOSAGE AND ISONIAZID INACTIVATION RATE
chemotherapy
3 15 18 2 2
4 10 13 0 2
5 13 6 2 6
6 8 8 4 0
7 4 2 4 4
8 6 4 4 6
9 6 2 8 8
10 8 2 4 6
1 1 8 0 4 8
12 6 0 6 8
Total patients
in analysis (range) b 54-48 52-49 54-46 52-49
Standardized percentage of patients a
Contrast between streptomycin high-
dosage and low-dosage patients
Streptomycin sensitivity Isoniazid sensitivity
Sensitive
Low High
Resistant
Low High
Sensitive Resistant
Low High Low High
13 18
8 12
13 6
10 4
4 2
6 6
8 4
6 0
6 2
4 0
4 2
2 4
2 6
4 6
4 6
4 6
6 6
6 8
8 6
10 6
54-49 52-49
Contrast between slow and rapid
Inactivators of isoniazid
lsoniazid sensitivity
Sensitive
Rapid Slow
16 15
18 5
16 6
19 0
8 0
16 0
14 2
8 0
11 0
5 0
38-36 67-62
Resistant
Rapid Slow
Sensitive
Rapid Slow
3 3 16 17
0 5 18 8
3 4 11 9
3 6 17 3
5 5 6 2
8 3 14 0
5 6 5 3
11 5 11 2
14 3 11 0
14 6 6 2
38-36 67-62 38-35 67-62
Resistant
Rapid Slow
3 2
0 2
8 1
3 2
6 3
8 3
14 5
8 3
11 3
13 5
38-35 67-62
a The figures In bold type show contrasts that are statistically significant at the 5% level.
b The highest and the lowest number of patients in the analysis at any of the months. Patients who died, who discharged
themselves against medical advice or who had their allocated chemotherapy terminated on account of toxicity are excluded there-
after. The policy for patients who had their allocated chemotherapy terminated on account of radiographic or clinical deterioration
is described on page 167.
1 positive culture at 10, 11 or 12 months, 36% had than in the high-dosage patients (39% of 36); how-
at least 1 isoniazid-sensitive culture and 46 % had at ever, this difference was non-significant (P=0.3).
least 1 streptomycin-sensitive culture (including 25 % The difference between the streptomycin high-dosage
with at least 1 culture sensitive to both the drugs). and the low-dosage patients in the proportion with
Table 21 sets out the corresponding proportions an isoniazid-sensitive culture was non-significant
(together with the total numbers of sensitive cultures) (P=0.1), as also was the difference between the slow
according to regimen, streptomycin dosage and and the rapid inactivators of isoniazid in the propor-
isoniazid inactivation rate. tion with a streptomycin-sensitive culture (P=0.4).
There was little evidence that the proportion of Considering next the findings in patients who had
patients with a sensitive culture was influenced by the positive cultures at almost all the months, (a) 5
regimen, all the differences being clearly non- (1 SH/SHOW, 4 SHZOW) had an isoniazid-sensitive
significant, both for isoniazid (P > 0.3) and for culture at 10 months, 11 months and 12 months;
streptomycin (P > 0.3). However, there was some a sixth patient (SHZOW) had an isoniazid-sensitive
evidence that the proportion with an isoniazid- culture at 10 months and at 12 months, all the
sensitive culture was higher in the rapid inactivators cultures at 11 months being negative; (b) 3 patients
of isoniazid (45 % of 56) than in the slow inactivators (2 SHZOW, 1 SHOW) had a streptomycin-sensitive
(21% of 34), a significant difference (P=0.04). culture at 10 months, 11 months and 12 months;
Similarly, there was a suggestion that the proportion a fourth (SHOW) had a streptomycin-sensitive cul-
with a streptomycin-sensitive culture was higher in ture at 10 months and at 11 months, all the cultures
the streptomycin low-dosage patients (52% of 48 at 12 months being negative; and (c) 1 patient
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TABLE 20
SHTW SERIES: RESULTS OF STREPTOMYCIN AND ISONIAZID SENSITIVITY TESTS.
RELATED TO STREPTOMYCIN DOSAGE AND ISONIAZID INACTIVATION RATE
Standardized percentage of patients a
T
Contrast between streptomycin high-
dosage and low-dosage patients
Contrast between slow and rapid
inactivators of isoniazidMO;;); $er
chemotherapy
T
Streptomycin sensitivity lsonlazid sensltlvltv lsoniazid sensitivity Streptomycin sensitivitv
Sensitive
L o w  High
a
Sensitive
iapid  Slav
17 26
9 11
13 4
7 4
0 3
4 2
0 2
7 0
2 2
2 0
16-42  98-9:
i:
-
i-
4
-
-
I I
i 1
Sensitive Resistant
L o w  Hioh
3 3
4 4
4 5
7 5
1  5
7 5
1 6
IO 5
9 5
9 5
14-73  69-64
Sensitive ResistantResistant
L o w  Higt
0 0
1 3
0 3
4 5
4 5
4 5
8 5
7 5
9 5
7 5
74-13  69-64
Resistant
16 32
11 IO
6 9
7 3
4 0
4 2
0 3
3 2
3 2
2 0
Low High
15 30
8 9
1 6
5 3
I 0
2 2
1 0
0 2
3 2
0 0
M-73 69-64
iapid Slow Iapid Slow
13 26
7 9
9 2
5 3
0 1
4 0
0 1
2 0
2 2
0 0
B-42 98-95
4 2
4 4
4 4
9 4
7 5
7 5
7 7
11 5
7 6
9 5
L46-42 98-95
Rapid Slow
0 0
2 2
0 2
7 3
7 3
7 3
7 6
7 5
7 6
7 5
M-42  98-95
3
4
5
6
7
8
9
IO
11
12
Tbtal  patients
In analysis (range) b 74-73 69-64
a The figures in bold type show contrasts that are statistically slonificant  at the 5% level.
bThe  highestand thelowestnumber of patients in the analysis at any of the months. Patients who died, who discharged them-
selves against medical advice or who had their allocated chemotherapy terminated on account of toxicity are excluded thereafter.
The policy for patients who had their allocated chemotherapy terminated on account of radiographic or clinical deterioration is
described on pages 157 and 167.
TABLE 21
PATIENTS WITH DRUG-SENSITIVE CULTURES AT IO,11  OR 12 MONTHS
I lsoniazld sensitivity I Streptomycin sensitivity
Patients with a
sensitive culture
at one or more
of these months
No. %b
IO 29 15 82 18 41
12 46 23 22 10 (45)
6 (43) 9 14 9 (64)
4 (25) 4 16 7 (44)
Total no. of
sensitive
cultures at 10,
‘;:!c’h’,’
-
18
20
12
7
20
37
17
40
-
Patients with s
test result at
l~;oJ,,o  A2
SHOW 34
SHZOW 26
SHISHOW 14
SHTW 16
High 37
Low 53
Slow 34
Rapid 56
14 39
25 52
12 39
2 1 51
17 46 29 36
15 28 22 48
lsoniazid
inactivation
rate 2: :: / “I 1 ::1
a Patients whose allocated chemotherapy was terminated for deterioration are included subsequently also (and regarded as
having resistant cultures), provided the last 2 sensitivity test results prior to the termination were resistant.
b Parentheses’indicate  that the bercentage is based on fewer than 25 observations.
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(SHZOW), included in (a) and (b), had cultures
sensitive to both isoniazid and streptomycin through-
out the year. Of these 9 patients (1 SH/SHOW,
6 SHZOW, 2 SHOW; 4 high, 5 low; 2 slow, 7 rapid),
7 received every single dose of chemotherapy
throughout the year and the remaining 2 missed only
1 dose. It is of interest that 8 of the 9 patients had
received the SHZOW or the SHOW regimen, that is,
once-weekly chemotherapy from the beginning, and
that 7 of the 9 patients were rapid inactivators of
isoniazid.
In summary, the proportion of patients with an
isoniazid-sensitive culture in the later months of
treatment was higher among the rapid inactivators of
isoniazid than among the slow inactivators. Similar-
ly, there was a suggestion that the proportion with
a streptomycin-sensitive culture was higher among
the streptomycin low-dosage patients than among the
high-dosage patients. Of 9 patients who persistently
produced cultures sensitive to isoniazid or strepto-
mycin (or to both the drugs) even in the later months
of treatment, 8 had received once-weekly chemo-
therapy from the beginning.
Sequence of emergence of resistance in patients with
an unfavourable response
In all, 81 patients had an unfavourable response to
treatment. Of these, 9 had died or had had their
allocated chemotherapy terminated in the first
3 months and 6, all of whom had received at least
90% of their allocated chemotherapy, had produced
only drug-sensitive cultures (to both streptomycin
and isoniazid) between 3 and 12 months, 1 (SHTW,
low, slow) on 1 occasion, 1 (SHZOW, low, rapid) on
2 occasions, 3 (2 SH/SHOW, low, rapid; 1 SHZOW,
high, rapid) on 4 occasions and 1 (SHZOW, low,
rapid) on 9 occasions.
Resistance emerged to at least 1 drug in the
remaining 66 patients with an unfavourable response;
the sequence of the emergence is set out in Table 22
according to the regimen, streptomycin dosage and
isoniazid inactivation rate.
Considering the two once-weekly regimens with
similar and relatively low efficacies, streptomycin
resistance emerged first in similar proportions in
the two series–namely, in 10 (36%) of 28 SHOW
patients and 6 (30%) of 20 SHZOW patients.
Amalgamating these two series, streptomycin resist-
ance emerged first (indicating a relative failure of
isoniazid) in 16 (33%) of 48 patients, as compared
with none of 8 who received the highly effective
twice-weekly regimen (SHTW). This difference,
although not statistically significant (P=0.1), sug-
gests that in moving from twice-weekly to once-
weekly chemotherapy, there has been a greater
TABLE 22
EMERGENCE OF RESISTANCE TO STREPTOMYCIN AND ISONIAZID IN PATIENTS
WITH AN UNFAVOURABLE RESPONSE a
SHOW
Regimen
SHZOW
SH/SHOW
SHTW
High
Low
lsoniazid
inactivation
rate
Slow
Rapid
Total
24
42    
Patients with an unfavourable response
and resistance to one or both drugs
Sequence of emergence of resistance
Simultaneous
10(36%) 1 17
6 (30%) 4 10
3 (30%) 1 6
0 2 6
14 (47%) 10
5 (14%) 29
0 4 20 (83%)
19 4 19 (45%)
a An unfavourable response to treatment is defined as death from tuberculosis, or bacterio-
logically active disease (including termination of the allocated chemotherapy for radiographic or
serious clinical deterioration) or bacteriologically relapsed disease at 1 year.
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reduction in the efficacy of isoniazid than of strepto-
mycin.
Streptomycin resistance emerged first in 14 (47 %)
of 30 patients who received the high dosage of 
streptomycin, as compared with 5 (14%) of 36 who
received the low dosage, a significant difference
(P <0.01). Similarly, isoniazid resistance emerged
first in 20 (83 %) of 24 slow inactivators of isoniazid
as compared with 19 (45 %) of 42 rapid inactivators,
a significant difference (P<0.01). Thus, in the
patients with an unfavourable response and drug
resistance, the resistance emerged relatively slowly to
streptomycin when it was given in low dosage
(indicating a relative deficiency of this drug), and
relatively slowly to isoniazid when it was inactivated
rapidly (indicating a relative deficiency of this drug).
Influence of pretreatment drug susceptibility on
response to treatment
Streptomycin. Table 23 relates the response to
treatment of patients in all four series combined to
TABLE 23
RESPONSE TO TREATMENT RELATED TO
STREPTOMYCIN SUSCEPTIBILITY ON ADMISSION a
Streptomycin susceptibility
on admission b
Minimal inhibitory
concentration
(µg/ml)
Resistance ratio
Proportion resistant
to 2 µg/ml
Proportion resistant
to 4 µg/ml
< 4 281
8 134
16 33
229
153
59
301
81
60
342
59
34
a All 4 treatment series combined.
b Result on first positive culture.
c That is, death from tuberculosis, or bacteriologically active
disease (including termination of the allocated chemotherapy
for radiographic or serious clinical deterioration) or bacterio-
logically relapsed disease at 1 year.
Total no.
of patients
Unfavourable
response c
No. %
40 14
29 22
9 27
31 14
28 18
16 27
43 14
15 19
23 38
55 16
13 22
13 38
the streptomycin susceptibility of the first pretreat-
ment culture; all these cultures were “ streptomycin-
sensitive ” according to standard definitions in use at
this Centre (page 149). Of 281 patients with an MIC
of 4 µg/ml or less on the first positive culture,
14 % had an unfavourable response to treatment ; the
corresponding proportions were 22% of 134 for
patients with an MIC of 8 µg/ml and 27% of 33 for
patients with an MIC of 16 µg/ml. The trend in
these percentages is statistically significant (P=0.02).
Similar trends were obtained with the RR (P=0.01),
the proportion of the bacterial population resistant
to 2 µg/ml (P <0.0001) and the proportion resistant
to 4 µg/ml (P<0.01). These findings demonstrate
that the degree of streptomycin susceptibility of the
sensitive cultures influenced significantly the out-
come of treatment.1
Table 24 examines, for each of the four series, the
streptomycin susceptibility of the first pretreatment
culture from patients with an unfavourable response
and from those with a favourable response. There is
some evidence in all the four series that the percent-
age of patients with less susceptible strains (de-
termined by different measures, e.g., MIC of 8 µg/ml
or more) was higher in the former than in the latter.
The contrasts appear to be most marked in the
SHTW series. For instance, in this series, the pro-
portions with 10% or more growth on 2 µg/ml were
45% of 11 for the patients with an unfavourable
response and 11% of 129 for the patients with a
favourable response, asignificant difference (P <0.01);
the corresponding proportions for 1% or more
growth on 4 µg/ml were 36 % and 8 %, respectively
(P=0.01).
Isoniazid. Analyses (not tabulated here) showed
that there was no association between the response
to treatment and the isoniazid susceptibility of the
first pretreatment culture; all these cultures were
“ isoniazid-sensitive ” according to standard defini-
tions in use at this Centre (page 149).
1 The degree of streptomycin susceptibility was broadly
similar for the SHTW and SHOW series in phases I and II,
and for the SHTW, SH/SHOW, SHZOW and SHOW series
in phases II and III. Further, within each series in phases I
plus II and in phases II plus III, it was broadly similar for
streptomycin high-dosage and low-dosage patients, and for
slow and rapid inactivators of isoniazid apart from 1 excep-
tion. This was in the SH/SHOW series in phases II plus III,
in which there was clear-cut evidence that the proportion of
patients with less susceptible strains was significantly lower
in the slow inactivators than in the rapid inactivators.
Statistical standardization was therefore undertaken but did
not affect the conclusion (page 172), the proportions with a
favourable response at 1 year being 95 % for the slow inactiv-
ators and 78 % for the rapid inactivators (P = 0.02).
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TABLE 24
RESPONSE TO TREATMENT OF PATIENTS IN THE INDIVIDUAL SERIES,
RELATED TO STREPTOMYCIN SUSCEPTIBILITY ON ADMISSION
Percentage of patients b
Series Response to Total
treatment a patients
Un favou rab le  11 (64) (18) (45) (36)
SHTW
Favourable 129 43 12 11 8
Unfavourable 12
SH/SHOW
(50) (33) (33) (17)
Favourable 89 31 9 10 6
Unfavourable 25 60 16 20 12
SHZOW
Favourable 75 27 15 9 4
Unfavourable 33 36 18 27 12
SHOW
Favourable 82 33 1 1 9 4
a An unfavourable response to treatment Is defined as death from tuberculosis, or bacteriolo-
gically active disease (including termination of the allocated chemotherapyfor radiographicor serious
clinical deterioration) or bacteriologically relapsed disease at 1 year. A favourable response to
treatment is defined as bacteriologically quiescent disease or disease of bacteriologically doubtful
status at 1 year.
b Parentheses Indicate that the percentage Is based on fewer than 25 observations.
PYRAZINAMIDE SENSITIVITY TEST RESULTS TABLE 25
RESULTS OF PYRAZINAMIDE SENSITIVITY TESTS
Table 25 presents the results of pyrazinamide
sensitivity tests in the SHZOW patients, as well as in Regimen
the control (SHOW) patients. Considering first the
SHZOW patients with sensitivity test results, the
proportion resistant showed a gradual increase
during treatment; thus, it was 7% on admission,
5% in months 3 and 4 combined, 11% in months 5
and 6 combined, 19 % in the period from month 7 to
month 9 and 28% in the period from month 10 to
month 12 (all the resistant cultures obtained during SHZOW
treatment were from patients with a sensitive cul-
ture on admission). In contrast, no such increase
occurred in the control patients, the proportion
resistant being 5 % on admission and 4 % at months
6 and 12 combined. These findings suggest that
resistance to pyrazinamide emerged in some of the
SHZOW patients.
There were 21 SHZOW patients who had bacterio-
logically active disease at 1 year, including 7 who had
the allocated chemotherapy terminated (in the 6th
month or subsequently) on account of radiographic
Control
(SHOW)
0 b 105
3 29
4 28
5 24
6 14
7 18
8 16
9 14
10 14
11 14
12 12
0 b
6
12
77
15
1 1
Resistant a
No. %
4 28
or serious clinical deterioration. A detailed examina- a Resistance is defined as growth on 100 µg/ml pyrazinamide
tion of the sensitivity test results for these patients of at least 1% of the bacterial population.b The sensitivity test result for the first positive culture hasshowed clear-cut evidence of the emergence of  been considered.
4 5
0
4
1
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pyrazinamide resistance (that is, at least 2 resistant
cultures in the last 6 months of chemotherapy) in
5 patients. This represents an incidence of 24% in
the 21 patients with bacteriologically active disease,
at 1 year and an incidence of 5 % in the 105 patients
treated with the SHZOW regimen.
DRUG CONCENTRATIONS IN SERUM
The mean and range of serum drug concentrations
attained at 1, 2, 3 and 6 hours after a dose of chemo-
therapy (streptomycin, 1 g or 0.75 g; isoniazid,
approx. 15 mg/kg body-weight ; pyrazinamide,
approx. 90 mg/kg body-weight) are set out in
Table 26. It will be seen that:
(1) the mean streptomycin concentrations at 1, 2,
3 and 6 hours are proportional to the dose of strepto-
mycin (1 g or 0.75 g) administered;
(2) the mean isoniazid concentrations are appreci-
ably higher in the slow inactivators of isoniazid than
in the rapid inactivators, the difference being the
largest at 6 hours; and
(3) pyrazinamide continued to be absorbed over
a long period, the serum concentrations of free
pyrazinamide are high (a concentration of 25 µg/ml
is known to inhibit a large proportion of the bacterial
population in wild strains (Tripathy, 1966)), and the
half-life is long.
INFLUENCE OF SERUM DRUG CONCENTRATIONS
ON RESPONSE TO TREATMENT AND TOXICITY
For each patient, the following measures were
obtained from the estimates of streptomycin and
isoniazid concentrations; (1) logarithm of the 6-hour
concentration, (2) logarithm of the highest con-
centration, (3) logarithm of the geometric mean of
the concentrations at 1, 2, 3 and 6 hours, (4) half-life
of the drug, calculated from the concentrations at
3 and 6 hours. In addition, for the SHZOW patients,
the values for measures (1), (2) and (3) were obtained
for free pyrazinamide and total pyrazinamide (i.e.,
free pyrazinamide plus pyrazinoic acid); measure (4)
was not considered for either since the 6-hour con-
centration was higher than or equal to the 3-hour
concentration in appreciable proportions (28 % and
18 %, respectively) of the patients.
Response to treatment
Analyses were undertaken relating the likelihood
of a favourable response (that is, bacteriologically
quiescent disease or disease of bacteriologically
doubtful status at 1 year) to each of the above
measures. In the case of streptomycin, high-dosage
and low-dosage patients in all four series were
considered together, since there was no clear-cut
evidence that a favourable response had occurred
more frequently in the former (page 169). For iso-
niazid, the analyses were performed separately for
TABLE 26
MEAN AND RANGE OF SERUM CONCENTRATIONS OF STREPTOMYCIN, ISONIAZID AND PYRAZINAMIDE
Drug Series
Serum concentration (µg/ml) at specified hours after
the administration of chemotherapy
No. of
patients 1 hour 2 hours 3 hours 6 hours
Mean  Rangea  Mean  Rangea  Mean  Rangea  Mean  Rangea
Streptomycin
High dosage (1 g) 192 52 28-90 49 29-88 38 18-78 18 6-39
Low dosage (0.75 g) 200 40 18-74 37 20-61 29 13-52 14 6-26
Slow inactivators 242 7.9  0.9-24.0 12.2 3.4-24.8 11.2 6.2-20.1 6.5 3.8-10.8
lsoniazid
Rapid Inactivators
Total pyrazinamide – 104  73  23-179  111 40-177  118  49-167  117 86-151
Free pyrazinamide 104 89 24-170 102 39-158 107 45-146 97 72-131
a The figures given are the range for the middle 95% of values, that is, excluding 2.5% at each extreme.
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the slow and the rapid inactivators, but amalgamat-
ing the three once-weekly series (SHOW, SHZOW
and SH/SHOW) since the rate of inactivation of
isoniazid was prognostically important in all of them
(page 172); patients in the SHTW series were not
considered, as for them the isoniazid inactivation
rate had no prognostic importance. For total and
free pyrazinamide, all the SHZOW patients were
considered. The findings will be reported in detail
later; in brief, none of the above measures was
associated with the outcome of treatment.
Toxicity
Streptomycin. 1 As in the paragraph above, high-
dosage and low-dosage patients in all four series
were considered together, since the differences be-
tween them in the incidence of toxicity were small
and non-significant (page 185). There was no differ-
ence in the serum streptomycin concentrations
between patients who had minor symptoms of
toxicity (giddiness, facial paraesthesia and tinnitus)
that did not require a reduction in streptomycin
dosage and those who had no symptoms. However,
giddiness necessitating a reduction in dosage or
cessation of streptomycin occurred significantly more
frequently in patients with higher streptomycin con-
centrations. Thus, considering the geometric mean
of the concentrations at 1, 2, 3 and 6 hours, the
proportion with a reduction or cessation of strepto-
mycin was 0% of 78 patients with a mean of less than
25 µg/ml, 1% of 94 in those with a mean of 25 µg/ml-
31 µg/ml, 3% of 133 in those with a mean of
32 µg/ml-39 µg/ml, and 5% of 86 in those with a
mean of 40 µg/ml or more, a significant trend
(P=0.01). Significant trends were also obtained
with the 6-hour concentration (P<0.01) and the
highest concentration (P=0.02), but not with the
half-life (P=0.2); the detailed findings will be
reported later.
Isoniazid. Isoniazid toxicity occurred predomi-
nantly in the slow inactivators of isoniazid (page 187).
However, among the slow inactivators, there was
little evidence that it occurred more often in the
patients with higher serum isoniazid concentrations;
the detailed findings will be reported later.
Pyrazinamide. As there was little evidence of
pyrazinamide toxicity (page 187), no attempt was
made to relate it to the serum pyrazinamide con-
centration.
VIII. PROGNOSTIC VALUE OF VARIOUS FACTORS ASSESSED ON
ADMISSION TO TREATMENT
This section relates the likelihood of an un-
favourable response to various factors assessed
on admission to treatment, and is based on patients
with an assessable response (that is, excluding
those who died of non-tuberculous causes, dis-
charged themselves against medical advice or had
their allocated chemotherapy terminated on account
of toxicity) from all three phases of the intake. An
unfavourable response to treatment is defined as
  death from tuberculosis, or bacteriologically active
disease (including termination of the allocated
chemotherapy for radiographic or serious clinical de-
terioration) or bacteriologically relapsed disease at
1 year.
The findings are presented (1) for all patients (that
is, irrespective of the regimen received) and (2) for
individual regimens. As the likelihood of an un-
favourable response cannot be smaller for patients
1 As the incidence of streptomycin toxicity cannot be
lower in patients with higher serum concentrations, l-tail
tests of significance have been employed.
with more severe disease at the beginning of treat-
ment than for those with less severe disease, P values
corresponding to l-tail tests of significance are
reported in this section.
ALL PATIENTS
Of 139 patients with extensive cavitation (Table 27)
23% had an unfavourable response as compared
with 18% of 239 with moderate cavitation and 9%
of 79 with slight or no cavitation; the trend in these
percentages is statistically significant (P < 0.01).
Considering next the total extent of disease, the pro-
portions with an unfavourable response were 26%,
23%, 18%, 14% and 0% for patients with gross,
extensive, moderate, limited and slight disease,
respectively (P < 0.01). Considering the direct smear
result of the first collection specimen, the proportions
with an unfavourable response were 23 %, 20 %, 12 %
and 14 % in patients with a 3-plus, 2-plus, 1-plus
and negative result, respectively (P = 0.01).
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TABLE 27
RESPONSE TO TREATMENT RELATED TO VARIOUS
FACTORS ASSESSED ON ADMISSION a
Unfavourable
response
No. %b
32 23
42 18
7 9
0 (0)
No. of
patients
139
239
77
2
Condition on admission
Extent of cavitation:
Extensive
Moderate
Slight
Nil
Total extent ofdisease:
Gross
Extensive
Moderate
Limited
Slight
34
102
188
118
15
Direct smear result of first
collection specimen:
3-plus
2-plus
1-plus
Negative
95
173
139
50
Total 457
9 26
23 23
33 18
16 14
0 (0)
22 23
35 20
17 12
7 14
81 18
a All 4 treatment series combined.
b Parentheses indicate that
fewer than 25 observations.
the percentage is based on
Analyses, not tabulated here, showed that 19 % of
294 males had an unfavourable response as com-
pared with 15% of 163 females (P = 0.4); also,
13 % of 114 patients aged under 25 years, 19% of
264 aged 25-44 years and 20% of 79 aged 45 years
or more had an unfavourable response, a non-
significant trend (P = 0.2). The proportions with an
unfavourable response were 20% in 148 patients
weighing less than 80 lb, 16 % in 230 weighing
80 lb-99 lb, and 19% in 79 patients weighing 100 lb
or more.
In summary, the extent of cavitation, the total
extent of disease and the direct smear result of the
first collection specimen of sputum influenced
significantly the response to treatment, whereas the
sex, the age and the weight did not do so.
In the SHTW series and the SH/SHOW series,
the numbers of patients with an unfavourable
response were relatively small, and there was little or
no evidence of an association between response to
treatment and the various factors assessed on admis-
sion (Table 28), all the differences being clearly non-
significant (P > 0.3). However, there was some
evidence of associations in the SHZOW series and
the SHOW series (both of which had an appreciable
number of patients with an unfavourable re-
sponse), especially the former. Statistical signifi-
cance was attained in two of the contrasts, both in
the SHZOW series–namely, an unfavourable
response in 33 % of the patients with gross, extensive
or moderate disease as compared with 6% of those
with limited or slight disease (P <0.01), and 33 % of
those with a 3-plus or 2-plus smear result as com-
pared with 11% in those with a 1-plus or negative
result (P = 0.02). However, the latter contrast
might have been influenced by the fact that the
proportion of rapid inactivators was substantially
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PATIENTS IN THE INDIVIDUAL SERIES higher in patients with a 3-plus or 2-plus result
than in those with a 1-plus or negative result (46%
and 13 %, respectively). Statistical standardiza-
tion for isoniazid inactivation rate was therefore
undertaken, and resulted in proportions with
unfavourable response of 29% in the former group
and 15% in the latter, still a significant difference
(P = 0.05).
IX. DRUG TOXICITY
It may be recalled that, except in the SHTW
series, slow inactivators of isoniazid responded
appreciably better than rapid inactivators (see pages
160 and 172). However, among the slow and among
the rapid inactivators, considered separately, none of
several measures obtained from the serum isoniazid
concentrations at 1, 2, 3 and 6 hours after a dose of
chemotherapy, influenced the outcome of treatment
(page 183). Similarly, none of several measures
obtained from the serum concentrations of strepto-
mycin and pyrazinamide had an effect on the
response to treatment (page 183).
The findings in this section are based on 476
patients in the main analyses from all three phases
combined. Patients were not questioned to elicit
complaints of drug toxicity; however, every sponta-
neous complaint to the musing or medical staff was
recorded, and was followed by careful questioning
by a physician.
STREPTOMYCIN
It will be recalled that neither the physicians nor
the patients were aware of the dosage of streptomycin
(1 g or 0.75 g) received by any individual patient.
In all, 11 patients had their streptomycin stopped
or the dosage reduced. Of these, 1 (low, SHTW) had
the allocated chemotherapy terminated in the 5th
month on account of cutaneous hypersensitivity to
streptomycin (and also to isoniazid), and 2 others
(both high; 1 SHTW, 1 SH/SHOW) in the 11th and
9th month, respectively, for giddiness which had
persisted despite a reduction in the dosage of
streptomycin (by one-third) in the 4th and 3rd
month, respectively. A further 6 patients, 3 on high
dosage (2 SH/SHOW, 1 SHZOW) and 3 on low
dosage (1 SHTW, 1 SH/SHOW, 1 SHOW), had a
reduction in dosage (by one-third) on account of
giddiness, in the 3rd, 6th, 2nd, 6th, 1st and 5th
month, respectively. Two patients (both high; both
SHTW) discharged themselves from treatment in
the 6th and 11th month, respectively, on account of
giddiness (in the former, a decision had already
been taken to reduce the dosage of streptomycin).
Thus, streptomycin toxicity (giddiness) was the
cause of a reduction in dosage or cessation of
streptomycin, or a premature discharge, in 10 (2.1%)
patients. The incidence was 0 % in 119 patients aged
under 25 years, 1.3 % in 155 patients aged 25-34
years, and 4.0% in 202 patients aged 35 years or
more, a significant trend (P = 0.01). Considering
next the incidence in the four series (the age-distribu-
tions for the four series were similar), the proportions
were 3 % of 148 in the SHTW, 4% of 106 in the
SH/SHOW, 1% of 105 in the SHZOW and 1% of
117 in the SHOW series; thus, there was a slight
suggestion of a higher incidence in the SHTW and
the SH/SHOW series. It is of interest that of the
4 SH/SHOW patients who had a reduction in
dosage of streptomycin, only 1 had the reduction
while receiving daily streptomycin (that is, in the
1st month). Lastly, there was a suggestion that the
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incidence was higher in the streptomycin high-
dosage than in the low-dosage patients (the age-
distributions for the two groups were similar), the
proportions being 3.0 % of 232 and 1.2 % of 244,
respectively (P = 0.3).
Minor complaints, not requiring a reduction in
streptomycin dosage, were made by 74 (16%)
patients. The incidence was (a) 17% in patients
aged under 25 years, 16 % in those aged 25-34 years
and 14% in those aged 35 years or more, (b) 14% in
the SHTW, 15% in the SH/SHOW, 21% in the
SHZOW and 13 % in the SHOW series, none of the
differences being significant (P > 0.2), and (c) 16%
in the streptomycin high-dosage patients and 15 %
in the low-dosage patients.
Some of the patients had more than one side-effect.
Giddiness, usually commencing within 3 hours of the
streptomycin injection and frequently lasting for the
rest of the day or longer, was complained of by
34 high-dosage and 33 low-dosage patients-namely,
18 SHTW (9 high, 9 low), 15 SH/SHOW (8 high,
7 low), 20 SHZOW (11 high, 9 low) and 14 SHOW
(6, high, 8 low) patients. The period the complaints
referred to was less than 1 month in 9 high-dosage
patients and 16 low-dosage patients, and 3 months
or more in 11 and 6, respectively. Complaints of
facial paraesthesia were made by 4 high-dosage
(2 SHTW, 1 SH/SHOW, 1 SHOW) and 2 low-dosage
(1 SHTW, 1 SH/SHOW) patients, and of tinnitus
by 2 patients (both low, both SHTW). Three
patients, 1 on high dosage (SHTW) and 2 on low
dosage (both SHZOW), complained of itching after
the injections (associated with urticaria in 1 of the
latter 2), the complaint referring to a period of
2 weeks in the first patient, 7 months in the second
and 8 months in the third; it is possible that pyrazin-
amide played a role in the 2 SHZOW patients.
In summary, streptomycin was stopped or the
dosage reduced in only a small proportion of the
patients; the incidence was significantly associated
with age, and there was a suggestion that it was
slightly higher in the SHTW and the SH/SHOW
patients and in the patients who received the high
dosage (1 g) of streptomycin. Minor complaints
were made by about one-sixth of the patients, but the
incidence was not influenced by the age of the
patient, the dosage of streptomycin or the regimen.
Rotating-chair test for vestibular function
The test procedure was as follows. The patient
was strapped to the seat of the rotating chair, fore-
arms resting horizontally on the arms of the chair,
feet spread apart against the vertical ends of the
foot-rest, head bent down (to stimulate the horizontal
canals) and eyes closed. The chair was manually
rotated for 20 seconds, at a steady speed of 1 revolu-
tion in approximately 2 seconds, in the clockwise
direction. At the end of this period, the chair was
stopped and the patient asked to look straight (head
erect) at a fixed point at a distance, while the assessor
recorded, with the aid of an assistant and a watch,
the duration of nystagmus. The end-point of the
nystagmus was taken as the point at which the least
quiver, horizontal or rotary, disappeared. The
procedure was repeated with the chair being rotated
in the anti-clockwise direction. The mean of the
2 readings (clockwise and anti-clockwise) has been
employed for analyses.
About 90 % of the rotating chair tests in this study
were undertaken by one of the Centre’s physicians
(the late Dr S. Velu) who was not involved in the
day-to-day management of the patients. The detailed
findings will be reported later; the main findings are
summarized below.
There was little evidence that streptomycin in the
high dosage (1 g) impaired vestibular function (as
assessed by the duration of nystagmus) to a greater
extent than in the low dosage (0.75 g). Thus, the
mean duration of nystagmus on admission to treat-
ment was 11.3 seconds for the high-dosage patients
and 12.3 seconds for the low-dosage patients, and
decreased at 12 months by 1.1 seconds in the former
as compared with 0.8 second in the latter, a non-
significant difference (P = 0.7). Also, analyses not
presented here showed that the over-all changes in
the duration of nystagmus between admission and
12 months in the SHTW, SH/SHOW, SHZOW and
SHOW series were similar.
In all, 39 patients complained of giddiness on 2 or
more occasions. At the time of the second complaint,
the rotating-chair test was undertaken for each of
these patients, as well as for a control patient of
similar age (usually ± 5 years) who had received
chemotherapy for a similar duration (± 2 months,
in about 70% of cases) but who had made no com-
plaints of giddiness. (The identity of the patient as
test subject or control was unknown to the assessor.)
The duration of nystagmus was less than 10 seconds
in 69% of the patients who had the complaints of
giddiness and in 45 % of the control patients, a signifi-
cant difference (P = 0.05); the mean durations for
the 2 groups were 7.2 and 10.1 seconds, respectively
(P = 0.02).
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In all, 8 patients had a reduction in streptomycin
dosage on account of toxicity (giddiness). For these
patients, the duration of nystagmus was 20, 16, 12,
12, 12, 9, 7 and 5 seconds on admission to treatment
(mean 11.6 seconds) and 15, 5, 18, 0, 0, 6, 6 and 3
seconds, respectively, at the time of the reduction
(mean 6.6 seconds); the decrease in the mean dura-
tion borders on significance (P = 0.06). Six of these
patients completed the year of chemotherapy and 5
had test results at 12 months; their mean duration of
nystagmus was 9.8 seconds at 12 months, the
corresponding means being 8.8 seconds at the time
of the reduction and 13.8 seconds on admission to
treatment. The remaining 2 patients, who had
values of 0 second and 6 seconds at the time of the
reduction, failed to tolerate the reduced dosage also
and had to have the streptomycin stopped, the dura-
tion of nystagmus at the time being 1 second and
5 seconds, respectively.
In summary, changes in the duration of nystagmus
did not appear to be influenced either by the dosage
of streptomycin or by the chemotherapeutic regimen.
However, there was some evidence that patients who
had complained twice of giddiness and those who
had a reduction in streptomycin dosage on account
of giddiness had impaired vestibular function
at the time, as demonstrated by a significantly
lowered duration of nystagmus.
ISONIAZID
It will be recalled from page 146 that 6 mg of pyri-
doxine was administered with every dose of isoniazid.
One patient (rapid, SHTW) had the allocated
chemotherapy terminated in the 5th month on
account of cutaneous hypersensitivity to isoniazid
(and streptomycin).
Isoniazid toxicity, which did not require a modi-
fication of the allocated chemotherapy, occurred
in 16 patients, the incidence being 6 (4%) in the
SHTW, 4 (4%) in the SH/SHOW, 2 (2%) in the
SHZOW and 4 (3 %) in the SHOW series. It occurred
more frequently in slow inactivators of isoniazid
(5.0% of 299) than in rapid inactivators (0.6% of
177), the difference being significant (P = 0.01). The
details are presented below.
Three patients (all slow inactivators) had convul-
sions. Of these, 2 had a single attack, 1 (SH/SHOW)
on the day of starting treatment (5 hours after the
administration of high-dosage isoniazid–see page
148) and the other (SHTW) in the 8th month; the
third patient (SHOW) had 2 convulsions, both on the
same day, in the 3rd month of treatment. A further
3 patients lost consciousness (it was uncertain
whether they had fainted or had had a convulsion)
once each, 1 (slow, SHTW) for half an hour in
the 5th month, 1 (slow, SHZOW) for 10 minutes
in the 8th month and 1 (rapid, SH/SHOW) for about
10 hours in the 12th month. (It is of interest that the
episode occurred after several weeks of treatment
in 5 of these 6 patients, despite the administration
of 6 mg of pyridoxine with every dose of isoniazid.)
Complaints of paraesthesia in the feet or limbs were
made by 11 patients–namely, 10 slow inactivators
(4 SHTW, 2 SH/SHOW, 1 SHZOW, 3 SHOW) and
the rapid inactivator (SH/SHOW) who lost con-
sciousness in the 12th month; one of the 10 slow
inactivators (SHTW) developed signs of peripheral
neuropathy.
In summary, complaints or episodes of isoniazid
toxicity, none of which required a modification of
the allocated chemotherapy, occurred in about
3 % of the patients despite the administration of 6 mg
of pyridoxine with every dose of isoniazid. The inci-
dence did not appear to be influenced by the regimen,
but was significantly higher in the slow inactivators
of isoniazid than in the rapid inactivators.
Joint pains
PYRAZINAMIDE
Of the 105 patients who received pyrazinamide
(SHZOW regimen), 5 complained of joint pains.
Of these, 2 had joint swellings as well, involving both
knees in one and the right knee and ankle in the
other. In all 5 patients, the allocated chemotherapy
was continued, phenylbutazone or aspirin being
prescribed, whenever necessary, to relieve the pain.
Toxicity to the liver
Jaundice occurred in 2 SHZOW patients and in
1 SHOW patient in the lst, 6th and 5th month,
respectively. One of the 2 SHZOW patients had an
SGOT activity of 90 Karmen units and an SGPT
activity of 50 Karmen units on admission to treat-
ment; jaundice was detected on the 16th day and
had cleared by the 28th day despite the patient
having received, in error, a dose of pyrazinamide
during this period; this patient may well have been
incubating infective hepatitis on admission. In the
second SHZOW patient, the pyrazinamide was
withdrawn for 8 weeks and then reintroduced
uneventfully.
Routine determinations of SGOT and SGPT
activity (see pages 147 and 148) did not reveal any
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evidence of toxicity to the liver in the SHZOW series.
Thus, the mean SGOT value in this series was 36.4.
Karmen units on admission, 34.7 Karmen units at
1 month and 35.2 Karmen units at 12 months, the
corresponding values in the control series (SHOW)
being 36.6, 37.6 and 32.9 Karmen units, respectively.
Further, the proportion of patients who had a high
SGOT, that is, 50 Karmen units or more (Sigma
Chemical Company, 1961), was 15 % on admission,
8 % at 1 month and 13 % at 12 months in the SHZOW
series, and 16 %, 13 % and 12%, respectively, in the
control series. The findings with the SGPT activity
were very similar.
Routine (once-weekly) tests for urobilinogen in
urine did not reveal any evidence of toxicity to the
liver in the SHZOW series. Thus, including the
patients with jaundice, 17 (0.4%) of 4749 tests in
SHZOW patients yielded a positive result as com-
pared with 21 (0.6 %) of 3506 in the control (SHOW)
patients; the proportions of patients who produced
one or more positive results were 8 % and 10%,
respectively. The patients with jaundice apart, a
positive result at 2 or more successive attendances
was obtained from 1 SHZOW and 2 SHOW patients;
in none of these was the finding associated with an
elevated SGOT or SGPT activity.
In summary, there was little evidence of pyrazin-
amide toxicity.
COMPLICATIONS REQUIRING ADMISSION TO HOSPITAL
OR SANATORIUM
Admission to hospital or sanatorium became
necessary for 15 patients (3 SHTW, 4 SH/SHOW,
2 SHZOW, 6 SHOW) on account of pulmonary
tuberculosis, the period in hospital or sanatorium
being less than 1 week for 4 (1 SH/SHOW, 3 SHOW), 
1-4 weeks for 4 (2 SHTW, 2 SH/SHOW), 5-8 weeks
for 3 (1 SH/SHOW, 1 SHZOW, 1 SHOW), and
11 weeks (SHTW), 15 weeks (SHOW), 34 weeks
(SHOW) and 49 weeks (SHZOW) for the remaining
4 patients. Further, 1 patient (SHTW) was hospi-
talized for 3 weeks on account of hypersensitivity
to streptomycin and isoniazid, and another (SHOW)
for 1 day on account of convulsions. In all, therefore,
17 (3.6%) of the 476 patients in the main analyses
required admission to hospital or sanatorium on
account of tuberculosis or drug toxicity.
X. REGULARITY OF ADMINISTRATION OF CHEMOTHERAPY
This section presents information on (1) the
proportion of the allocated chemotherapy received
by the patients, (2) the relationship between this
proportion and the response to treatment, and (3)
the acceptability of the four regimens. The analyses
are based on patients with an assessable response
(defined on page 183) from all three phases of the
intake, apart from 7 (2 SHTW, 2 SHZOW, 3 SHOW)
who failed to complete 1 month of treatment due
to death from tuberculosis or termination of the
allocated chemotherapy on account of serious
clinical deterioration; none of the 7 had missed any
of the prescribed doses of drugs. The number of
patients in the analyses is 450 (138 SHTW, 101
SH/SHOW, 99 SHZOW, 112 SHOW), including 16
who did not complete the year of treatment, 1
(SHOW) having died of tuberculosis in the 2nd
month and 15 (1 SHTW, 7 SHZOW, 7 SHOW) hav-
ing had their allocated chemotherapy terminated on
account of radiographic or serious clinical deteriora-
tion in the 2nd month or later; for these 16 patients,
the period up to the time of death or termination
has been considered.
For patients who completed the year of treatment,
the scheduled number of doses was 104 for the
SHTW regimen, 72 for the SH/SHOW regimen and
52 for the SHZOW and SHOW regimens.
PROPORTION OF ALLOCATED CHEMOTHERAPY
RECEIVED
Most of the patients received a very high propor-
tion of their allocated chemotherapy during the
year. Table 29 summarizes the findings by setting
out, for the various contrasts, the percentages of
patients who had received at least 90% of their
allocated chemotherapy. All but one of the per-
centages are 90 or above. Similar analyses were
undertaken for the first 3 months of chemotherapy
(as the early months of treatment are known to be
especially important prognostically), and yielded the
same conclusion. Thus, there was no evidence that
patients allocated to the SHZOW or SHOW regi-
mens, both of which proved to be unsatisfactory, had
received proportionately fewer doses of the allocated
chemotherapy than those allocated to the more
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TABLE 29
PERCENTAGES OF PATIENTS WHO RECEIVED AT LEAST 90% OF THEIR
ALLOCATED CHEMOTHERAPY DURING THE YEAR
lsoniazid
inactivation
rate
Total
Phases I and II
SHTW
High 96
Low 95
Slow 95
Rapid 97
96
SHOW
100
96
98
98
98
Phases II and III
SHTW  SH/SHOW SHZOW  SHOW
98 100
98 95
95 97
100 97
97 97
effective SHTW or SH/SHOW regimens, nor did
rapid inactivators of isoniazid or streptomycin low-
dosage patients in any of the four series receive fewer
doses than the corresponding slow inactivators or
high-dosage patients.
RESPONSE TO TREATMENT RELATED TO THE PERCENTAGE
OF ALLOCATED CHEMOTHERAPY RECEIVED
95% of their chemotherapy than in those who had
received 95 % or more. In the SHOW series, how-
ever, 5 of 10 patients in the former category had an
unfavourable response as compared with 25 of 102
in the latter, a suggestive but non-significant differ-
ence (P = 0.1). Amalgamating the four series, an
unfavourable response was observed in 17 %, 15 %,
15 % and 17 % of the patients who had received less
than 90 %, 90 %-94 %, 95 %-99 % and 100 %, respect-
ively, of their allocated chemotherapy.
Table 30 relates the response to treatment in the In summary, there was little evidence of an asso-
four series to the percentage of allocated chemo- ciation between response to treatment and the per-
therapy received during the year. In the SHTW, centage of allocated chemotherapy received; how-
SH/SHOW and SHZOW series, there was no evi- ever, it should be noted that only 18 patients (4%) in
dence that an unfavourable response occurred more this study missed more than 10% of their chemo-
frequently in patients who had received less than therapy.
TABLE 30
RESPONSE To TREATMENT IN RELATION TO THE PERCENTAGE OF ALLOCATED CHEMOTHERAPY
RECEIVED DURING THE YEAR
 S H T W  s e r i e s  S H / S H O W  s e r i e s     S H Z O W  s e r i e s      S H O W  s e r i e s  All series
Percentage
of allocated
chemo-
Unfavourable Unfavourable
No. of
therapy
response a No. of response a No. of response
received
patients
No .  % b
patients
No .  % b
patients
< 90 9 0 4 1 3 0 2 2 18 3
1
(5) (8) (10)
(17)
(50)
90-94 10 8 0 7 1 8 3 33 5 15
95-99 78 6 42 9 19 4 24 6 163 25 15
7 12 25 25
100 41 2 47 2 70 18 78 19 236 41 17
a That is, death from tuberculosis or bacteriologically active disease (including termination of the allocated chemotherapy
for radiographic or serious clinical deterioration) or bacteriologically relapsed disease at 1 year.
b Parentheses indicate that the percentage is based on fewer than 25 observations.
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ACCEPTABILITY OF THE REGIMENS
In general, patients were expected to make their
own arrangements to attend the Centre for treatment.
However, an ambulance was employed to bring
them to the clinic on 55 occasions (that is, 0.2 % of a
total of approximately 31 600 occasions on which
chemotherapy was administered in the study), and
chemotherapy was administered at home on 138
(0.4%) occasions for patients who were very ill. In
a further 133 (0.4%) occasions, chemotherapy was
administered to patients while they were in hospital
or sanatorium. When assessing the acceptability of
the regimens, the above 326 (1.0%) occasions have
been excluded.
Regularity of attendance on the appointed day
Table 31 sets out the distribution of patients in the
four series according to the percentage of occasions
on which they attended the Centre punctually for
treatment; attendances which were early by 1 or
more days did not cause any extra work for the
Centre’s staff, and have also been regarded as
punctual. (For the SH/SHOW patients, only the
once-weekly phase of chemotherapy (that is, from
week 4 to week 52) has been considered. During the
daily phase, the patients were very regular, 95% of
them attending on at least 90 % of the occasions.)
All four regimens were highly acceptable, the
mean regularity being 93 % in the SHTW series, 91%
TABLE 31
REGULARITY OF ATTENDANCE FOR ADMINISTRATION
OF DRUGS
Percentage of
occasions on which
patients attended
on the appointed
day (or earlier)
100
96-99
90-94
                 80-89
70-79
<70
Total patients
Mean regularity
1
SHTW
No.  %
14
62
55
32 23
21 15
6 4
3 2
38 99
93%
1
SW
SHOW a
No.  %
49
22 22
17 17
9 9
4 4
01 101
91%
SHZOW SHOW
No.  % No .  %
18
46
30
24 24
16 16
8 8
5 5
28
59
38
20 18
15 13
8 7
3 3
99 99 112 100
93%
a Excluding the first 4 weeks, during which the patients
received daily chemotherapy.
a Excluding the first 4 weeks, during which the patients
received daily chemotherapy.
in the SH/SHOW, 91% in the SHZOW and 93 % in
the SHOW series.
Punctual attendance related to duration of treatment
The regularity with which patients attended the
Centre punctually during the four quarters of the
year of treatment is summarized in Table 32. In
the SHTW series, the proportion of patients who
attended the Centre punctually on at least 90% of
the occasions was 89 % in the first quarter, 75 % in the
second, 70% in the third and 63 % in the fourth
quarter; the trend in these percentages is highly
significant (P <0.00001). The trend was less marked
in the SH/SHOW (P = 0.1), the SHZOW (P <0.01)
and the SHOW series (P <0.01). Considering all the
three once-weekly series together, punctual attendance
on at least 90 % of the occasions was noted in 82 %,
75%, 73 % and 68 % of the patients in the four
quarters, respectively, the trend being highly signifi-
cant (P <0.0001). In summary, there was a tendency,
particularly prominent in patients receiving the twice-
weekly regimen, for fewer punctual attendances in the
later months of treatment. However, this did not
greatly affect the amount of chemotherapy received
in the later months, since the patients usually came for
their treatment a day or two later, either on their own
or because of the efforts made by the clinic staff (see
page 147).
Patients who took their discharge against
medical advice
In all, 13 (2.7 %) of the 476 patients in the main
analyses took their discharge against medical advice
TABLE 32
PERCENTAGES OF PATIENTS WHO ATTENDED ON THE
APPOINTED DAY (OR EARLIER) ON AT LEAST 90%
OF THE OCCASIONS
Twice-
weekly Once-weekly series
Period series
(months)
SH/
SHTW S H O W  S H Z O W  S H O W Total
74 a 83 88 82
73 75 78 75
70 70 79 73
65 66 72 68
during the year of treatment-namely, 5 (2 high,
3 low) of 148 SHTW, 3 (1 high, 2 low) of 106
SH/SHOW, 4 (1 high, 3 low) of 105 SHZOW and 1
(low) of 117 SHOW patients. The incidence did not
appear to be influenced either by the dosage of
streptomycin or the rhythm of administration of
chemotherapy. Thus, it was 1.7% of 232 in high-
dosage patients as compared with 3.7% of 244 in
low-dosage patients (P = 0.3), and 3.4% of 148 in
the twice-weekly series as compared with 2.4% of
328 in the three once-weekly series combined
(P = 0.8).
Of the 13 patients who took their discharge against
medical advice, 46% attended punctually on less
than 75% of the occasions (before they took their
discharge) as compared with only 5% of the 450
patients (see page 188) who did not, a highly signifi-
cant difference (P<0.001). The mean proportion
for punctual attendance was 74 % (range 30 %-94 %)
for the former, as compared with 92 % (range 46 %-
100%) for the latter.
URINE TESTS FOR INGESTION OF ISONIAZID
In all, 1225 urine specimens were collected at
surprise visits to patients’ homes, 2-24 hours after
the supervised administration of chemotherapy. Of
these, 94% yielded a positive result for acetyl-
isoniazid or isonicotinic acid. Thus, there was little
evidence of patients not having swallowed isoniazid,
when it was administered under the supervision of a
nurse.
Of a total of approximately 20 500 urine speci-
mens, collected once weekly from all the patients
(at their routine visits to the clinic during the year
of treatment) prior to the administration of drugs
(that is, 3-7 days after the previous dose of drugs),
141 (0.7%) yielded a positive result for acetyl-
isoniazid or isonicotinic acid. This suggests that
patients did not supplement their allocated chemo-
therapy with isoniazid from other sources; in other
words, the administration of chemotherapy in this
study was, in fact, truly intermittent.
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XI. PATIENTS WITH DRUG-RESISTANT ORGANISMS ON ADMISSION TO STUDY
In all, 56 patients were excluded from the main
analyses because they had drug-resistant organisms
on admission. Careful questioning by the physicians
prior to admission and at 3 months failed to elicit a
history of more than 2 weeks of previous chemo-
therapy in any instance. It may therefore be pre-
sumed that all 56 patients had been infected with
resistant organisms. Of these, 32 had isoniazid-
resistant cultures and 37 streptomycin-resistant cul-
tures, including 13 with cultures resistant to both
the drugs. Thus, the incidence of primary drug
resistance was 5.9% to isoniazid and 6.8% to
streptomycin, including 2.4 % to both the drugs (these
percentages are based on a total of 542 patients).
The response to treatment of the 56 patients with
primary drug resistance is summarized below. The
findings are not presented separately for the four
regimens, in view of the small numbers of patients
involved.
RESISTANCE TO ISONIAZID ONLY
Of 19 patients who had organisms resistant to
isoniazid only, 14 (74%) had a clear-cut bacterio-
logical response initially, including 8 (42%) with a
favourable response at 1 year (Table 33). There is
some evidence that a favourable response at 1 year
occurred more frequently in slow inactivators of
isoniazid than in rapid inactivators (P = 0.05), and a
suggestion that it occurred more frequently in
patients who received the high dosage of strepto-
mycin than in those who received the low dosage.
RESISTANCE TO STREPTOMYCIN ONLY
Of 24 patients who had organisms resistant to
streptomycin only, 22 (92 %) had a clear-cut bacterio-
logical response initially, including 13 (54%) with
a favourable response at 1 year (Table 33). Again,
there is a suggestion that slow inactivators of
isoniazid and patients receiving the high dosage of
streptomycin had a more satisfactory response.
RESISTANCE TO EITHER ISONIAZID OR STREPTOMYCIN
In all, there were 43 patients with primary resist-
ance to either isoniazid or streptomycin (but not
both). Of these, 36 (84%) had a clear-cut bacterio-
logical response initially, including 21 (49%) with a
favourable response at 1 year (Table 33). The pro-
portions with a favourable response were 72% of 18
for slow inactivators of isoniazid and 33 % of 24 for
rapid inactivators, a significant difference (P = 0.03),
and 59 % of 27 for streptomycin high-dosage patients
and 31% of 16 for low-dosage patients (P = 0.1).
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RESISTANCE TO BOTH ISONIAZID AND STREPTOMYCIN
Of 13 patients with primary resistance to both
isoniazid and streptomycin, 4 had a clear-cut bac-
teriological response initially. Of these, one had a
favourable response at 1 year and another had the
allocated chemotherapy terminated in the 10th
month on account of persisting sputum positivity;
the other two took their discharge against medical
advice in the 6th and 7th month, respectively, both
having had only negative cultures in the preceding
4 months (no specimens could be obtained sub-
sequently from either patient).
In summary, a favourable response to treatment
was observed in about half the patients with primary
resistance to either isoniazid or streptomycin; there
was some evidence that it occurred more often in
slow inactivators of isoniazid than in rapid inactiva-
tors, and in streptomycin high-dosage patients than
in low-dosage patients. In patients with primary
resistance to both isoniazid and streptomycin, the
response was almost always unfavourable. It must
be emphasized, however, that these conclusions are
based on small numbers of patients, and do not take
into account the radiographic and bacteriological
condition of the patients on admission to treatment..
XII. DISCUSSION
The investigations reported here constitute vir-
tually two studies, the patients in both of which were
prescribed intermittent chemotherapy for a year.
The first study was a concurrent controlled com-
parison of a twice-weekly regimen of streptomycin
(1 g or 0.75 g) plus high-dosage isoniazid (15 mg/kg
body-weight), the SHTW regimen, and a once-
weekly regimen consisting of the same two drugs in
the same dosages, the SHOW regimen. In the
second controlled study, the same two regimens
were investigated together with two modifications
of the once-weekly regimen. One of these was the
SHZOW regimen, in which high-dosage pyrazin-
amide (90 mg/kg body-weight) was administered at
the same time as the streptomycin plus high-dosage
isoniazid, making a once-weekly triple-drug regimen.
The other was the SH/SHOW regimen, in which an
initial daily phase of four weeks of streptomycin
(1 g or 0.75 g) plus moderate-dosage isoniazid
(400 mg) preceded the once-weekly phase of 48 weeks
of streptomycin plus high-dosage isoniazid. In both
studies, the regimen and the streptomycin dosage for
each patient were determined by a random alloca-
tion process; further, the studies were conducted
double-blind in respect of streptomycin dosage, in
order to avoid the possibility of bias in the assess-
ment of streptomycin toxicity. There was a period
of overlap between the two studies, which resulted
in over half the SHTW and the SHOW patients
being common to them. The results of these two
controlled clinical trials are considered separately
when comparing therapeutic efficacies; however,
for certain other aspects (for example, toxicity,
acceptability), it is advantageous to consider the
findings in all patients who were prescribed the same
regimen, regardless of the study to which they were
admitted.
In both studies, despite random allocation to
treatment, there were unusually large differences
between the series in the proportion of rapid inactiv-
ators of isoniazid. As the response of rapid in-
activators was considerably less satisfactory than
that of slow inactivators (pages 160 and 172), sta-
tistical standardization of the results was undertaken
to allow for these differences, and only statistically
standardized percentages have been employed when
making comparisons of therapeutic effectiveness. In
the event, however, the differences between the
standardized and the unstandardized percentages
were almost always small (for example, see Tables 9
and 15).
EFFICACY
Comparisons between the SHTW and SHOW
regimens
The comparisons are based on 123 SHTW and
117 SHOW patients, all of whom had a positive
sputum and the majority of whom had moderate or
extensive cavitation on admission. In all, 90% of
the SHTW and 72% of the SHOW patients had
a favourable response at 12 months (P<0.001),
defined purely in bacteriological terms. Thus, twice-
weekly chemotherapy with isoniazid plus strepto-
mycin, even when given from the very outset of
treatment, was highly effective, confirming the
findings in an earlier study from this Centre (Tuber-
culosis Chemotherapy Centre, Madras, 1964). In
contrast, the once-weekly regimen (SHOW) was
substantially inferior. Even so, it is noteworthy
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that the efficacy ‘of this regimen is practically the
same as that attained with daily isoniazid (as a single
dose), in a dosage of 9 mg/kg body-weight (Tuber-
culosis Chemotherapy Centre, Madras, 1960) or
in a dosage of 14 mg/kg body-weight (Tuberculosis
Chemotherapy Centre,  Madras, 1963b).
The inferiority of the SHOW regimen was also
demonstrated by (1) the numbers of patients who
died from pulmonary tuberculosis or had their
allocated chemotherapy terminated on account of
radiographic or serious clinical deterioration
(3 SHTW, 11 SHOW), (2) the proportions of patients
with considerable or exceptional radiographic
improvement over the year (SHTW 76x, SHOW
600/,), and (3) the proportions of patients with
resistance to isoniazid (SHTW 8 %, SHOW 19%)
and resistance to streptomycin (SHTW 7%, SHOW
18 %) at 1 year.
i
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response being almost identical for slow and rapid
S&Z inactivators and identical for streptomycin high-
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z=3
2 ; r‘
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streptomycin played a role, for 78% of the patients
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favourable response (P = 0.2). Further evidence of
p g:;;m the influence of streptomycin dosage in the SHOW
0 m c series is available from the pattern of the sensitivityez vE 8 ‘ii test results during treatment (Table 17).
8 $.g It may be concluded that the SHTW regimen,
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which consisted of a weight-adjusted dosage of
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isoniazid and one of two dosages of streptomycin
4 g $
(1 g or 0.75 g), was highly effective, and unintluenced
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either by the rate of inactivation of isoniazid or by the
%f g ‘;;; dosage of streptomycin; these findings suggest that it
ii@ a can be applied with considerable confidence  inm I-
“2 P
populations where the patients are, on the average,
.s!?EC heavier (the average weight of the patients in this
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study was 85 lb (38.6 kg)), or which contain a higher
*au proportion of rapid inactivators of isoniazid (the
proportion was approximately one-third in this
study). The SHOW regimen was substantially
inferior in therapeutic efficacy, considerably influ-
enced by the rate of inactivation of isoniazid and
probably influenced by the streptomycin dosage.
Comparisons between the SHTW, SH/SHOW,
SHZOW and SHOW regimens
The comparisons are based on 104 SHTW, 106
SH/SHOW, 105 SHZOW and 79 SHOW patients.
The addition of once-weekly pyrazinamide to the
SHOW regimen resulted in little improvement in the
therapeutic efficacy, 74 % of the SHZOW and 68 %
of the SHOW patients having a favourable response
at 12 months (P = 0.4). On the other hand, the
introduction of an initial daily phase of streptomycin
plus moderate-dosage isoniazid for 4 weeks led to a
significant increase in efficacy (P <0.01), 88 % of the
SH/SHOW patients having a favourable response;
this proportion approaches the level of success
attained with the SHTW regimen, namely 94 %.
It is noteworthy that all of 13 patients who had
their allocated chemotherapy terminated on account
of radiographic or serious clinical deterioration and 5
of 6 patients who died of tuberculosis had received
either the SHZOW or the SHOW regimen, that is,
once-weekly chemotherapy from the outset of
treatment.
and the SHZOW series that the response of the
high-dosage (1 g) patients was better than that of the
low-dosage (0.75 g) patients. In the other two
series, there was a suggestion of a dosage effect, the
proportions with a favourable response being 74 % in
the high-dosage and 63 % in the low-dosage patients
in the SHOW series, and 92 % and 84 %, respectively,
in the SH/SHOW series; neither difference was
significant (P > 0.2). However, in the SHOW series,
there was other evidence of a streptomycin dosage
effect, from the pattern of the sensitivity test results
during treatment (Table 17).
Other criteria of efficacy-radiographic progress
and emergence of drug resistance-ranked the four
regimens in the same order. Thus, over the year,
considerable or exceptional radiographic improve-
ment was shown by 79 % of the SHTW, 73 % of the
SH/SHOW, 65 % of the SHZOW and 57% of the
SHOW patients. Further, the proportions of patients
with an isoniazid-resistant culture at 12 months
were 5 %, 9%, 16% and 22%, respectively, while
those with a streptomycin-resistant culture were 4%,
8 %, 16 % and 19 %, respectively.
In conclusion, the SHTW regimen was highly
effective and uninfluenced either by the rate of
inactivation of isoniazid or by the dosage of strepto-
mycin. Of the three once-weekly regimens, the
SH/SHOW regimen approached it in terms of over-
all therapeutic efficacy; however, it was considerably
influenced by the rate of inactivation of isoniazid,
and possibly influenced by the streptomycin dosage.
Therefore, if this regimen is applied in populations
with a high proportion of rapid inactivators-for
example, Eskimos (Armstrong & Peart, 1960) or
Japanese (Sunahara, 1962)–the results are likely to
be appreciably less satisfactory than those reported
here. They might also be less satisfactory in heavier
patients than those under treatment in the present
study, on account of a streptomycin inadequacy.
The SHZOW regimen was substantially inferior to
the SHTW regimen, especially in rapid inactivators
of isoniazid, and the SHOW regimen was the least
effective, and was considerably influenced by the
rate of inactivation of isoniazid and probably
influenced by the streptomycin dosage.
Influence of the rate of inactivation of isoniazid
and streptomycin dosage
In the SHTW series, the isoniazid inactivation
rate was of little prognostic importance. However,
in all the three once-weekly series, the slow inactiva-
tors responded significantly better than the rapid
inactivators, the proportions with a favourable
response being 95 % and 76 % with the SH/SHOW
regimen, 87 % and 53 % with the SHZOW regimen
(85% and 60% after standardization for pretreat-
ment differences in the bacterial content of the
sputum), and 76% and 56% with the SHOW
regimen. Considering next the influence of strepto-
mycin dosage, there was no evidence in the SHTW
A point of immediate practical importance arises
from the finding of high efficacy (95%) of the
SH/SHOW regimen in slow inactivators of isoniazid.
This is that the regimen would be of great value, if
patients could be identified both easily and speedily
as slow or rapid inactivators of isoniazid and the
regimen prescribed only for the slow inactivators.
However, the determination of the rate of inactiva-
tion of isoniazid, whether by chemical or micro-
biological assay, requires a considerable degree of
technical skill and cannot be readily undertaken as a
routine procedure in many laboratories. A new
test, the sulfadimidine test, is technically less difficult
to perform, requires an examination of urine rather
than blood (which is usually necessary with the other
methods), and can easily and speedily be undertaken
on large numbers of patients. This test, based on
the work of Evans & White (1964), has been devel-
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oped at this Centre by Rao et al. (1970), who have
demonstrated very satisfactory agreement between
the classification of patients (as slow or rapid
inactivators) based on this method and that based
on microbiological assay of isoniazid by a vertical
diffusion method.
FACTORS OF PROGNOSTIC IMPORTANCE
Amalgamating all the series and considering the
factors usually investigated for prognostic import-
ance, the extent of cavitation, the total extent of
disease and the bacterial content in sputum on
admission were all associated significantly with
response, but sex, age and weight were not. The
associations were more prominent with the less
effective SHOW and SHZOW regimens.
Serum concentrations of streptomycin and iso-
niazid, and pyrazinamide also for the SHZOW
patients, were determined at 1, 2, 3 and 6 hours after
an appropriate dose of chemotherapy (streptomycin,
1 g or 0.75 g; isoniazid, 15 mg/kg body-weight;
pyrazinamide, 90 mg/kg body-weight). Several mea-
sures (for example, highest concentration, 6-hour
concentration, geometric mean) were obtained from
these estimations for each patient, and related to the
response to treatment. In the case of isoniazid, since
it was known that the slow inactivators had re-
sponded substantially better than the rapid inact-
ivators (page 172), the analyses were undertaken
separately for the two groups. None of the measures
was associated with the outcome of treatment, a
finding of considerable importance in view of the
recommendation made by Russell & Middlebrook
(1961) that serum concentrations should be estimated
and the dosages of the drugs then adjusted appro-
priately for each individual patient until a satisfactory
concentration is obtained. It follows that there is a
need to view more critically this approach to the
chemotherapy of tuberculosis. The value of serum
  drug concentrations in adjusting dosage with a view
to prevent drug toxicity is, however, a separate issue
(page 200).
BACTERIOLOGICAL FINDINGS DURING TREATMENT
The bacteriological findings in this study will now
be summarized and the mechanisms that may
explain them discussed.
Speed of sputum conversion
A remarkable feature of this study was the finding
that the rates of sputum conversion (to culture
negativity) in the first 2 months of treatment were
broadly similar for the four regimens (Fig. 3 and 4),
despite considerable differences between them in the
frequency of drug administration. It will be recalled
that the latter ranged from daily administration in
the first month (SH/SHOW regimen) to once-weekly
administration from the outset of treatment (SHOW
and SHZOW regimens). It follows, therefore, that
intermittent chemotherapy was highly effective in
reducing the population of viable bacilli from the
outset of treatment. Next, amalgamating all four
series, the speed of sputum conversion in the first
2 months was the same for slow and rapid inactiva-
tors of isoniazid, and for streptomycin high-dosage
and low-dosage patients. Lastly, in patients with
bacteriologically quiescent disease at 1 year, there
was no evidence that persisting culture negativity
had commenced earlier with the more effective
regimens or in streptomycin high-dosage patients or
in slow inactivators of isoniazid.
Very different findings have been obtained in
experimental tuberculosis with the mouse. For
instance, lung viable counts at 3 months after the
start of treatment were much lower in mice receiving
a daily regimen of streptomycin plus isoniazid than
in those receiving a twice-weekly regimen of strepto-
mycin plus isoniazid (Grumbach et al., 1964) or,
indeed, a regimen consisting of isoniazid daily and
streptomycin on alternate days (Grumbach, 1962).
This discrepancy raises the possibility that in man,
unlike in the mouse, the bactericidal activity of
drugs is largely determined by the physiological
state of the tubercle bacilli, that is, by the proportion
of organisms that are actively metabolizing at the
time.
Emergence of differences between the four series
in culture results and occurrence of drug resistance
At 3 months, clear differences emerged between
the four series in the proportion of patients with a
positive culture (Fig. 4). These differences persisted
for the rest of the year, the proportions with a
positive culture at monthly examinations during this
period (4-12 months) ranging from 25 % to 31% in
the SHOW, 18 % to 26% in the SHZOW, 7% to
13 % in the SH/SHOW, and 4 % to 10% in the
SHTW series (Table 12). The proportion of patients
with an isoniazid-resistant culture at 4-12 months
ranged from 19% to 24%, 12% to 16%, 3% to 9%
and 3 % to 6 % in the four series, respectively, and
the proportion with a streptomycin-resistant culture
from 9% to 19%, 10% to 16%, 1% to 8% and 2% to
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6%, respectively (Table 13). Thus, drug resistance
emerged more frequently with the less effective
SHOW and SHZOW regimens. It also occurred
more rapidly with these regimens; for instance, the
proportions of positive cultures with resistance to
isoniazid at 3 months were 47 % in the SHOW, 35 %
in the SHZOW, 16% in the SH/SHOW and 10% in
the SHTW series. These findings suggest that failure
of chemotherapy was often associated with the
emergence of drug resistance.
Elimination of drug-sensitive organisms
A further feature of the sensitivity test results
(available from 3 months onwards) was the slower
elimination of drug-sensitive organisms by the less
effective SHOW and SHZOW regimens (Table 16).
This is also illustrated by the finding that of 222
patients treated with the SHOW or the SHZOW
regimen, 8 persistently produced isoniazid-sensitive
or streptomycin-sensitive cultures even in the later
months of treatment, as compared with only 1 of 254
patients treated with the SHTW or the SH/SHOW
regimen. All 9 patients were very regular in receiving
their supervised chemotherapy, none having missed
more than one dose during the whole year. This
phenomenon, namely, persistent production of sen-
sitive cultures despite a high degree of regularity
in drug-intake, has not been observed in any of
6 previous studies at this Centre, in which a total of
916 patients was treated with a daily regimen of
isoniazid alone, of isoniazid plus PAS or of isoniazid
plus thioacetazone (Tuberculosis Chemotherapy
Centre, Madras, 1959, 1960, 1963a, 1963b, 1964,
1966).
At first sight, it seems paradoxical that, on the
one hand, drug-sensitive organisms were eliminated
more slowly by the less effective SHOW and SHZOW
regimens, and, on the other, drug resistance emerged
more frequently and more rapidly with these regi-
mens. However, an examination of the pattern of
the sensitivity test results within each of the four
series provides some explanation.
Pattern of sensitivity test results within each series
With the SHOW regimen (Table 17), isoniazid-
sensitive organisms were eliminated more slowly by
rapid inactivators of isoniazid than by slow inactiva-
tors, indicating a relatively low efficacy of isoniazid
in the former. These isoniazid-sensitive organisms
must have included streptomycin-resistant mutants,
which increased in number on account of multiplica-
tion of the organisms between successive once-
weekly doses (see below), thereby causing the fre-
quent and rapid emergence of streptomycin resis-
tance. After an interval of several months, secondary
resistance emerged to the first drug, namely, iso-
niazid. Similarly, an inadequacy of streptomycin in
the low-dosage patients was indicated by a slower
elimination of streptomycin-sensitive organisms,
frequent and rapid emergence of isoniazid resistance
and, finally, secondary resistance to streptomycin.
Employing the same method of interpretation, an
isoniazid inadequacy was detected in rapid inactiva-
tors in the SHZOW series (Table 18) and in the
SH/SHOW series (Table 19); however, in neither
series was there any evidence of a streptomycin
inadequacy in the streptomycin low-dosage patients.
With the SHTW regimen (Table 20), there was no
evidence of an inadequacy of either isoniazid or
streptomycin, using the above method of interpreta-
tion.
Multiplication of drug-sensitive organisms
As indicated above, a feature of the sensitivity
pattern in the three once-weekly series was the
slower elimination of organisms sensitive to a drug
acting with relatively low efficacy, and the frequent
emergence of resistance to the companion drug. In
explaining this phenomenon, it was tacitly assumed
that multiplication of drug-sensitive organisms
occurred between successive doses of once-weekly
chemotherapy. The evidence for this assumption
will now be considered.
During daily chemotherapy, intervals when drug
concentrations are low exist, but even so, there is
evidence, reviewed by Mitchison (1965), that multi-
plication of sensitive organisms ceases soon after
the start of treatment. Among the lines of evidence
quoted are, first, that growth of sensitive organisms
has been found to be inhibited for several days
following an exposure to isoniazid or streptomycin
in vitro. Secondly, if it is really necessary for a
bacteriostatic concentration of isoniazid to be present
throughout the day in order to prevent growth, the
efficacy of daily regimens containing isoniazid may
be expected to depend on the length of time for
which a bacteriostatic concentration of isoniazid
is maintained, and in particular, the efficacy may
be expected to be lower in rapid inactivators of
the drug than in slow inactivators. However, no
such relationship has been found with daily regimens
of isoniazid alone; instead, the efficacy was found to
be related to the peak serum concentration attained
(Gangadharam et al., 1961). Further, no appreciable
differences in response have been found between
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slow and rapid inactivators of isoniazid treated with
daily regimens, either at this Centre (Table 34) or
elsewhere (Harris, 1959, 1961; Scottish Thoracic
Society, 1962; see also the review by Schmidt, 1962).
Thirdly, if sensitive organisms did multiply during
treatment, it might be expected that some patients,
even though regular in their intake of drugs, would
produce sensitive cultures persistently; however,
such a phenomenon has not been observed with any
daily regimen at this Centre (page 196).
It is likely that the SHTW regimen, although an
 intermittent one, also inhibited the multiplication
of drug-sensitive organisms soon after the start of
treatment. In the in vitro experiments of Dickinson
& Mitchison (1966), the maximal lag period before
growth restarted was 10 days after exposure to
streptomycin and 7 days after exposure to isoniazid,
periods which were considerably longer than the
interval of 3-4 days between successive doses of the
SHTW regimen. Next, although it has been estim-
ated that, following a dose of chemotherapy which
included isoniazid 15 mg/kg body-weight, a bacterio-
static concentration of isoniazid (0.2 µg/ml) is
maintained for a considerably longer period in slow
inactivators of the drug than in rapid inactivators–
namely, for 30 hours and for 14 hours, respectively
(Tuberculosis Chemotherapy Centre, Madras, un-
published data)-there was little difference between
them in their response to the SHTW regimen,
either in this study (Table 9), or in an earlier
one (Tuberculosis Chemotherapy Centre, Madras,
1964) in which the proportions with a favourable
response were 92% of 36 for slow inactivators and
97% of 36 for rapid inactivators. Finally, of 227
patients treated with the SHTW regimen in this and
the earlier study, none produced isoniazid-sensitive
or streptomycin-sensitive cultures persistently, al-
though there were 9 patients who were persistently
culturepositive during the year of treatment.
In contrast, there are reasons for presuming that
multiplication of sensitive organisms occurred
between doses in patients who received once-
weekly regimens of chemotherapy. First, the
interval between the doses approached fairly closely
the duration of the maximal lag induced by exposure
to streptomycin (10 days) or isoniazid (7 days) in
the in vitro experiments of Dickinson & Mitchison
(1966); it is likely, therefore, that on some occasions,
growth would have just restarted before the next
dose of chemotherapy was administered. Secondly,
unlike the experience with daily regimens and the
SHTW regimen, the response of rapid inactivators of
isoniazid was substantially inferior to that of slow
inactivators with each of the three once-weekly
regimens. (In the experiments of Dickinson &
Mitchison (1966), a lag before the recommencement
of growth occurred if the period of exposure to
isoniazid was 24 hours or more, but did not occur
if the period of exposure was 12 hours or less. This
finding suggests that the multiplication of sensitive
organisms between once-weekly doses of chemo-
therapy was greater in the rapid inactivators of
isoniazid than in the slow inactivators.) Finally,
unlike the experience with daily regimens and the
SHTW regimen, there were 9 patients in the once-
weekly series who, although extremely regular in
receiving their supervised chemotherapy, persistently
produced drug-sensitive cultures even in the later
months of treatment.
Thus, the most likely explanation for the differ-
ences in therapeutic efficacy between the once-
weekly regimens on the one hand and the twice-
weekly regimen on the other is that multiplication of
drug-sensitive organisms had occurred, particularly
in patients with an unfavourable response, between
the widely spaced doses of the once-weekly regimens,
whereas no such multiplication had occurred between
doses of the twice-weekly regimen. If this were so,
TABLE 34
INFLUENCE OF ISONIAZID INACTIVATION RATE ON
RESPONSE TO TREATMENT
WITH DAILY REGIMENS OF CHEMOTHERAPY
Regimen
Low-dosage isoniazid
(4.5 mg/kg)
Moderate-dosage
isoniazid
(8.7 mg/kg)
Slow 69 48 70
Rapid 59 36 61
High-dosage isoniazid Slow 81 56 69
(14 mg/kg) Rapid 62 41 66
lsoniazid (4.5 mg/kg) Slow 140 125 89
plus PAS (0.2 g/kg) Rapid 75 61 81
lsoniazid (6.9 mg/kg)
plus thioacetazone
(3.4 mg/kg)
Slow 33 30 79
Rapid 27 23 35
a That is, bacteriologically quiescent disease or disease of
bacteriologically doubtful status at 1 year.
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the SHOW regimen would be inferior to the SHTW
regimen because the multiplication of sensitive
organisms would frequently produce large numbers
of resistant mutants, or occasionally result in the
persistence of sensitive cultures. The substantial
superiority of the SH/SHOW regimen over the
SHOW regimen suggests that once the growth of
sensitive organisms had been halted by the initial
phase of daily chemotherapy, their further growth
during the once-weekly phase was relatively small
and much delayed. It is of interest that of 12
SH/SHOW patients who had an unfavourable re-
sponse, 6 had a sputum conversion to culture
negativity followed by a bacteriological relapse
during the year of treatment (Table 15), as compared
with 4 of 26 in the SHOW series (none of the 10
patients who had a relapse was irregular in drug-
intake, all having received more than 95% of the
allocated chemotherapy).
In view of the evidence from 3 months onwards
that the elimination of drug-sensitive organisms
occurred more slowly with the less effective regimens,
the finding that the rates of sputum conversion in
the first 2 months of treatment were broadly similar
for the 4 regimens may seem surprising. In this
context, it may be noted that with the once-weekly
regimens, the majority of patients who were culture-
positive at 1 and 2 months eventually had a favour-
able response. In these patients, as well as in others
who had a favourable response, it is likely that
little multiplication of drug-sensitive organisms had
occurred between successive doses of chemo-
therapy, and consequently the bactericidal activity
of streptomycin and isoniazid was not adversely
affected by the fact that the rhythm of administration
was once weekly. On the other hand, the patients
who remained positive from the third month on-
wards were mainly those with an eventual unfavour-
able response. In these patients, multiplication of
drug-sensitive organisms had probably occurred to
a greater extent between successive doses, the result
being a slower elimination of sensitive organisms
and the emergence of drug resistance.
It is likely that early tuberculous death and early
serious clinical deterioration, which occurred pre-
dominantly in the SHOW and the SHZOW series,
were caused by multiplication of sensitive organisms
to a considerable extent, particularly in the first few
weeks of treatment. It follows, therefore, that a
short initial course of daily chemotherapy would be
valuable because it would halt the multiplication of
sensitive organisms in the early stages of treatment.
Role of pyrazinamide in the SHZOW regimen
The addition of once-weekly pyrazinamide to the
SHOW regimen appeared to have compensated for a
streptomycin deficiency in patients receiving the
lower dosage (0.75 g) of streptomycin but not for an
isoniazid deficiency in the rapid inactivators of
isoniazid (Tables 17 and 18). In consequence, the
efficacy of the SHZOW regimen was unaffected by
the dosage of streptomycin (1 g or 0.75 g), but was
considerably higher in the slow inactivators of
isoniazid than in the rapid inactivators. A possible
explanation for these findings is offered below.
Streptomycin is more active at an alkaline pH
than at an acid pH (Waksman et al., 1944; Mitchison
& Spicer, 1949), pyrazinamide is active only at a
very acid pH (McDermott & Tompsett, 1954; Wasz-
Höckert et al., 1956) and the activity of isoniazid is
little affected by pH (Mitchison, 1952). Therefore, it
is possible that, with the SHOW regimen, the lower-
ing of the streptomycin dosage to 0.75 g reduced the
activity of the drug on organisms growing in an
acid environment (mainly intracellularly) to a greater
extent than on those growing under more alkaline
conditions (mainly extracellularly and in caseous
material). In these circumstances, isoniazid-resistant
mutants present in the intracellular acid environment
would grow better in patients receiving the lower
dosage of streptomycin, resulting eventually in a
lowered efficacy of the regimen. In such a situation,
the addition of pyrazinamide would inhibit the
growth of the isoniazid-resistant mutants, thereby
compensating for the streptomycin deficiency in the
low-dosage patients.
In contrast, the growth of streptomycin-resistant
mutants (this would be greater in rapid inactivators
of isoniazid) would be only marginally affected by
the addition of pyrazinamide, since this drug is
active only at a very acid pH, and there is evidence
suggesting that the proportion of organisms in an
acid environment is relatively small (see below).
Consequently, the difference in response between
slow and rapid inactivators of isoniazid would not
alter appreciably due to the addition of pyrazina-
mide to the SHOW regimen.
Finally, although the SHZOW patients received
a high dosage (90 mg/kg body-weight) of pyrazina-
mide, only 5 (24%) of 21 patients with bacterio-
logically active disease at one year showed clear-cut
evidence of the emergence of pyrazinamide resist-
ance. Also, it has been demonstrated that, at acid
pH levels, even a short exposure to pyrazinamide can
produce a lag in the growth of tubercle bacilli that
TWICE-WEEKLY AND ONCE-WEEKLY REGIMENS IN THE TREATMENT OF TUBERCULOSIS 199
can last for at least 1 week (Mitchison, paper in
preparation), so that multiplication of sensitive
organisms between successive doses would be very
limited, Taken together, these findings suggest that
the proportion of organisms present in an acid
environment in the lesions was small, in which case
it is not surprising that the efficacy of the SHZOW
regimen was not appreciably higher than that of the
SHOW regimen.
Relative efficacies of streptomycin and isoniazid
In order to develop intermittent regimens further
on a logical basis, it would be useful to examine the
causes for unfavourable response with the regimens
in the present study.
The response to the SHTW regimen was highly
satisfactory, and similar in slow and rapid inactiva-
tors of isoniazid and in patients receiving high and
low dosages of streptomycin. Even so, an examina-
tion of the causes of failure in the few patients who
had an unfavourable response showed that the
streptomycin susceptibility of the pretreatment
strains tended to be lower for these patients than for
those who had a favourable response (Table 24). No
such association was, however, present with isoniazid
susceptibility. (Consistent variations in susceptibility
to streptomycin and isoniazid have been demon-
strated in pretreatment ‘sensitive’ strains from
British patients (Lefford et al., 1966) and Madras
patients (Tuberculosis Chemotherapy Centre, Ma-
dras, unpublished data).) These findings suggest
that the few instances of failure of the SHTW
regimen were due more to a failure of streptomycin
than of isoniazid.
The response to each of the three once-weekly
regimens was substantially inferior in the rapid
inactivators of isoniazid than in the slow inactivators.
Even so, no association was found between isoniazid
susceptibility of the pretreatment strains and
response to treatment. It may therefore be concluded
that the relatively poor response in the rapid inac-
tivators was due more to multiplication of isoniazid-
sensitive organisms between doses than to variations
in isoniazid susceptibility of the pretreatment strains.
Considering next the influence of streptomycin
dosage, there was some evidence of a dosage effect
in the SHOW series (Tables 9 & 17), and a suggestion
of such an effect in the SH/SHOW series (Table 15).
In both the series, however, the influence of strepto-
mycin dosage was considerably less than that of the
rate of inactivation of isoniazid. Finally, in the
SHZOW series, there was no evidence of a strepto-
mycin-dosage effect (Tables 15 & 18).
A consideration of the sequence of emergence of
drug resistance in patients with an unfavourable
response at 1 year suggested that a deficiency of
isoniazid was a more important cause of failure with
the three once-weekly regimens than with the twice-
weekly regimen. Thus, streptomycin resistance
emerged first, indicating a relative failure of iso-
niazid, in 36% of 28 SHOW patients, 30 % of 20
SHZOW and 30% of 10 SH/SHOW patients as
compared with 0% of 8 SHTW patients. However,
the failure of isoniazid in the once-weekly regimens
was largely in rapid inactivators of isoniazid (Tables
17, 18 and 19). In this context, it is of interest that
Dickinson et al. (1968) found, in experimental tuber-
culosis of the guinea-pig, that an increase in the
interval between successive doses from 4 days to
8 days resulted in a larger decline in the efficacy of
isoniazid than in that of streptomycin. The dosages
employed in these experiments included some which
yielded serum concentrations similar to those
obtained in the treatment of tuberculous patients;
furthermore, the half-life of isoniazid in the guinea-
pig was fairly similar to that of human rapid inac-
tivators of the drug.
In conclusion, the few instances of failure of the
SHTW regimen were due more to a failure of
streptomycin than of isoniazid. The addition of a
third drug-for instance, pyrazinamide, since it
appeared to compensate for a streptomycin defi-
ciency in streptomycin low-dosage patients (Tables 17
and 18)–might eliminate most, or even all, of
these failures. Alternatively, since the pattern of
sensitivity test results suggested that there was an
inadequacy of streptomycin in SHOW patients who
received the low dosage of the drug (Table 17) but
not in the corresponding SH/SHOW patients
(Table 19), an initial phase of daily chemotherapy
with streptomycin (1 g) plus moderate-dosage
isoniazid (400 mg) might be prescribed for 4 weeks
prior to starting treatment with the SHTW regimen.
In the three once-weekly regimens, isoniazid ap-
peared to be the more deficient drug. However,
should it prove possible to increase the efficacy of
isoniazid in rapid inactivators of the drug, then
streptomycin is likely to be the more deficient drug.
There appear to be, therefore, two stages in the
process for strengthening once-weekly regimens.
The first is to increase the efficacy of isoniazid in
rapid inactivators by providing more sustained
serum concentrations; this might be achieved by an
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increase in the dosage of isoniazid or by the addition
of PAS 1 (which also might enhance serum isoniazid
concentrations-see Gangadharam et al., 1961) or
by the use of a slow-release preparation of isoniazid
in which absorption from the gut would be pro-
longed. The second is to replace streptomycin with a
drug that might be even more potent in intermittent
chemotherapy, for example, ethambutol (Dickinson
et al., 1968) or rifampicin (Dickinson, 1969), or to
add an appropriate third drug (for example, pyrazin-
amide, as indicated above) to the regimen.
TOXICITY
Streptomycin
The study was conducted double-blind in respect
of streptomycin dosage-that is, neither the physi-
cians nor the patients knew whether an individual
patient received the high dosage (1 g) or the low
dosage (0.75 g) of streptomycin. In all, 7 (3.0% of
232 high-dosage patients and 3 (1.2%) of 244 low-
dosage patients had a reduction in streptomycin
dosage or took their discharge on account of
giddiness (P = 0.3); in 2 of the high-dosage patients,
the giddiness persisted despite the reduction and
the streptomycin had to be stopped. There was a
suggestion that the incidence was slightly higher in
the SHTW (3%) and the SH/SHOW (4%) series
than in the SHZOW (1%) and the SHOW (1%)
series. Finally, there was a significant association be-
tween age and the incidence, the latter being 0% of
119 for patients aged under 25 years, 1.3 % of 155
for those aged 25-34 years and 4.0 % of 202 for those
aged 35 years or more (P = 0.01). A similar asso-
ciation has been reported with daily streptomycin
by Johnston et al. (1964).
Minor complaints (mainly giddiness), not requir-
ing a reduction in streptomycin dosage, were made
by 74 (16%) patients; the incidence was not in-
fluenced by the age of the patient, the dosage of
streptomycin or the regimen.
Considering the influence of serum streptomycin
concentrations on toxicity, reduction in dosage or
cessation of streptomycin became necessary signifi-
cantly more frequently in patients with higher concen-
trations; for instance, the proportions were 0 % of 78,
1% of 94, 3 % of 133 and 5 % of 86 in patients with
(geometric) mean concentrations of less than 25 µg/ml,
1 A subsequent controlled study at this Centre has shown
that neither an increase in the dosage of isoniazid nor the
addition of PAS improves the efficacy of the SH/SHOW
regimen in rapid inactivators of isoniazid.
25 µg/ml- 31 µg/ml, 32 µg/ml-39 µg/ml and 40 µg/ml
or more, respectively (P = 0.01). However, patients
who had minor complaints of streptomycin toxicity
had concentrations similar to those who had no
complaints.
As regards impairment of vestibular function, the
over-all change between the commencement and the 
end of the year of treatment in the duration of nystag-
mus after the rotatingchair test was not influenced
either by the streptomycin dosage or by the chemo-
therapeutic regimen. However, patients who com-
plained twice of giddiness and those who had a
reduction in streptomycin dosage on account of 
giddiness had impaired vestibular function at the
time, as demonstrated by a significantly lowered
duration of nystagmus.
Isoniazid
No patient had the allocated chemotherapy ter-
minated on account of isoniazid toxicity. How-
ever, toxicity which did not require a modification
of the allocated chemotherapy occurred in 16
(3.4%) patients, despite the administration of 6 mg
of pyridoxine with every dose of isoniazid. This
tiding suggests that the dosage of pyridoxine was
probably inadequate; however, it should be noted
that even a high dosage may not be able to prevent
toxicity in all patients (Past African/British Medical
Research Council Isoniazid Investigation, 1960).
The incidence of toxicity was similar in the four
series,–namely, 4% in the SHTW, 4% in the
SH/SHOW, 2% in the SHZOW and 3% in the
SHOW series. It was significantly higher (P = 0.01)
in slow inactivators of isoniazid (5.0% of 299) than
in rapid inactivators (0.6 % of 177), suggesting that
the toxicity was due, in fact, to the isoniazid (among
the slow inactivators, however, there was little
evidence that it was higher in the patients with
higher serum isoniazid concentrations). Similar
associations have been reported with daily moderate-
dosage (9 mg/kg body-weight) isoniazid (Devadatta
et al., 1960) and daily high-dosage (14 mg/kg body-.
weight) isoniazid (Tuberculosis Chemotherapy Cen-
tre, Madras, 1963b).
Considering the details of isoniazid toxicity, 3
patients (all slow inactivators) had convulsions, 2 on
a single occasion and the third on 2 occasions. Loss
of consciousness on a single occasion occurred in
3 other patients (2 slow, 1 rapid); it was uncertain
whether the patients had had a convulsion or had
fainted. One of these (rapid) complained of paraes-
thesia in the limbs, as did 10 others (all slow).
TWICE-WEEKLY AND ONCE-WEEKLY REGIMENS IN THE TREATMENT OF TUBERCULOSIS 201
Pyrazinamide
Of 105 patients treated with the SHZOW regimen
(it may be recalled that the individual dose of pyra-
zinamide was very high–namely 90 mg/kg body-
weight), 5 complained of joint pains and 2 had jaun-
dice; there is suggestive evidence (page 187) that 1 of
the latter was incubating infective hepatitis on admis-
sion. Routine liver function tests (SGOT, SGPT
activity) and urine tests for urobilinogen were under-
taken on all the patients and did not reveal any evi-
dence of hepatic damage.
ACCEPTABILITY
In an earlier study (Tuberculosis Chemotherapy
Centre, Madras, 1964), 9% of 79 SHTW patients
(all of whom received 1 g of streptomycin) took their
discharge against medical advice as compared with
1% of 71 patients who received a standard daily
regimen of isoniazid plus PAS; this tiding raised
the possibility that undetected side-effects due to
streptomycin might have resulted in the greater
degree of non-cooperation with the SHTW regimen.
However, in the present study, the corresponding
proportions for the SHTW regimen were 2 (3%) of
71 among the patients who received 1 g of strepto-
mycin and 3 (4%) of 77 among the patients who
received 0.75 g, findings which suggest that toxicity
to streptomycin is unlikely to have been an important
cause for non-cooperation.
In all, 3.4% of 148 patients in the twice-weekly
series took their discharge against medical advice as
compared with 2.4% of 328 patients in the three
once-weekly series combined (P = 0.8). Further,
among the remaining patients, all four regimens
were acceptable to a high and similar extent, the
mean proportion of punctual attendances (that is,
attendances on the appointed day or earlier) being
93 % in the SHTW, 91% in the SH/SHOW, 91%
in the SHZOW and 93% in the SHOW series (it
 may be recalled that the scheduled numbers of
attendances in a year were 104, 72, 52 and 52 in the
four series, respectively). However, in all four series,
there was a tendency for fewer punctual attendances
in the later months of treatment.
It must be noted that the patients in this study had
to attend the clinic from distances of up to 5 miles
(8 km), not infrequently on foot, in a hot humid
tropical climate. However, they were selected
initially as being co-operative and were well indoc-
trinated on the importance of regular drug-intake;
furthermore, facilities at this Centre for retrieving
defaulters are very good. Under field conditions,
indoctrination is likely to be leas intense and facilities
would not be so good. Therefore, the aim should be
to decentralize the actual administration of the
supervised chemotherapy to sub-clinics, dispensaries
and injection centres, so that the patient can receive
his chemotherapy at or near his home or place of
work or en route between them.
If regular contact with the staff of a clinic can
motivate patients (as is often supposed), it is possible
that the frequent attendance for supervised admi-
nistration of chemotherapy would be self-perpetuat-
ing, thereby reducing the occurrence of default.
PRIMARY DRUG RESISTANCE
The incidence of primary drug resistance, based
on a total of 542 patients, was 5.9 % to isoniazid and
6.8% to streptomycin, including resistance to both
drugs in 2.4 %.
An interesting finding in this study, in view of the
fact that all the patients received intermittent chemo-
therapy, is that 36 (84%) of 43 patients with primary
resistance to either isoniazid or streptomycin (but
not both) had a clear-cut bacteriological response
initially, including 21 (49%) with a favourable re-
sponse at 1 year. The proportions with a favourable
response at 1 year were 72 % of 18 for slow inactiva-
tors of isoniazid and 33% of 24 for rapid inactiva-
tors, a significant difference (P=0.03), and 59% of
27 for streptomycin high-dosage patients and 31%
of 16 for low-dosage patients (P=0.1).
Patients with primary resistance to both isoniazid
and streptomycin had a relatively bad prognosis, for
only 4 (31%) of 13 had a clear-cut bacteriological
response initially, including 1 with a favourable
response at 1 year and 2 who took their discharge
against medical advice.
It may be concluded that, even when chemo-
therapy is administered intermittently, primary drug
resistance to either isoniazid or streptomycin does
not automatically imply that the response to treat-
ment will be unfavourable. A similar conclusion
was reached with respect to primary isoniazid
resistance in patients treated with daily regimens of
isoniazid alone or isoniazid plus PAS (Devadatta
et al., 1961; Tripathy et al., 1969).
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XIII. CONCLUSIONS
An intermittent regimen of isoniazid (14 mg/kg-
15 mg/kg body-weight) plus streptomycin (1 g), both
drugs being administered twice weekly (at the same
time) from the very outset of treatment to newly
diagnosed tuberculous patients with cavitated disease
and drug-sensitive cultures, has been demonstrated
to be highly effective in this study as well as in an
earlier one (Tuberculosis Chemotherapy Centre,
Madras, 1964). The efficacy of this regimen was
unaffected by lowering the streptomycin dosage
from 1.0 g to 0.75 g. Also, the efficacy was very
similar in slow and rapid inactivators of isoniazid.
These findings suggest that the regimen is likely
to be highly effective even in populations with
heavier patients and higher proportions of rapid
inactivators of isoniazid. Finally, bacteriological
quiescence attained with this regimen has been
demonstrated to be at least as stable over a 4-year
period of follow-up as that attained with a standard
daily regimen of isoniazid plus PAS (Ramakrishnan
et al., 1969).
Several other groups of workers have reported
favourably on the twice-weekly regimen, nearly all
having used it after an initial period of daily chemo-
therapy (Dawson, 1966; Chaulet et al., 1968;
Sbarbaro & Johnson, 1967; International Union
Against Tuberculosis 1; Polansky 2). It may there-
fore be concluded that the twice-weekly regimen of
streptomycin plus high-dosage isoniazid is no longer
an experimental regimen but is of established value
in the primary treatment of tuberculosis.
A regimen consisting of daily chemotherapy for
4 weeks with isoniazid 400 mg plus streptomycin 1 g
followed by once-weekly chemotherapy for the rest
of the year with isoniazid 15 mg/kg body-weight plus
streptomycin 1g approached closely the twice-
weekly regimen in terms of over-all therapeutic 
efficacy but, unlike the twice-weekly regimen, it was
considerably less effective in rapid inactivators of
isoniazid than in slow inactivators. If a method of
compensating for this deficiency can be found, the
prospects for evolving a highly effective once-
weekly regimen, as a valuable alternative to the
twice-weekly regimen, are excellent.
1  International Union Against Tuberculosis (1969)
A controlled trial of three regimens of self-administered and
supervised chemotherapy for pulmonary tuberculosis. Paper
presented to the Twentieth International Tuberculosis Con-
ference, New York, September, 1969.
2 Polansky, F. (1969) Study of sanatorium treatment
including a comparison of standard and intermittent continua-
tion chemotherapy. Paper presented to the Twentieth Inter-
national Tuberculosis Conference, New York, September,
1969.
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RÉSUMÉ
ÉTUDE COMPARATIVE CONTRÔLÉE D'UN SCHEMA COMPORTANT UNE PRLSE BIHEBDOMADAIRE
DE MÉDICAMENTS ET DE TROIS SCHÉMAS COMPORTANT UNE PRISE HEBDOMADAIRE
DANS LE TRAITEMENT INITIAL DE LA TUBERCULOSE PULMONAIRE
On a traité 554 patients atteints de tuberculose pulmo- deux fois par semaine; b) schema SHOW: strepto-
naire par chimiothérapie intermittente pendant un an, mycine (1 g ou 0,75 g) et isoniazide (15 mg/kg) donnés
en utilisant 4 schémas de cure ambulatoire: a) schema simultanément une fois par semaine; c) schéma SHZOW:
SHTW: streptomycine (1 g ou 0,75 g) et isoniazide streptomycine (1 g ou 0,75 g), isoniazide (15 mg/kg) et
(15 mg/kg de poids corporel) donnés simultanément pyrazinamide 90 mg/kg) donnés simultanément une
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fois par semaine; d) schéma SH/SHOW: streptomycine
(1 g ou 0,75 g) et isoniazide (400 mg) donnés quotidien-
nement pendant 4 semaines, puis streptomycine (1 g ou
0,75 g) et isoniazide (15 mg/kg) administrés simultané-
ment une fois par semaine. Tous les malades ont reçu
6 mg de pyridoxine avec chaque dose d’isoniazide pour
prévenir les effets toxiques secondaires de ce dernier
produit.
Chaque patient s’est vu assigner un schéma de traite-
ment et un dosage de streptomycine (1 g ou 0,75 g) par
repartition aléatoire; le double anonymat a été respecté
en ce qui conceme les doses de streptomycine.
L’étude a comporté trois phases. Au cours de la
premiere, on a administré l’un des schémas SHTW ou
SHOW à 106 malades; au cours de la deuxième, les
quatre schémas ont été utilisés (364 malades); enfin,
dans un troisième temps, 84 malades ont reçu l’un des
schémas SHTW, SHZOW ou SH/SHOW.
L’analyse a porté essentiellement sur 476 malades qui,
au debut du traitement, présentaient des cultures sen-
sibles à l’isoniazide et à la streptomycine. La grande
majorité d’entre eux (93%) n’avait jamais bénéficié de
la chimiothérapie, les autres n’y ayant été soumis que
pendant 2 semaines au maximum. Lors de la mise en
traitement, 83 % des malades étaient porteurs de lesions
cavitaires moyennes ou étendues, 72% étaient modéré-
ment, fortement ou très fortement atteints et 89%
avaient été recormus positifs à l’examen direct du premier
échantillon de crachats. On comptait parmi les malades
près de deux tiers d’inactivateurs lents de l’isoniazide et
un tiers d’inactivateurs rapides.
L’efficacité respective des schémas SHTW et SHOW
a été comparée chez les patients traités dans les 1re et
2e phases; celle des quatre schémas l’a été chez les mala-
des inclus dans les 2e et 3e phases. Au debut du traite
ment, les données cliniques, radiographiques et bacté-
riologiques étaient en général semblables pour les patients
appartenant aux différentes series, et dans chaque série
pour les sujets traités par la streptomycine à forte ou
faible dose ainsi que pour les inactivateurs lents ou rapi-
des de l’isoniazide. On relevait cependant deux excep-
tions: a) la proportion des inactivateurs rapides était
notablement plus élevée dans la série SHOW et b) dans
la série SHZOW, les inactivateurs rapides excrétaient un
 nombre nettement plus élevé de bacilles que les inacti-
vateurs lents. On s’est efforcé par une normalisation
statistique de tenir compte de ces différences.
L’étude comparative de 123 malades SHTW et de
117 malades SHOW traités aux 1re et 2e phases permet
un certain nombre de constatations. Durant l’année,
4 malades (1 SHTW et 3 SHOW) sont morts de tuber-
culose pulmonaire, et 10 (2 SHTW et 8 SHOW) ont dû
cesser le traitement par suite d’une aggravation des
signes radiologiques ou d’une deterioration sérieuse de
l’état de santé. Après un an, 90% des malades SHTW
et 72% des malades SHOW ont été considérés comme
ayant réagi favorablement au traitement sur la base des
résultats des cultures des 10e, 11e et 12e mois. Durant
l’année, on a noté une amelioration considérable ou
exceptionnelle des signes radiographiques chez 76% des
malades SHTW et 60% des malades SHOW, avec dans
respectivement 48% et 43% des cas disparition des
cavernes. Une resistance à l’isoniazide est apparue chez
4% des malades SHTW et 17% des malades SHOW
après 3 mois, chez 6% et 16% d’entre eux après 6 mois
et chez 8% et 19% après 12 mois. En ce qui regarde la
resistance à la streptomycine, les chiffres correspondants
ont été de 0% et 3 % au 3e mois, de 6% et 10% au
6e mois et de 7% et 18% au 12e mois.
La comparaison des résultats obtenus après emploi
de doses fortes ou faibles de streptomycine chez les
malades SHTW et SHOW traités aux 1re et 2e phases
fait ressortir des taux de reactions favorables après un
an de 90 % (doses élevées) et de 90 % (doses faibles) dans
la série SHTW et de 78% et 67% dans la série SHOW.
Pendant l’année, des proportions similaires de malades
traités à fortes ou à faibles doses, dans chaque série,
ont présenté une amelioration considérable ou excep-
tionnelle des signes radiographiques.
Une comparaison portant sur les inactivateurs lents
et rapides de l’isoniazide des séries SHTW et SHOW
traités aux 1re et 2e phases a montré que la proportion
des patients réagissant favorablement au traitement après
un an était de 92 % chez les inactivateurs lents et de 91%
chez les inactivateurs rapides dans la série SHTW
contrastant avec une proportion de 82% et 60% respec-
tivement dans la série SHOW. Au cours de l’année, la
proportion des améliorations radiographiques notables
ou exceptionnelles a été du même ordre parmi les inacti-
vateurs lents ou rapides dans chaque série.
L’étude comparative de 104 malades SHTW, de
106 malades SH/SHOW, de 105 malades SHZOW et de
79 malades SHOW traités aux 2e et 3e phases révèle
un certain nombre de faits. Durant l’année, 6 malades
(1 SHTW, 2 SHZOW et 3 SHOW) sont morts de tuber-
culose pulmonaire et 13 (7 SHZOW et 6 SHOW) ont dû
interrompre le traitement en raison d’une aggravation
des signes radiologiques ou d’une deterioration notable
de l’état général. Après un an, 94% des malades SHTW,
88 % des malades SH/SHOW, 74 % des malades SHZOW
et 68% des malades SHOW ont été considérés comme
ayant réagi favorablement au traitement d’après les
résultats des cultures des 10e, 11e et 12e mois. Pendant
l’année, on a constaté une amelioration nette ou excep-
tionnelle des signes radiographiques chez 79% des
malades SHTW, 73 % des malades SH/SHOW, 65 % des
malades SHZOW et 57% des malades SHOW, avec
disparition des cavernes dans respectivement 48 %, 43 %,
29 % et 45% des cas. Une resistance à l’isoniazide est
apparue au 3e mois chez 2 % des malades SHTW, 3 %
des malades SH/SHOW, 11% des malades SHZOW
et 19 % des malades SHOW; au 6e mois, les proportions
correspondantes étaient de 5 %, 5 %, 12 % et 20 % et au
12e mois, de 5 %, 9%, 16% et 22%. Pour ce qui est de la
resistance à la streptomycine, les chiffres ont été au
3e mois de 0 % (SHTW), 2 % (SH/SHOW), 6 % (SHZOW)
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et 5% (SHOW), au 6e mois de 4%, 2%, 10% et 11%, et
au 12e mois de 4%, 8%, 16% et 19%.
La comparaison des résultats obtenus après emploi de
doses faibles ou fortes de streptomycine chez les malades
SHOW, SH/SHOW, SHZOW et SHOW traités aux 2e et
3e phases révèle une proportion de reactions favorables
après un an de 93% pour les doses élevées et de 95%
pour les doses faibles dans la série SHTW, de 92% et
84% dam la série SH/SHOW, de 70 % et 78 % dans la
série SHZOW et de 74 % et 63 % dans la série SHOW.
Pendant l’année, des proportions similaires de malades
traités par des doses fortes ou faibles, dans chaque série,
ont présenté une amelioration importante ou exception-
nelle des signes radiologiques.
Lorsque la comparaison a porté sur les inactivateurs
lents ou rapides de l’isoniazide, pour l’ensemble des
malades des series SHTW, SH/SHOW, SHZOW et
SHOW traités aux 2e et 3e phases, la proportion des
patients réagissant favorablement au traitement après un
an a été de 97 % (inactivateurs lents) et de 91% (inactiva-
teurs rapides) dans la série SHTW, de 95 % et 76 % dans
la série SH/SHOW, de 85 % et 60 % dans la série SHZOW
et de 76% et 56 % dans la série SHOW. Au cows de
l’année, on a noté une proportion similaire d’améliora-
tions notables ou exceptionnelles des signes radiogra-
phiques parmi les inactivateurs lents ou rapides dans
chaque série.
Au cours des deux premiers mois de traitement, les
taux de négativation de l’expectoration ont été dans
l’ensemble similaires dans les séries SHTW, SH/SHOW,
SHZOW et SHOW, en dépit de fortes differences dans
la fréquence d’administration des médicaments. En
outre, chez les patients présentant après un an une
affection bactériologiquement non évolutive rien n’in-
dique que la négativation soit survenue plus tôt chez ceux
qui recevaient les traitements les plus actifs, ou chez ceux
qui recevaient de fortes doses de streptomycine, ou
encore chez les inactivateurs lents de l’isoniazide.
Dans la série SHOW, un manque de streptomycine
chez les patients traités par de faibles doses (0,75 g)
s’est manifesté par une élimination plus lente des germes
sensibles à partir du 3e mois et par une incapacité relative
d’empêcher l’apparition de la resistance à l’isoniazide et,
par la suite, de la resistance secondaire à la strepto-
mycine. De même, chez les inactivateurs rapides de
l’isoniazide, la carence en ce produit s’est traduite par une
élimination plus lente des bacilles sensibles à l’isoniazide
et par une impuissance relative à empêcher le développe-
ment de la resistance à la streptomycine, puis de la
résistance à l’isoniazide.
Si l’on analyse de la même manière les résultats des
épreuves de sensibilité, on ne relève dans les séries
SHZOW, SH/SHOW et SHTW aucun signe d’une
carence en streptomycine chez les patients traités par de
faibles doses (0,75 g). Quant au manque d’isoniazide, il
est trés apparent chez les inactivateurs rapides dans les
series SHZOW et SH/SHOW, mais non dans la série
SHTW.
Chez 9 malades, dont aucun n’avait négligé de prendre
sa dose de médicament à plus d’une reprise, les cultures
se sont révélées constamment sensibles à l’isoniazide et
à la streptomycine, même pendant les derniers mois du
traitement. Huit d’entre eux (6 SHZOW, 2 SHOW)
avaient été traités par chimothérapie hebdomadaire dès le
debut et le 9e (SH/SHOW) dès la 4e semaine du traitement.
Sur 21 malades SHZOW atteints d’une affection
bactériologiquement évolutive après un an, 5 (24%)
montraient des signes évidents d’apparition d’une resis-
tance à la pyrazinamide, ce qui correspond à une inci-
dence de 5 % pour l’ensemble des 105 malades de la série.
Les différences notées entre malades sous le rapport
des concentrations sériques de streptomycine et de pyra-
zinamide n’ont eu que peu d’influence sur la réponse au 
traitement. Néanmoins, on a été beaucoup plus fré-
quemment amené à réduire les doses de streptomycine
ou à interrompre le traitement (en raison de vertiges)
chez les malades présentant des concentrations sériques
de streptomycine élevées. Les differences entre les taux
sériques d’isoniazide chez lea inactivateurs lents et chez
les inactivateurs rapides n’ont pas eu d’action appreciable
sur les résultats du traitement et l’apparition de reactions
toxiques.
L’étendue des lésions cavitaires, la gravité globale
de la maladie et la richesse en bacilles de l’expectoration
lors de la prise en charge du malade ont eu une influence
nette sur la réponse au traitement. Cette influence a été
très perceptible chez les malades recevant les schémas les
moins actifs, SHZOW et SHOW.
Il semble que, dans la série SHTW notamment, les
souches initialement sensibles à la streptomycine l’étaient
dans une mesure moindre chez les malades qui n’ont
guère bénéficié du traitement que chez ceux qui y ont
réagi favorablement. Une telle difference de sensibilité
n’a pas été retrouvée pour les souches sensibles à l’isonia-
zide avant le traitement.
Les effets toxiques de la streptomycine ont amené à
réduire les doses du médicament ou à le supprimer chez
10 malades (2,1%). La fréquence de, ces reactions a
atteint 3 % (sur 148 malades) dans la série SHOW, 4 %
(sur 106) darts la série SH/SHOW, 1% (sur 105) dans la
série SHZOW et 1% (sur 117) dans la série SHOW; elle
a été de 3,0% chez 232 malades traités par de fortes
doses (1 g) et de 1,2% chez 244 malades recevant de
faibles doses (0,75 g). L’étude du nystagmus provoqué
(épreuve rotatoire) a permis de déceler une atteinte de la
fonction vestibulaire chez les malades qui, par suite de
vertiges, avaient vu leur traitement par la streptomycine
réduit ou supprimé, ainsi que chez ceux qui s’étaient
plaint de ces symptômes à deux reprises.
Des effets toxiques dus à l’isoniazide, qui n’ont pas
contraint à modifier les doses prescrites, ont été observes
chez 16 malades (3,4%) malgré l’administration conco-
mitante de 6 mg de pyridoxine. Leur fréquence a été de
4% dans les séries SHTW et SH/SHOW, de 2% dans la
série SHZOW et de 3 % dans la série SHOW; ils se sont
manifestés chez 5% des 299 inactivateurs lents et chez
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0,6% des 177 inactivateurs rapides. Sur les 16 malades,
3 (1 SHTW, 1 SH/SHOW et 1 SHOW) ont présenté
des convulsions et 3 autres (1 SHTW, 1 SH/SHOW et
1 SHOW) ont perdu connaissance à une occasion.
La pyrazinamide n’a posé aucun problème de toxicité.
Les mesures systématiques des taux des transaminases
sériques et de l’urobilinogène urinaire n’ont mis en
évidence aucun trouble de la fonction hépatique chez les
malades de la série SHZOW.
Au total, 13 malades (2,7%) ont abandonné le traite-
ment au cours de l’année, malgré l’avis contraire de
l'autorité medicale. On comptait parmi eux 5 malades
SHTW (sur 148), 3 SH/SHOW (sur 106), 4 SHZOW
(sur 105) et 1 SHOW (sur 117). Le taux moyen d’assiduité
de ceux qui se sont présenté au jour fixé (ou plus tôt)
au centre de traitement a été de 93% (series SHTW et
SHOW) et de 91% (series SH/SHOW et SHZOW).
Du point de vue bactériologique, de bons résultats
ont été obtenus imtialement chez 14 malades, sur 19,
présentant une resistance primaire à l’isoniazide unique-
ment, et chez 22 malades, sur 24, porteurs de bacilles
uniquement résistants à la streptomycine. Dans 43 cas
de résistance primaire à l’un ou l’autre médicament,
21 reactions favorables (49%) ont été notées après un
an. Les taux de réponses favorables ont atteint 72 % chez
18 inactivateurs lents de l’isoniazide et 33 % chez 24 inac-
tivateurs rapides (les resultats de l’épreuves d’inactivation
faisant défaut dans un cas), 59% chez 27 malades rece-
vant des doses élevées de streptomycine et 31% chez
16 malades traités par de faibles doses. Sur 13 malades
présentant une resistance primaire double à l’isoniazide
et à la streptomycine, 4 ont réagi au debut du traitement
d’une façon nettement favorable du point du vue bacté-
riologique, ces résultats se maintenant dans 1 cas après
un an.
Cette étude confirme qu’administré sous contrôle
strict un schéma bihebdomadaire associant l’isoniazide
à forte dose (14-15 mg/kg) a la streptomycine (1 g)
pendant un an permet de traiter très efficacement les
patients atteints de tuberculose pulmonaire récemment
diagnostiquée et porteurs de bacilles sensibles aux médi-
caments. Cette efficacité n’est pas influencée par le taux
d’inactivation de l’isoniazide ou par une reduction du
dosage de la streptomycine à 0,75 g. Un schéma compor-
tant l’administration quotidienne d’isoniazide à doses
modérées (400 mg) et de streptomycine (1 g) pendant les
quatre premières semaines, puis la chimiothérapie hebdo-
madaire par l’isoniazide à forte dose (15 mg/kg) et la
streptomycine (1 g) pendant le reste de l’année donne des
résultats tout aussi favorables que le traitement bihebdo-
madaire chez les inactivateurs lents, mais se révele beau-
coup moins actif chez les inactivateurs rapides.
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